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Abstract 
Ethanol is a poison that adversely affects the health of individuals and is 
detrimental to society as a whole. Analysis of ethanol in biological matrices is 
the most frequent test carried out in forensic toxicology laboratories with 
application across a range of cases types including fatalities, road traffic 
accidents, criminal investigations and workplace drug testing. 
The interpretation of ethanol concentrations in post mortem samples can be 
challenging in relation to medico-legal investigations. The source of ethanol can 
be as a result of the ingestion of an alcoholic beverage or it may have been 
formed after death. The stability of alcohol is also adversely affected by the 
presence of bacteria, high temperatures and unsuitable storage containers. 
A robust and sensitive method was developed for the analysis of common 
volatiles such as ethanol, methanol, isopropanol, acetone and n-propanol using 
headspace gas chromatography coupled with a flame ionization detector (HS-GC-
FID). The method was validated in accordance with ISO/IEC 17025, and was used 
to investigate the stability of volatiles in blood when stored under different 
conditions, and to investigate the prevalence of volatiles in different biological 
matrices collected post-mortem.  
Storage of blood samples in the freezer within sample vials containing 
preservative and antioxidant improved the stability of all volatiles with the 
exception of methanol which remained stable under all conditions investigated. 
The identification of ethanol or acetone in vitreous humour was found to be a 
suitable alternative matrix in cases where femoral blood was unavailable or 
ethanol production was suspected. The concentration of ethanol in bile 
correlated well with femoral blood but to a lesser extent than vitreous humour. 
Urine was not a suitable matrix for estimating blood ethanol concentrations. 
Alcohol biomarkers, β-Hydroxybutyrate (BHB) and fatty acid ethyl esters (FAEEs) 
have been reported as useful markers for, investigating the role of alcoholic 
ketoacidosis (AKA) in post-mortem cases, and foetal exposure to chronic 
maternal alcohol consumption, respectively. Methods were developed and 
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validated in accordance with ISO/IEC 17025 for BHB in blood and urine using gas 
chromatography - mass spectrometry (GC/MS), and for FAEEs in meconium by 
liquid chromatography - tandem mass spectrometry (LC/MS/MS).  
Post-mortem case samples submitted to the Forensic Medicine and Science (FMS) 
toxicology laboratory for routine tests were analysed for BHB using the validated 
method. The findings highlighted the importance of measuring BHB in blood in 
all cases where the deceased has a history of alcohol misuse and where the 
cause of death cannot be determined following the post-mortem. The role of 
alcoholic ketoacidosis in the cases analysed in this study was significantly under-
reported. 
Meconium samples collected from infants born at the Princess Royal Maternity 
Hospital, Glasgow, were analysed for FAEEs, using the validated method to 
investigate the prevalence of each FAEE (ethyl laurate, ethyl myristate, ethyl 
palmitate, ethyl stearate, ethyl oleate, ethyl linoleate, ethyl linolenate, and 
ethyl arachidonate). The study found evidence of chronic maternal alcohol 
consumption in approximately one third of the cases tested, in contrast to self-
reported use and highlights the importance of screening for the presence of 
FAEEs in meconium. The identification of suitable biomarkers of excessive 
maternal alcohol consumption during pregnancy, carried out as part of screening 
program, in addition to clinical evaluation would help to diagnose and support 
newborns with Foetal Alcohol Spectrum Disorder (FASD).   
The method developed for the analysis of BHB in blood and urine was 
successfully adapted and validated for analysis of structurally similar drugs such 
as β-hydroxy-β-methylbutyrate (HMB), a legal dietary supplement, in plasma and 
urine collected from 8 subjects, pre- and post-administration of a 3g dose of 
HMB. A significant increase was observed in urine and plasma following 
administration of of HMB. The method was then applied to the analysis of post-
mortem blood and urine to investigate the concentrations of exogenous and 
endogenous levels of γ-hydroxybutyrate (GHB).  
 
xvii 
List of Abbreviations  
ABV   Alcohol by volume 
ACN   Acetonitrile 
AKA   Alcoholic ketoacidosis 
ADH   Alcohol dehydrogenase  
ALDH   Acetaldehyde dehydrogenase 
ALT   Alanine aminotransferase 
AMU (amu)  Atomic Mass Unit 
ARBD   Alcohol-related birth defects 
ARND   Alcohol-related neuro-developmental disorders 
AST   Aspatate aminotransferase 
BAC   Blood alcohol concentration 
1,4BD   1,4-Butanediol  
BHB   Beta-hydroxybutyrate 
BSTFA + 1% TMCS N,O-Bis (Trimethylsilyl) trifluoroacetamide + 1%  
trimethylchlorosilane 
CDT   Carbohydrate deficient transferrin 
CV%   Coeffecient of Variation percentage 
CI    Confidence interval 
R2    Correlation Coefficient 
CSF   Cerebral spinal fluid 
D5-FAEE  Deuterated fatty acid ethyl esters 
DKA   Diabetic ketoacidosis 
EI    Electron impact (or ionisation) 
EDTA   Ethylene diamine tetraacetic acid 
ELISA   Enzyme-linked immunosorbent assay 
ESI   Electrospray ionisation 
EtOH   Ethanol 
FAEE   Fatty acid ethyl esters 
FAME  Fatty acid methyl esters 
FAS   Foetal alcohol syndrome 
FASD   Foetal alcohol spectrum disorder 
FB   Femoral blood 
FBM   Femur bone marrow 
FID   Flame ionization detector (or detection) 
FMS   Forensic Medicine and Science 
FS    Full scan  
EtG   Ethyl glucuronide 
GABA    Gamma-Aminobutyric acid  
GC     Gas chromatography    
GC/MS    Gas chromatography-mass spectrometry 
GBL    γ-Butyrolactone 
GGT   γ-Glutamyl transferase 
GHB   γ-hydroxybutyrate 
GTOL   Glucuronidated 5-hydroxytryptophol 
HMB   β-Hydroxy-beta-methylbutyrate 
HPLC   High performance liquid chromatography  
HS   Headspace 
5-HIAA  5-hydroxyindole-3-acetic acid  
5-HTOL  5-hydroxytryptophol 
xviii 
IEC   The International Electrochemical Commission 
ISO   International Organisation for Standardisation 
ISTD   Internal standard 
L    Liter 
LC   Liquid chromatography 
LC/MS   Liquid chromatography-mass spectrometry 
LC/MS/MS  Liquid chromatography-tandem mass spectrometry 
LLE    Liquid liquid extraction 
LOD    Limit of detection 
LOQ   Limit of quantification 
LLOQ    Lower limit of quantification 
MeOH    Methanol 
mg   Milligrams 
mL   Millilitre 
m/z   Mass to charge ratio 
NaF   Sodium fluoride 
NAD+            Nicotinamide adenine dinucleotide 
NADH   Nicotinamide adenine dinucleotide reduced form 
NICE   National Institute for Health and Clinical Excellence 
P    Preserved 
PEth   Phosphatidylethanol 
PFAS   Partial foetal alcohol spectrum 
PP   Protein precipitation 
QA   Quality assurance 
QC   Quality control 
RTA   Road traffic accident 
SIM   Selective ion monitoring 
SPE   Solid Phase extraction 
SPME   Solid phase micro-extraction 
SSALD   Succinic semialdehyde  
SSA-Dehydrogenase  Succinic semialdehyde dehydrogenase 
SSA-Reductase  Succinic semialdehyde reductase  
St Dev.  Standard Deviation 
SE    Standard Error of mean 
TIC   Total ion chromatogram 
UAC   Urine alcohol concentration 
ULOQ   Upper limit of quantification   
UP   Unpreserved 
VAC   Viterous humour alcohol concentration 
VH   Vitreous humour 
v/v                       Volume to volume 
WHO   World Health Organisation 
wt/v    Weight to volume   
wt/wt   Weight to weight 
 
 
1 
Chapter 1 - Introduction 
1.1 History of Alcohol Use 
The exact date of the first use of ethanol (commonly known as alcohol) as a 
beverage is not known, but it is thought to have occurred  as early as 10,000 
BC.(1) Archaeologists have found evidence that barley had been used to make 
beer for centuries. The Egyptians made beer from corn, while in China an 
alcoholic drink “samshu” appeared around 7000 B.C. along with “sake” in Japan 
which is made from rice. Wine and beer became the daily thirst quenchers for 
many years until water suitable for human consumption became more widely 
available in the 19th century.(1) 
Religious references to alcohol are both positive and negative. In the Bible an 
abundance of wine is used as an example of God's blessing, while a lack of wine 
is used as an example of God's punishment. Negative references include warnings 
against abusing alcohol and advocating abstinence if drinking will cause “a 
brother to stumble”. (2) In Islam, alcohol consumption is completely forbidden 
as it is believed that the harm associated with alcohol far outweighs its benefits. 
For the benefit and betterment of man, Islamic religion criminalizes the 
consumption, production, transportation, and sale of alcoholic beverages, 
although the strictness by which this prohibition was, and is, enforced varies 
between Islamic countries.(3;4)  
The first half of the 20th century saw a period of alcohol prohibition in several 
countries, including some provinces in Canada (1907 -1948), the United States 
(1920 to 1933), and Russia and the Soviet Union (1914-1925).(4) After several 
years, prohibition was deemed a failure in North America and other countries as 
bootlegging (rum-running) became widespread and organized crime took control 
of the distribution of alcohol. Prohibition generally came to an end in the late 
1920s or early 1930s.(4)  Figure 1-1 is an example of the posters displayed at the 
time. 
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Figure 1-1:  Alcohol Prohibition Poster. 
" Reproduced with permission from druglibrary.org"(5) 
In the United Kingdom, the sale or consumption of commercial alcohol has never 
been prohibited by law and is freely available to purchase in licensed premises if 
you are 18 years of age or older. However, for over 100 years the village of 
Bournville near Birmingham has not sold alcohol in any of their pubs, bars, or 
shops. Residents fought to maintain their alcohol-free zone, winning a court 
battle in March 2007 with Tesco (the largest supermarket chain in Britain) to 
prevent them from selling alcohol in its local outlet.(4)  
1.1.1 Alcohol Standard Measure 
Alcohol units are a measure of the volume of pure alcohol in alcoholic 
beverages. The standard drink is used in many countries to quantify alcohol 
intake. The standard drink contains one unit of alcohol and varies from one 
country to another according to how each country defines the unit of alcohol. 
The terms used for alcoholic drink measures include, units, alcohol by volume 
(%ABV), proof, pints, litres(L) and millilitres(mL).(6) One unit of alcohol in the 
United Kingdom is defined as 10 mL (8.0 grams of pure alcohol). This compares 
with 10 grams (12.7 mL) in Australia, while in the USA 1 unit of alcohol is equal 
to 17.7 mL and 1 pint  equates to 473.176473 mL.(7) 
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The number of units of alcohol in a drink can be calculated by multiplying the 
volume of the drink in milliliters by the percentage alcohol content and then 
dividing by 1000.  The alcohol content is expressed on the label as (%ABV).(7)  
1.2 Prevalence of Alcohol Use 
In 2005 (Figure 1-2), the total recorded worldwide consumption of alcohol by 
persons aged 15 years or older was 6.13 litres of pure alcohol per person. The 
highest consumption levels can be found in the developed world whilst the 
lowest consumption levels can be found in the countries of North Africa and sub-
Saharan Africa, the Eastern Mediterranean region, and southern Asia and the 
Indian Ocean. These regions represent large populations of the Islamic faith, 
which have high rates of abstention.(8;9) 
 
Figure 1-2:  Consumption of Pure Alcohol in Litres Per Person (>15 years old) in 2005.  
" No permission is required if used for research private study or with noncommercial 
document with limited circulation such as an academic thesis or dissertation.(8)" 
Scotland, a small northern European country with a population of approximately 
5 million people has the eighth highest rate of ethanol consumption in the world. 
Estimated at 11.9 litres of pure alcohol per person based on sales figures, 
alcohol consumption in Scotland is significantly higher than that of England and 
Wales by 2.4 litres (9.6 litres).(10)  In 2009, the population of men in Scotland 
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exceeding “sensible” drinking limits was more than half (53%) of the 25-34 age 
group, and 44% for women in the same age group. (10)   
The UK Governments guidelines for sensible drinking recommends maximum 
daily drinking limits for men that should not exceed more than 3 - 4 alcohol units 
per day and for women a maximum of 2 - 3 units of alcohol per day. It is also 
advised that people should have at least two alcohol free days each week and as 
such weekly limits are set at no more than 21 units for men and 14 units for 
women.(11)  
Although there is no official internationally agreed definition of “binge drinking” 
the Scottish Health Survey 2009(11) used the same definitions that were used in 
the Health Survey for England and the General Lifestyle Survey(12;13) to allow 
for comparability with other major alcohol consumption surveys in Britain. Binge 
drinking was defined as daily alcohol intake of more than 8 units for men and 
more than 6 units for women.(10;11) The prevalence of “binge drinking” was 
reported for 2009 with 26% of men and 17% of women drinking more than twice 
the recommended daily limit. 
1.3 Alcohol-Related Harm  
The World Health Organisation (WHO) objectives for public health policies and 
initiatives are to reduce the hazards caused by the harmful use of alcohol.(8;9) 
Alcohol is identified by the WHO as the third highest risk factor for ill health in 
developed countries, behind only tobacco and high blood pressure.(9) 
Many health medical onditions are linked to alcohol. These conditions may be 
acute or chronic diseases or injuries. Two types of alcohol-related conditions 
were identified in the Scottish report of alcohol statistics for 2011.(10) The first 
were those wholly attributable to alcohol misuse, such as alcoholic liver disease, 
mental and behavioural disorders, alcoholic polyneuropathy, myopathy, 
cardiomyopathy, gastritis, degeneration of the nervous system, intentional and 
accidental poisoning by alcohol, toxic effects of alcohol, foetal alcohol syndrome 
and alcohol-induced chronic pancreatitis. 
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The second group are those partly attributable to alcohol, such as cancers of the 
lip, oral cavity and pharynx, oesophagus, liver, larynx, colorectum and breast, 
and injuries resulting from road traffic accidents, assaults, fire injuries, falls, 
and intentional self-harm. Other medical issues include coronary heart disease, 
stroke, hypertensive diseases and cardiac arrhythmias, gastrointestinal diseases 
including liver disease, oesophageal varices, chronic  pancreatitis, psoriasis, 
spontaneous abortion, and epilepsy.(10)  
Alcohol misuse is also associated with several infectious diseases including 
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome 
(AIDS), tuberculosis, and sexually transmitted infections. Alcohol consumption 
weakens the immune system and has a negative effect on patients’ adherence to 
antiretroviral treatment.(9)  
To investigate the extent of harm associated with alcohol use in Scotland, adults 
were classified into four different drinking categories based on the number of 
units consumed in one week.(10) These categories included “non-drinkers”, 
“moderate drinkers”, “hazardous drinkers” and “harmful drinkers”.  
The study concluded that while those classified as hazardous drinkers  (men who 
consume between 21 – 50 alcohol units weekly and women between 14-35 units) 
may not have serious affects in the short-term, their excessive drinking could 
cause problems in the long-term.(10;11) The harmful drinking category included 
men who consumed over 50 units of alcohol weekly and women over 35 units, 
and were associated with causing physical, social, or psychological harm to 
themselves. 
1.3.1 Alcohol-Rehlated Social Harm 
Ninety-seven per cent of respondents to the Scottish Crime and Justice Survey 
considered alcohol abuse in Scotland to be a problem, with almost three 
quarters (74%) perceiving it as a “big problem”. “Vomiting” and “having an 
argument” were the most common negative effects of alcohol to reported by 
children.(10) It is estimated that 65,000 children live with a parent with an 
alcohol problem. (14)  
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In 3 out of 5 incidents of violent crime (62%), victims believed their attacker to 
be under the influence of alcohol, while in almost a third of incidents of violent 
crime, victims were under the influence of alcohol themselves.(10)  
1.3.2 Alcohol-Related Deaths 
Alcohol-related deaths include acute intoxication, chronic alcoholism, trauma, 
hypothermia, accidents, suicides, and homicides.(6;14-16) Alcohol-related death 
rates in Scotland are twice as high as in England and Wales, and have doubled 
over the last 15 years.(14) One Scot dies of an alcohol-attributable cause every 
three hours.(14) and deaths related to alcohol in some areas in Scotland are 6 
times higher than the UK average.(17) The alcohol-related mortality rate for 
males was more than twice that for females (30.0 per 100,000 population 
compared to 14.4 per 100,000 population, respectively).(10) 
The dark purple colour in Figure 1-3 represents the highest mortality rate from 
alcohol misuse, corresponding to northern Scotland and the central belt cities of 
Glasgow, Dundee, and Edinburgh. This data does not include many other causes 
of death to which alcohol may have contributed, such as deaths due to cancer 
and liver disease.(18) 
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  Figure 1-3:  Regional Variations in Alcohol-Related Mortality in Great Britain.  
  "Reproduced with permission from department of Geography University of Sheffield (18)" 
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1.3.3 Road Traffic Incidents Involving Alcohol 
The offence of being drunk and incapable of some tasks, such as operating 
machinery, was first recognised in the 18th and 19th centuries.(6)  In 1872, 
penalties were imposed for drunkenness of persons who were in charge of the 
safety of others, such as engine drivers, ship masters, taxi drivers, and service 
personnel.(6) The prescribed limits for alcohol in the current UK legislation 
(Road Traffic Act 1988)(6) are 80 mg/100 mL in blood, 107 mg/100 mL in urine 
and 35 µg/100 mL in breath. The ability of a driver to judge speed and distance 
while dealing with the unexpected is impaired when under the influence of 
alcohol with the risk of being involved in an vehicle accident increasing sharply 
if the blood alcohol concentration (BAC) of the driver is above the legal limit.(6) 
The transport legal limits for alcohol in blood vary considerably in different 
countries and two alcohol blood legal limits were reported for some countries 
such as india, the reason is not clearly stated but the highest limit is the one 
used as summarised in Table 1-1.  
Table 1-1:  Legal Drink Drive Limit by Country for Ethanol in Whole Blood (19;20) 
 
 
 
 
In Scotland, there were 8,504 offences of drunk driving in 2009-10(10) which was 
a decrease of 13% from 9,800 drunk driving offences in 2008-09. A total of 
Country Legal limit (Blood) Legal Limit (Blood) mg% 
United States 0.08 g/100 mL 80 
Great Britain 80 mg/100 mL 80 
Netherlands 0.50 mg/mL 50 
Sweden 0.20 mg/g 20 
Norway 0.20 mg/g 20 
Australia 0.05 % 50 
Canada 0.08 % 80 
Japan 0.03 % 30 
India 0.03/0.015 % 30/15 
Saudi Arabia 0.00 % 0 
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18,536 motorists were known to be involved in injury-producing road accidents 
in 2009. This figure does not include drivers involved with hit and run accidents 
who were not traced. Out Of the 18,536 motorists, 10,924 (59%) were requested 
to take a breath test. Of these only 429 (3.9%) cases gave a positive breath test  
including motorists who refused to take the test which equates to 2.3% of the 
total number of tests carried out (18,536).(10) In 2008 it was estimated that 40 
people were killed in accidents involving motor vehicle drivers or riders with 
alcohol levels, above the current drink-drive limit of 80 mg of alcohol per 100mL 
of blood.(10) 
1.3.4 Foetal Alcohol Spectrum Disorders (FASD) 
People have the misguided belief that the effects of ethanol on the foetus have 
only recently been recognised. However, the link between ethanol and birth 
defects are noted throughout history. The Ancient Greek Philosopher, Aristotles 
(384-322 B.C.) noticed that the children of drunken women were often “morose 
and languid”(21) and in 1500 A.D., St. Francis warned women against consuming 
wine or strong drink during pregnancy to prevent the child from becoming 
“lunatic” (one who had imperfect memory).(21) 
 
 Figure 1-4:  William Hogarth 1697-1764 (Gin Lane).  
 "This work has been identified as being free of known restrictions under copyright law"(22) 
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In 18th century Britain, the epidemic consumption of gin made people believe 
that it could lead to birth defects. When the price of gin decreased, the infant 
mortality rate increased and in 1834, the British House of Commons recognised 
the impact of ethanol and reported that “children from alcoholic mothers have a 
starved, shrivelled and imperfect look”. In 1860, a French physician noted that 
children exposed to ethanol have nervousness, a small head, and strange facial 
features.(21) 
Babies born to mothers who are suspected of misusing alcohol during pregnancy 
are at an elevated risk of developing foetal alcohol spectrum disorders (FASD) 
and Foetal Alcohol Syndrome (FAS).(23;24)  Foetal exposure to alcohol can cause 
central nervous system dysfunction, pre- and post-natal growth problems, 
cardiac defects in neonates, attention deficit disorders and may also lead to 
mental retardation. Ethanol crosses the placenta and interferes with the brain 
and other organ development and can cause pre-term delivery, spontaneous 
abortion and foetal death. The effects associated with foetal alcohol exposure 
are permanent, irreversible and impact both the child and family for life. The 
greatest incidence of infant cognitive deficiency occurred in pregnant women 
who engaged in binge drinking.(23;25) 
 FASD is a non–diagnostic umbrella term identifying a range of disorders as a 
result of gestational alcohol exposure, including Foetal Alcohol Syndrome (FAS), 
Partial Foetal Alcohol Syndrome (PFAS), Alcohol-Related Birth Defects (ARBD) 
and Alcohol-Related Neurodevelopmental Disorders (ARND).(23;26) The severity 
associated with these disorders is thought to depend on the amount of alcohol 
consumed during pregnancy and at what time point during the pregnancy 
maternal consumption of ethanol occurred. 
FAS is the most clinically recognized of the FASD conditions, exhibiting the full 
presentation associated with a pattern of anomalies including facial 
dysmorphism, permanent impairment of brain function due to damage to the 
central nervous system that may also lead to development disabilities, attention 
deficit disorder, hyperactivity, learning disabilities, receptive language deficits 
and pre and post growth deficiency.(23;26) The term partial FAS (PFAS) applies 
when there is a confirmed history of prenatal exposure and some characteristics 
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of the full syndrome but not enough to establish the diagnosis of FAS. The terms 
ARBD and ARND are two terms used when a complex pattern of behavioural and 
cognitive abnormalities are noted that could not be otherwise explained and 
when there is known significant maternal alcohol use.(26) 
To facilitate early diagnosis and treatment and to prevent undesirable 
outcomes, clinical diagnosis and screening for alcohol biomarkers may confirm 
maternal alcohol consumption. Relying only on the mothers self-report is not an 
accurate means of confirming alcohol exposure, due to feelings of guilt, 
embarrassment, and fear of punitive action.(27;28)  
Specific assessment techniques used to make definitive clinical diagnosis of FASD 
are still a matter of debate.(29) In order to prevent FASD it requires detection of 
in pregnancy maternal risk drinking. Surveys conducted in the UK have reported 
an increase in the percentage of women who gave up drinking during pregnancy, 
from 24% in 1995 to 34% in 2009.(16) However, in 2009, 61% continued to 
consume alcohol albeit to a lesser extent, while 4% admitted no change in their 
drinking pattern.  In contrast, 11.6% of pregnant women aged 15-44 in the 
United States admitted to using alcohol in the month prior to the survey, while 
16% of pregnant women aged 15-17 consumed approximately 24 drinks in the 
past month, with an average of 4 drinks on the day that they drank.(30;31) 
The prevalence of FAS and FASD is underreported in the UK due to lack of 
reliable data collection methods and consistency. The likely reasons could be the 
complexity in diagnosing FASD disorders, the lack of available standardised 
methods to diagnose FASD and the associated costs.  FAS is now widely known 
and accepted as a clearly diagnosed disorder, however, it is believed that the 
prevalence of FASD is three times greater than FAS.(31)   
It has been reported that in Scotland there are as many as 300 babies a year who 
have been affected by maternal alcohol consumption during pregnancy, however 
the incidence of FAS in Scotland is based on estimates from other European 
countries and USA statistics.(25;32) Considering the difficulty of diagnosing FASD 
Than FAS, a global research suggests that the prevalence of FASD worldwide is 1 
in 100 live births.(33) Using this to estimate FASD in Scotland would correspond 
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to a cumulative total of approximately 8000 children (infants to 16 years old). 
This figure could be generated if the total population of children (infants to 16 
years old) in Scotland was around 800,000. Relying on the figures from the USA 
statistics, there are approximately 7 cases per 10,000 births according to the 
birth monitoring program in USA and when this is translated to Scotland, the 
cumulative figure is expected to be 560 children (infants to 16 years old) based 
on a population of 800,000.(32) Table 1-2 summarises the statistics on the 
prevalence of FAS and FASD by country.  
 Table 1-2:  Summary of Statistics on Prevalence of Foetal Alcohol Exposure by Country 
Country Prevalence of FASD and FAS References 
USA 
FAS - 0.3–5.6 per 1000 live births 
FAS - estimated 0.5-2.0 per 1000 live births 
FAS - 2-7 per 1000 live births 
(25) 
(33) 
(34) 
CANADA FASD - 1 in every 100 live births (35) 
 
ITALY 
 
FAS - 3.7-7.4 per 1000 children 
FASD - 20.3–40.5 per 1000 children 
 
(36) 
 
FAS - 4.0-12.0 per 1000 children 
PFAS - 18.1-46.3 per 1000 children 
FASD - 2.3-6.3% of children 
(37) 
AUSTRALIA FASD - 4.7 per 1000 live births (23) 
SOUTH AFRICA FASD - 68.0–89.2 per 1000 children (38) 
ENGLAND FAS - 95 in 2000–01, 90 in 2001–02 and 128 
in 2002–03 
(23) 
SCOTLAND FAS - 4 in 2000, 5 in 2001, 4 in 2002, 2 in 
2003 
(23) 
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In the USA, the recommendation from the Surgeon General is for pregnant 
women not to drink any alcohol during pregnancy to avoid the negative impacts 
on the health of both mother and foetus and to eliminate the chance of giving 
birth to a baby with FASD.(39) Fifteen states consider substance abuse during 
pregnancy to be child abuse under civil child-abuse.(40)  Canada promotes 
alcohol-free pregnancy but has no law against consuming alcohol while 
pregnant.(41) 
In the UK, there have been no universal strategies focusing specifically on 
preventing FASD.(23) The Department of Health and the National Institute for 
Health and Clinical Excellence (NICE) published guidance warning pregnant 
women or women trying to conceive to avoid drinking alcohol to protect the 
baby. If they choose to drink they should not drink more than 1-2 units of alcohol 
once or twice a week.(42);(43)  
Several governments have introduced a label or logo as a health warning for 
pregnant women to be applied to all alcoholic drinks including different types of 
containers.(21) In the UK, voluntary labelling is preferred. For ethanol drink 
containers exported outside Britain labelling is sent out with necessary warnings 
as per the requirement of the importing country. However the same ethanol 
drink containers do not have the warning label when sold in Britain.(21) 
1.3.5 Alcohol-Related Harm Reduction Plan in Scotland 
In response to the growing scale of the problem associated with ethanol misuse, 
the Scottish Government published a new strategy for reducing alcohol related 
harm setting out proposed changes to legislation to build on those already in 
place, specifically the Licensing (Scotland) Act 2005 introduced in September 
2009.(44;45) The Alcohol etc. (Scotland) Act 2010 was passed by the Scottish 
Parliament on the 10th November 2010 and bans quantity discounts on alcohol 
purchases, restricts alcohol-related promotions, introduces a Challenge 25 age 
verification scheme for licenced premises and aims to introduce social 
responsibility for those who profit from the sale of alcohol. The original Bill had 
also included minimum pricing for alcohol but this was not supported by all 
parties represented within the Scottish coalition government.(45) 
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1.4 Interpretative Challenges Associated with Medico-
legal Investigations Involving Ethanol 
Due to the prevalence of ethanol use and misuse across all areas of society, a 
wide range of case types and samples are submitted to forensic toxicology 
laboratories for ethanol analysis. Modern laboratories must develop methods 
which are suitably robust, sensitive and specific in accordance with national and 
international standards (e.g. ISO/IEC 17025) but must also consider additional 
factors for better interpretation of alcohol results in medico-legal cases. These 
include; the circumstances surrounding the death, whether there is a history of 
alcohol abuse, the type of sample and site of collection, whether the sample has 
been collected in an appropriate sample container with preservative and stored 
at the correct temperature. In addition, depending on the type of case and 
sample availability, the identification of specific ethanol biomarkers could 
provide significant insight into the role of ethanol.  
It is therefore important for forensic toxicologists to understand in addition to 
alcohol distribution and elimination from the body, other factors affecting the 
stability of alcohol, alcohol biomarkers and related volatiles to aid 
interpretation of the measured concentration. 
1.5 Pharmacokinetics of Ethanol 
Ethanol can be absorbed into the body in different ways; through the skin, 
inhalation, intravenously or orally. The oral route is the most common with 80% 
of ethanol absorbed from the small intestine and 20% from the stomach into the 
blood by simple diffusion.(46) Ethanol enters the blood through the portal vein 
to the liver, and then travels to the right side of the heart and on to the lungs 
where gas exchange can occur. Ethanol dissolves in the blood and distributes 
into other tissues or fluids according to their water content, the greater the 
water content, the greater the ethanol concentration. Tissue with high water 
content will have more alcohol than tissues rich with fat.(46)  
It is commonly assumed that women have less body water than men due to 
smaller body mass and a higher proportion of body fat. However, women achieve 
a higher blood alcohol concentration (BAC) than men after drinking the same 
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amount of alcohol. Equilibrium between the tissues and blood is achieved within 
1-2 hours.(6) Absorption is most rapid when the stomach is empty.  There is also 
considerable intra and inter individual variation in the absorption rate.(46-48) 
Figure 1-5 summarises the many factors affecting the BAC in the body after 
drinking. 
 
Figure 1-5:  Factors Affecting Blood Alcohol Concentrations. 
"Reproduced with permission from Dr. Jones A. Wayne".(47) 
The metabolism of ethanol as summarised in Figure 1-6, is predominantly via 
oxidation to acetaldehyde (CH3CHO) by alcohol dehydrogenase (ADH) and then 
by aldehyde dehydrogenase (ALDH) to acetic acid (CH3COOH). Approximately 5% 
is excreted unchanged in breath, urine, and sweat. Less than 0.1% undergoes 
non-oxidative metabolism in the liver in a phase II conjugation reaction to 
produce a water soluble metabolite ethyl-glucuronide, which is then excreted in 
urine.  
 
 Figure 1-6:  Ethanol Metabolism.  
“Reproduced with permission from Dr. Jones A. Wayne".(47) 
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The elimination of ethanol from the body occurs mainly by oxidative metabolism 
by a Class I isoenzyme of ADH in the liver.  Ethanol is an example of a drug in 
which the Michaelis-Menten kinetic enzymatic model applies.(49) 
ADH becomes saturated with substrate after the first few drinks and the rate of 
disappearance of ethanol therefore follows zero-order kinetics which is 
adequate to describe the decreasing phase of the BAC profile in most forensic 
situations (BAC >20 mg/dL).(49) When the BAC decreases below 10 mg/dL, the 
ADH is no longer saturated and the rate of disappearance changes to first–order 
kinetics in which only a fraction of ethanol is eliminated per unit time. Low 
BAC’s are however not relevant in most forensic situations.(50)   
The elimination rate on an empty stomach was reported to be lower than in non-
fasting subjects. The presence of the food in the stomach boosts the rate of 
ethanol metabolism and the profile of BAC returns to zero earlier than with an 
empty stomach when the same dose of ethanol was consumed. It is spectaculted 
that ethanol binds with some type of amino acid such as glycine.(49) 
Food in the stomach is an effective way not only to lower and delay the BAC 
peak but also to increase the rate of clearance of ethanol from the body. Food 
increases the blood flow in the liver, making the liver more efficient and 
facilitating exposure of ethanol to metabolizing enzymes in the liver.(50)  
According to a survey on ethanol elimination rates carried out by Jones in 
2010.(49) The survey was based on a large number of peer reviewed publications 
that met defined standards of experimental design, dose of alcohol given and 
blood sampling protocol. It was concluded that the physiological ethanol 
elimination rates range from 10-35 mg/100 mL/h.  In moderate drinkers the rate 
is 15 mg/100 mL/h, while in arrested drivers 19 mg/100 mL/h, many of whom 
were binge drinkers or alcoholics. The results of this survey could be used as a 
guide when questions arise about elimination rates in alcohol-related crimes. 
Ultra-rapid elimination rates accounting for rapid metabolism could be related 
to the induction of the CYP2E1 enzyme pathway of ethanol oxidation as a 
consequence of heavy drinking, however, the dose and duration of drinking 
required to boost the CYP2E1 enzymes have not yet been established.(51) 
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Detoxification with high concentrations of ethanol and genetic predisposition of 
hypermetabolic rate could be another reasons for ultra-rapid ethanol 
elimination.(52) 
1.6 Other Volatiles of Interest 
Volatile compounds other than ethanol can be found in blood in both living 
subjects (acetone, isopropanol, n-propanol, isobutanol, butanone and ethyl 
esters (ethyl acetate), and at post-mortem (acetaldehyde, acetone, isopropanol, 
n-propanol, butanone, isobutanol, iso-amyl alcohol, d-amyl alcohol, acetate, 
propionate, butyrate, isobutyrate, and ethyl esters such as ethyl acetate and 
glycerol).(53) 
The significance of the presence of these volatile compounds is particularly 
important as the presence of volatile compounds not found in living subjects 
could be good markers for post-mortem putrefaction or external contamination 
of the body.(53) 
In many cases the presence of these volatiles is a result of microbial production 
postmortem but others are as a result of antemortem alcohol consumption, 
while the presence of acetone may be endogenous in individuals who are 
diabetic or fasting.(53) In addition, acetone concentrations can increase due to 
intoxication from barbiturates or alcohol, hypothermia, metabolic ketoacidosis 
and isopropanol intoxication. Isopropanol is rapidly oxidized to acetone, which 
can be measured for several days afterward.(54) Acetone is one of the ketone 
bodies that can be considered as a the potential markers of alcoholic 
ketoacidosis (AKA) in addition to β-hydroxybutyrate (BHB) and acetoacetate.(55)  
Isopropanol or rubbing alcohol is commonly used as an antiseptic and 
disinfectant. Although it is less toxic than methanol and ethylene glycol, it 
produces greater central nervous system depression than ethanol.(54) 
n-Propanol is produced in large quantities post mortem and may continue 
increasing in concentration even when ethanol has reached its peak. It has been 
reported that an n-propanol concentration greater than 10% of ethanol in muscle 
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and greater than 5% in blood confirms putrefaction.(53)  n-propanol is considered 
a marker for ethanol formation as well as an indicator of putrefaction.(54)  
Methanol or wood alcohol is commonly used as a solvent in the chemical industry 
and is highly toxic. It is first converted to formaldehyde and then to formic acid 
by reaction with ADH and ALDH, respectively, and causes metabolic acidosis that 
can be fatal.(54)  
Ethylene glycol is the active constituent of antifreeze.  It is not as volatile as 
methanol and isopropanol and is very toxic compound. The diol converts in the 
body to oxalic acid which then reacts with calcium in the body and produces 
insoluble calcium oxalate. Calcium oxalate precipitates in the kidney and the 
brain leading to death.  Ethylene glycol intoxication is often identified without 
post-mortem toxicological analysis because the crystals of the calcium oxalate 
can be seen microscopically in the kidney or brain section.(46) 
1.7 Sample Selection for the Analysis of Volatiles  
The location from which a specimen is obtained from the body for analysis is 
important. During absorption, the alcohol concentration in different parts of the 
body may vary.(56) In living individuals, arterial blood is reported as an ideal 
blood sample for ethanol determination because the ethanol concentration 
correlates well with central nervous system (CNS) impairment.(57) Plasma, 
serum, urine, cerebrospinal fluid (CSF) and saliva contain more water than whole 
blood; therefore, they are expected to have a higher concentration of ethanol at 
equilibrium. Serum-blood ethanol concentration ratios vary from 1.12-1.17, 
whereas plasma-blood ratios range from 1.10-1.35, with an average of 1.18. 
There is no significant difference between the serum-blood and plasma-blood 
ratios.(58) The mean saliva-blood alcohol ratio is 1.08, and is independent of the 
sampling time.(59) The advantage of saliva is that it is easy to be collect by non-
invasive methods and there is a high correlation between saliva alcohol 
concentration and venous blood, and breath-alcohol concentration.(60)  
Many studies have evaluated the correlation between the urinary alcohol 
concentration (UAC) and the BAC. The majority of these studies suggest that the 
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ratio is 1.3:1, however, many factors may affect the concentrations in urine such 
as the time after drinking when the bladder is emptied and the remainder of any 
residue of alcohol-free urine present before the individual started to drink. This 
would tend to dilute the urine after ethanol consumption.(61) Collecting urine 
specimens for forensic purposes must be carefully supervised to avoid tampering 
with the specimen and must also be collected in a vial with an appropriate 
preservative.(62) In Road Traffic cases, two successive void samples are 
collected for urine, where the purpose of the first void is to empty the bladder 
from any old urine.(56)  
In postmortem cases, interpretation of the significance of alcohol found is more 
difficult if there is insufficient information regarding the type of death, the 
stage of ethanol distribution in the body, storage conditions and temperature of 
the specimens available.  
Whenever possible, femoral/peripheral blood should be collected at post 
mortem. Cardiac blood (aorta, vena cava) is commonly collected in the US 
forensic centres but interpreted with caution where contamination in a case is 
suspected (56;63), while in the UK and Ireland, collection of heart blood is only 
recommended when femoral blood is unavailable.(64) Blood collected from the 
chest or thoracic (pericardial blood, pleural cavity) cavity are not ideal as they 
may be susceptible to contamination from the stomach.(65) Cardiac blood and 
post-mortem femoral venous blood ethanol concentrations may reflect blood 
ethanol concentrations at the time of death, however, some peri-mortem 
physical factors associated with death, e.g. cardio pulmonary resuscitation (CPR) 
or suffering massive bleeding, may affect exogenous ethanol concentrations in 
cardiac blood.(66) 
In many death situations including death from severe trauma, blood from central 
and peripheral sites is not available during autopsy, and other body fluids are 
used to investigate the ethanol concentration, such as urine, vitreous humour 
(VH) and bile.(46)  
With urine, the presence of sugar and yeast can be converted to ethanol by 
fermentation.(61;67;68) There is a greater chance for bacterial contamination if 
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the specimen is not stored properly. Vitreous humour (VH) is the sample of 
choice in situations where the body has undergone extensive trauma.(69) Post-
mortem formation of alcohol in vitreous humour is negligible and therefore any 
ethanol present in VH most likely reflects alcohol consumed and is not formed. 
(70;71)  De Lima and Midio (1999)(72) reported that the vitreous alcohol 
concentration (VAC) is higher than the BAC during the post absorption phase due 
to the high water content in VH. According to study that was carried by Honey et 
al. 2005(73) the ratios varied between specimens ranging from 1.01-2.20. 
Possible reasons for the BAC ≥ VAC would be where death occurs before 
equilibrium is achieved, if endogenous ethanol forms in post-mortem, or if the 
blood sample is contaminated during sample collection. 
It has been reported(56) that the bile-BAC is less variable and more reliable than 
other tissues to predict the blood alcohol concentration in both post-absorption 
and pre-absorption phases. A range of alternative biological fluids and tissues 
have been evaluated in comparison to blood for detecting ethanol in the living 
and after death and are summarised in Table 1-3. 
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Table 1-3:  Ratio of Alcohol in Alternative Biological Specimens to BAC*. 
*BAC- Blood Alcohol Concentration 
The following scenarios may help to differentiate whether the presence of 
ethanol is endogenous or exogenous; 
1) the presence of ethanol in chest blood but not in vitreous humour or urine;  
2) the presence of ethanol in body fluids, especially VH; 
3) the presence of n-propanol and iso-propanol in the specimens;  
4) the circumstances of the death.(72) 
5) a history of alcohol abuse.  
Matrix Ratio Mean (Range)  N Ref. 
Urine 
1rst  Void                            Mean 1.345 (1.68-1.75) 
2nd  Void                            Mean 1.221 (1.43-1.47) 
 
450 (61) 
Acute Alcohol Poisoning     Mean 1.18  (0.87-1.53) 
Alcohol Death                    Mean 1.30  (0.87-2.10) 
628 
647 
 
(67) 
 
Serum/Plasma 
Plasma                              Mean 1.18  (1.10- 1.35) 
Serum                               Mean 1.16  (1.12- 1.17) 
20 
- 
(58) 
(56) 
 
Vitreous Humour 
                                     Mean 1.19  (0.63-1.75) 
                                     Mean 1.24  (1.01-2.20) 
672 
322 
(71) 
(73) 
Bile 
                                   Mean 1.01  (0.44-1.40) 
                                      Mean 1.03  (0.32- 2.91) 
33 
- 
(74) 
(75) 
Saliva                                        Mean 1.08 (1.065-1.088) 336 (75) 
CSF                                     Mean 1.14  (0.79-1.64) 54 (70) 
Brain                                     Mean 0.86  (0.64-1.2) 33 (70) 
Liver 
Violent Death                    Mean  0.63  (0.51-0.83) 
Acute Alcohol Death          Mean 0.60  (0.54-0.72) 
 
- (76) 
Kidney                                     Mean 0.66  (0.57-0.76) - (76) 
Bone Marrow 
Actual                               Mean 1.94  (1.34-3.22) 
Corrected                         Mean 1.29  (0.94-1.64) 
42 
63 
(74) 
Synovial fluids                                     Mean 1.01  (0.58-2.41) 12 (77) 
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Finally, cases may be presented where blood transfusions have taken place 
resulting in antemortem dilution of the blood potentially leading to a low or 
false negative result for alcohol. Although rare in the UK, bodies that have been 
embalmed present a real challenge as embalming fluid replaces most of the 
blood and the embalming fluids contain both formaldehyde and methanol. 
Although ethanol may be present in some cavity fluid, vitreous humour would be 
the preferred matrix in these cases.(63) 
1.8 Stability of Alcohol in Post-Mortem Blood 
Understanding the source and stability of common volatiles in blood is important 
when interpreting alcohol results to help distinguish whether alcohol was 
endogenous or exogenous. The presence of alcohol (ethanol) in post-mortem 
samples can result from the ingestion of an alcoholic beverage or formation 
after death. The formation of ethanol may be due to physical contamination 
from embalming fluids or from microorganisms in the presence of an appropriate 
substrate and ideal temperature conditions.(78) Another source of 
contamination during the post-mortem examination could result from a blind 
external chest stick via cardiac fluid or from the stomach contents in cases 
where death occurred soon after alcohol consumption.(79) Ethanol formation in 
post-mortem blood has also been reported in the absence of a preservative in 
the collection vessel.(80) 
There is also the potential for loss or gain of alcohol from the specimen analyzed 
depending upon the time delay from sample collection to analysis. The loss of 
ethanol is due mainly to evaporation, enzyme-mediated oxidation, or as a result 
of the action of micro-organisms.(81;82) Many different microbes utilize ethanol 
as a substrate for metabolism.(81-83) Loss of ethanol was reported from 
unpreserved specimen containers that contained a high number of microbes and 
a large headspace.(84) Oxidation of ethanol to acetaldehyde is another factor 
affecting ethanol loss, as reported by Brown et al. (1973).(81) 
Dubowski et al. (1997) (85) found that alcohol loss was negligible in the presence 
of an azide, however, the azide-free specimen had losses of less than 5% over a 
one-year period and for that reason, researchers concluded that the use of azide 
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is unnecessary. In another study, ethanol production increased as glucose levels 
increased, indicating that Candida albicans (C.albicans) produced ethanol from 
glucose especially in blood diluted by ante-mortem intravenous infusions that 
included glucose.(86) Loss of ethanol from preserved blood samples stored in the 
refrigerator (ranging from 13 to 39 months) varied in 25 samples out of 32 
samples, the most significant loss was 0.015 g/dL (15 mg/dL), which was 
observed in previously opened tubes compared to a mean loss of 0.010 g/dL in 
unopened tubes.(87)  
Sodium fluoride (NaF) is commonly used as a preservative for biological samples. 
The fluoride ions prevent the formation of polysaccharides by the microbes 
which leads to the prevention of microbial growth.(88) Although NaF inhibits 
most organisms, ethanol production in the presence of C.albicans at room 
temperature has been reported.(89;90) Other reports indicate that 1% NaF is 
efficient at inhibiting C.albicans in urine specimen.(88;91;92) The concentration 
of NaF as a preservative in the ethanol specimens varied from 0.25 to 1%. Two 
percent NaF is reasonable in combination with a low temperature and might 
prevent alcohol degradation.(82) Sodium metabisulfite is used as a disinfectant, 
antioxidant, and preservative agent and has been used to prevent the oxidation 
of alcohol.(93) 
1.9 Analysis of Ethanol and Related Volatiles 
Ethanol is most commonly measured in breath by police officers at the road-side 
using a hand-held device and in blood or urine by scientists using large high-
throughput immunoassay-based analysers or headspace gas chromatography 
coupled with a flame ionisation detector (HS-GC-FID).  
Immunoassay-based analysers are used to screen large numbers of samples 
quickly to identify presumptive positive samples and eliminate negative samples. 
These screening assays are used by laboratories offering workplace drug testing 
where the majority of samples will be negative. Positive samples required to be 
confirmed by HS-GC-FID. Modern forensic toxicology laboratories offering 
analysis of medico-legal casework use HS-GC-FID systems to ensure accurate, 
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robust and legally-defensible identification and quantification of ethanol and 
related volatiles. (54;79;80;94;95) 
1.9.1 Headspace Gas Chromatography-Flame Ionization Detection 
(HS-GC-FID) 
Analysis of ethanol using HS-GC-FID (Figure 1-7) requires dilution of the sample 
with an aqueous solution of internal standard, mixed and allowed to equilibrate 
at approximately 50 to 60°C in an airtight glass vial with a rubber septa and 
crimp cap. The vapour of the diluted sample will be aspirated by the automated 
headspace device and then injected onto the chromatographic column. In 
forensic work, it is advisable to use dual columns made from two different 
stationary phases especially with putrefied blood or tissue samples, as this will 
help reduce the risk of obtaining coincident retention times.(50)  
 
 
 
 
 
 
 
 
Figure 1-7:  Gas Chromatogram with Headspace Autosampler (GC-HS)  
 
Ionization of column eluent of the carrier gas and analyte molecules takes place 
where the hydrogen and air flame burns in the flame ionisation detectors 
(FID’s).  There is a constant electrical potential between the electrodes in the 
detector and the gap between them acts as a variable resistance. As the analyte 
molecules ionize, the resistance decreases and more current flows. This 
amplified current is the detector response. FID is known to be sensitive with 
broad applicability.(96)  
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1.9.2 Selection of a Suitable Internal Standard for Analysis of 
Volatiles  
The use of n-propanol, isobutanone, butanone, and n-butanol as internal 
standards is not recommended, because these volatiles may be present in post-
mortem blood. Instead, Acetonitile was recommended in literature as a 
promising compound to be used as an internal standard since it is not a product 
of microbial activity.(53) 
n-propanol is a major putrefaction product that is not contained in alcoholic 
beverages or specimens from living subjects and could therefore be considered 
as a marker for post-mortem ethanol synthesis.(66) n-propanol is present in 
larger quantities because its production continues even when ethanol production 
has reached its maximum limit.(53)  Ethanol that is formed postmortem is more 
likely to be lower than 0.7 g/L (equivalent to 70 mg/dL) and, more commonly, is 
less than 0.3 g/L (equivalent to 30 mg/dL). (83) The ratio of ethanol to n-
propanol concentration has been used to confirm postmortem formation of 
ethanol.(97)  
The presence of n-propanol in postmortem specimens renders it unsuitable as an 
internal standard when using HS-GC-FID for volatiles in post-mortem specimens 
but this does not apply to samples collected from the living.  
Isobutanol is present in bodies recovered from water and has been also 
considered a good indicator of post-mortem ethanol production.(53) 
It has been reported by Kuhlman, et al.(1991), (98) and Schuberth (1991),(99) 
that butanone was not produced in specimens as a result of microbial activity 
and that it, together with methanol, should be considered indicative of either 
ante-mortem exposure (e.g., consumption of alcoholic beverages) or 
contamination (e.g., methanol is found in embalming fluid).(100) 
 According to Canfield et al. (1998)(54) 2,800 blood samples from pilot fatalities 
were analysed over 8 years to assess levels of volatiles related to aviation 
accidents. An evaluation between three internal standards (propionaldehyde, 
propionic acid methyl ester, and t-butanol) was investigated and  t-butanol met 
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the selection criteria, namely; the internal standard should not exist either in 
living or post-mortem samples; it should have similar properties to the analyte 
of interest; the retention time should be in the middle range of the retention 
time of the analytes being separated; and it should be separated from all 
components of the mixture.(54) 
 In addition, the standard deviation of replicate measurements of ethanol when 
using t-butanol as internal standard was better than n-propanol and the 
retention time for t-butanol was in the middle range of compounds being 
separated, while n-propanol was not. t-butanol was not found following 
examination of 2,880 post-mortem samples from pilot fatalities.(54) 
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Table 1-4:  Published advantages and disadvantages of Different Internal Standards Used 
for the Analysis Volatiles by HC-GC-FID 
Internal Standards Advantages Disadvantages Ref 
Methyl Ethyl Ketone 
Resolved from ethanol, acetone, 
methanol & other putrefactive 
volatiles. 
Used  with Carbowax  packed  
column,  No information 
provided about using it with 
GC capillary column 
(53;95) 
Acetonitrile 
Not a product of microbial 
activity- separated well using Rtx 
BAC1 or ALC1 capillary columns  
Not commonly use. 100% 
overlapping with acetone 
using Rtx-BAC2 and ALC2 
capillary columns 
)53(  
Propionaldehyde 
Considering internal standard 
criteria, it was selcted as a 
potential replacement fo n-
propanol 
Its retention time close to ethanol 
retention time  
Does not have acceptable base 
line separation for compounds 
commonly found post mortem 
(54) 
Propionic acid methyl 
ester 
Considering internal standard 
criteria , it was selcted as a 
potential replacement fo n-
propanol 
Its retention time close to ethanol 
retention time  
Not stable and decreases over 
time, affecting quantitation (54) 
t-butanol Meets the criteria of selection for suitable internal standards 
Concentration may decrease 
with increasing fat content.  (54;94) 
n-propanol Can be separated from acetone 
Major putrefaction product 
and the retention time is not 
in the range of the analytes 
being separated. 
(53;66;79) 
Isobutanol 
Well separated from other 
volatiles using using Rtx-BAC2 
column  
Could  serve as a potential 
indicator of ethanol 
production (post mortem) 
(53;80) 
Methanol   Not produced in specimens as a result of microbial activity 
Could be indicative of either 
ante-mortem exposure or due 
to contamination from 
embalming fluid 
(98;99) 
 
Although t-butanol could be a suitable internal standard for volatile analysis, it 
has been reported that the level of t-butanol as an internal standard might 
decrease when the fat content of the sample analysed is increased.(94) Table 1-
4 summarises the advantages and disadvantages associated with using different 
internal standards for the analysis of volatiles. 
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1.9.3 Analytical Considerations for Method Development 
(Volatiles) 
Before starting the process of developing a method for the analysis of volatiles 
in biological matrices, it is important to first establish the sensitivity and linear 
range required. Table 1-5 summarises the volatile concentrations reported in the 
literature from a range of cases where low levels of volatiles were measured 
through to high concentrations in volatile-related fatalities. These provide an 
indication of both the lower limit of quantitation (LLOQ) and upper limit of 
quantitation (ULOQ) for each volatile. 
For legal purposes it is highly recommended that all determinations of blood-
ethanol concentration are made in duplicate with a cut-off point of 10 mg/dL.  
Table 1-5:  Alcohol and Other Volatile Levels in Blood. 
Alcohol 
Name 
Endogenous 
blood level 
 
Toxic 
(Fatal) 
blood level 
(mg/dL) 
References 
 
Ethanol 0.04-0.1  mg/dL 80-100 (>350) (101;102) 
 
Methanol 
      <10  mg/dL 
 
20 
(>89 ) (101;102) 
(0.1-2.3)  mg/dL Two fatalities (219, 196) 
 
(103) 
Acetone Serum  2.3-3.5  mg/L Non-diabetic (n=218)  <10 mg/L    
20-30 
55 (55;102) 
Isopropanol 0.1 - 0.2   mg/kg >40 >150 (102;104) 
n-Propanol 
 
Post-mortem blood  3-7  mg/dL 
 
UK workplace exposure limit  
250ppm (625 mg/m3) (53;83;105) 
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1.10 Analytical Biomarkers of Alcohol Consumption  
1.10.1 Introduction 
Biological markers, or biomarkers, are parameters tested and measured in the 
blood, tissue or body fluids as indicators of biologic state and are commonly used 
for diagnostic testing to monitor the presence of disease or to predict the 
various stages of disease and mortality.  Biomarkers have also been used to 
detect drug or alcohol consumption.(106) Biochemical biomarkers are usually 
evaluated in terms of specificity and sensitivity and the ideal marker should be 
100% sensitive and specific but this has not as yet been achieved. (29) 
Alcohol biomarkers are useful as indicators of chronic and acute alcohol 
consumption, due to the fact that the time frame for a positive identification of 
ethanol is limited with ethanol concentrations decreasing rapidly over time.(107) 
Also, ethanol can be produced naturally at very low concentration as a result of 
yeast proliferation after carbohydrate-rich meals, with formation also occurring 
after sampling due to microbial contamination and fermentation.(108)  
The three major classes of alcohol biomedical markers include “relapse 
markers” which are used in tests sensitive enough to detect even a single intake 
of alcohol such as ethanol, methanol or 5- Hydroxytryptophol (5HTOL). The 
second class of maker are called “state markers” for hazardous alcohol 
consumption. This type of marker can indicate disturbed metabolic processes or 
malfunctioning body organs and tissue damage caused by long-term exposure to 
alcohol. Examples of these markers include, γ-Glutamyl transferase (GGT), 
aspartate (AST) and alanine aminotransferase (ALT), mean corpuscular volume 
(MCV) and carbohydrate-deficit transferring (CDT). “Trait markers” are used in 
tests that indicate whether or not a person has a genetic disposition for alcohol 
abuse, such as the monoamine oxidase (MAO) enzyme.(109) A lower activity of 
MAO in the blood platelets of alcoholics compared with those of control groups 
has been reported.(110)  It is not only alcohol that may lower the activity of MAO 
as a separate study indicated that tobaco had the same effect on ethanol.(111) 
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1.10.2 Markers of Acute and Chronic Alcohol Consumption 
In addition to ethanol, methanol and 5HTOL several biomarkers have been found 
in urine and blood that may indicate recent alcohol consumption. These include; 
acetaldehyde, acetate, the ratio of 5HTOL to 5-Hydroxyindole-3-acetic acid (5-
HTOL/5-HIAA) and the direct ethanol metabolites ethyl glucuronide (EtG) and 
ethyl sulphate (ETS).   
Acetaldehyde is present in low concentrations (<1% of ethanol concentration) 
and rapidly converts to acetate. Additionally, its binding to various endogenous 
molecules such as protein in the peripheral venous blood will further reduce the 
concentration of free acetaldehyde.(109)  In the presence of ethanol, 
acetaldehyde may be formed artificially even after sampling. Acetate appears to 
be independent of blood ethanol concentration and remains elevated as long as 
ethanol is being metabolised.(109;112)  
5-HTOL and 5-HIAA are the minor and major metabolites of serotonin 
respectively, 5-HTOL increases in urine after drinking alcohol and it is 
considered to be a marker for recent alcohol consumption. Results are expressed 
as the ratio of 5-HTOL/5-HIAA rather than the 5-HTOL/creatinine to compensate 
for variations in 5-HTOL concentrations caused by urine dilution and to eliminate 
a false positive of those two metabolites in urine due to dietary serotonin from 
food known to produce serrotinin such as banana, pineapple, kiwi fruit and 
walnuts. The advantage of 5-HTOL/5-HIAA ratio over ethanol and methanol to 
detect recent drinking is that the serotonin metabolites can persist for several 
hours longer. The disadvatages are that 5-HTOL/5-HIAA ratio can be also 
increased with treatment with aldehyde dehydrogenase (ALDH) inhibitors such as 
disulfiram and cyanamide.(109) Formation of ethanol in urine due to bacterial 
action may be a source of misinterpretation of the 5HTOH/5-HIAA ratio.(113) As 
much as 80 % of 5-HTOL is excreted as glucuronidated 5-hydroxytryptophol 
(GTOL) which offers promising results in the detection of previous alcohol 
consumption and can be determined by ELISA.(114)  
Less than 0.1% of ingested ethanol undergoes non-oxidative metabolism in the 
liver in a phase II conjugation reaction to produce a water soluble metabolites 
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ethyl-glucuronide and ethyl sulfate which are then excreted in urine.(47) Both 
ETG and ETS are considered to be indicators for acute ethanol ingestion.(109)  
The delayed elimination of EtG may lead to false positive results and in cases 
where the deceased died within a few hours of consuming alcohol, the positive 
detection of EtG may be due to a previous episode of drinking.(115)  Secondly, 
the short time lag between the time ethanol ingestion took place and the 
possible detection of EtG in blood, may also lead to false negative results.(115)  
In addition to the classic markers of chronic alcohol intake, namely; CDT, GGT 
and MCV(113), other markers of chronic alcohol consumption include, AST, ALT, 
phosphotidyl-ethanols (PEth), fatty acid ethyl esters (FAEEs) and β-
hydroxybutyrate (BHB). 
Carbohydrate–deficient transferring (CDT) is a reliable marker for the detection 
excessive alcohol consumption and refers to changes in the microheterogeneity 
of the iron transport glycoprotein transferring in serum after contenious 
excessive prolonged alcohol consumption. (116) 
The main advantage of CDT, compared with other alcohol biomarkers,  is its high 
specificity for alcohol and the associated lower risk of a false negative from 
heavy alcohol consumption.(109) Although CDT is able to identify heavy drinkers 
with a higher specificity than GGT, heavy drinkers can be detected only when 
daily alcohol consumption is greater than 60 g. (117) False positive results may 
be found for individuals with non-alcoholic related diseases, such as biliary 
cirrhosis, or chronic active hepatitis, and with rare defects such as glycoprotein 
defect.(106;109)  
The advantage of GGT, AST and ALT markers is availability with low associated 
costs in most clinical laboratories, however GGT is non-specific for alcohol 
misuse and its level may increase due to other pathological conditions. MCV 
indicates the size of red blood cells and it is a part of routine blood count test.  
An elevated MCV is often observed in alcoholic patients and has a higher 
specificity than GGT and can be used in combination with other biochemical 
parameters. Cell size may take several months to return to normal.(109)       
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 PEths are phosphatidylethanols and refer to a group of abnormal negatively 
charged diacyl phospholipids formed in the presence of ethanol from other 
naturally occuring phospholipids such as phosphatidylcholines. PEths are direct 
ethanol metabolites that may degrade depending on the storage of specimens.  
Blood samples that contain ethanol can be stored in the refrigerator for up to 72 
hours or frozen in liquid nitrogen and stored at -80ºC without affecting PEth 
levels.(118);(119);(120) Disadvantages associated with PEths are that they are 
impossible to analyse in clotted post-mortem blood samples and can also be 
formed in the presence of ethanol.(121)  
FAEEs have been analysed in meconium and hair as indicators of gestational 
alcohol exposure,(106) while both FAEEs and EtG have been measured in hair as 
markers for chronic alcohol consumption.(122)  BHB is considered a potential 
marker of alcoholic ketoacidosis (AKA) and diabetic ketoacidosis (DKA). FAEE's 
and BHB will be discussed in more detail in the following sections.  
Tables 1-6 summarises information relating to the many types of acute and 
chronic alcohol biomarkers, the matrices they are measured in and the detection 
window. 
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Table 1-6:  Acute and Chronic Alcohol Biomarkers. 
Alcohol   
Biomarkers Matrix 
Markers of 
Acute/Chronic Detection time (hours) 
Ethanol Blood,serum, Plasma ,Urine, Saliva, sweat and Breath Acute  1-2( Depends on dose) 
Methanol Blood,serum, Plasma ,Urine, Saliva, sweat and Acute  2-3 
Acetaldehyde Blood Acute  -* 
Acetate Blood Acute  -* 
EtG and EtS Urine, serum, Hair, Vitreous Humor ,bone marrow, Acute  
EtG in urine was 
elevated 24-48 hours 
after ingestion. 
5-HTOL/5-HIAA Urine Acute  Longer that ethanol and methanol.(113) 
GTOL Urine Acute  -* 
CDT Serum Chronic Over 1.5-2 weeks(109) 
GGT,AST and ALT Serum, Blood Chronic -* 
MCV Blood Chronic -* 
Phosphotidylethanols 
(PEth) Blood Chronic 
14 days after sustained 
ethanol intake.(123) 
Fatty Acid Ethyl Esters 
(FAEEs) Serum, Hair and meconium Chronic 
Decrease within 29 
hours, and can be 
detectable for long time 
after intake. (124) 
β-Hydroxybutyrate 
(BHB). 
Serum,Postmortem Blood , 
Urine Chronic -* 
Proteomics Blood,serum, Plasma Chronic -* 
*Detection time not documented 
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1.11 β-Hydroxybutyrate (BHB)  
BHB is considered a potential marker of alcoholic ketoacidosis (AKA), (125-128)  
a metabolic disturbance resulting from prolonged consumption of alcohol.  AKA 
is attributed to the combined effects of alcohol and starvation in glucose 
metabolism. Alcohol blocks the hepatic gluconeogenesis which prevents glucose 
production, increases lipolysis, and fatty acid metabolism and results in the 
formation of ketone bodies as summarised in Figure 1-8.(129)  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8:  Formation of Ketone Bodies 
[Reproduced from Iten&Meier (127) and Umpierrez, et al.(130)] 
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The accumulation of ketone acids reduces the pH of the body and results in 
ketoacidosis. The most common ketone bodies produced in the body are 
acetone, acetoacetate and β-hydroxybutyrate. 
In many alcohol-related sudden death cases, the pathologist is unable to 
determine the cause of death with little findings of note at autopsy (other than 
a severely enlarged fatty liver) and no indications of the cause of death 
following routine histological, microbiological and toxicological investigations. In 
some cases the only positive findings, other than a fatty liver, are traces of 
ethanol in the blood and elevated acetone levels.(131) It is commonly believed 
that alcoholic cases of unexpected sudden death with no indication of the cause 
of death may be due to AKA.(108)  
BHB is the analyte of choice among other ketone bodies when investigating AKA 
because BHB concentrations are higher (approximately two-thirds of all ketone 
bodies in healthy persons) compared with acetoacetate and acetone. There is a 
close association with the increase in NADH:NAD+ and BHB. According to Iten et 
al.(127) there is no indication of BHB formation during storage or degradation in 
blood in vitro or in the corpse.(127) Acetone is neutral and does not contribute 
to an acidosis, and both acetoacetate and acetone are unstable in the blood. 
The production of volatile compounds due to putrefaction may interfere with 
acetone analysis. (55;127)  
In contrast diabetic ketoacidosis (DKA) is a metabolic acidosis associated with 
type 1 diabetes and is related to insulin deficiency. Insulin controls the level of 
glucose in the body coupled with an increase in glucagon levels and produces 
maximum gluconeogenesis. This leads to severe hyperglycaemia and 
accumulation of ketone bodies due to the enhanced metabolism of free fatty 
acids that are librated from peripheral adipose tissue and may end with 
ketoacidosis.(129),(125) Both DKA and AKA are common medical emergencies 
and are life threatening if they are not treated promptly.(130)  
Diabetic alcoholics may present with AKA; however, this distinction is difficult, 
particularly when the blood glucose level is moderately or mildly elevated. In 
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cases of starvation, ketosis alone usually causes a mild ketoacidosis, and the 
clinical presentation of AKA might distinguish it from starvation ketosis.(132)  
Umpierrez et al.(130) concluded that differentiation between DKA and AKA 
should be based on the history of diabetes or alcoholism and on the blood 
glucose level at admission. The clinical diagnosis with AKA and DKA are similar; 
and they are both associated with vomiting, nausea, abdominal pain, 
dehydration, Kussmaul breathing (slow deep respiration associated with 
acidosis), and coma. A summary of the differences between AKA and DKA is 
shown in Table 1-7.  
Table 1-7:  Main Differences Between AKA and DKA.(55;130)  
DKA  AKA  
Glucose level ( Hyperglycaemia) 
 578± 67 mg/dL  
Glucose level ( Hypoglycaemia)  
118 ± 11 mg/dL 
BHB/Acetoacetate Ratio 3:1 BHB/Acetoacetate Ratio 7:1 
Lactate/Pyruvate Ratio 11:1 Lactate/Pyruvate Ratio 19:1 
Glycated Haemoglobin (HbA1) 5-13% Glycated Haemoglobin (HbA1) <5.6% 
 
Low or absent blood ethanol along with elevated levels of acetone do not in 
themselves determine the cause of death, but these findings, in combination 
with a history of chronic alcohol abuse, suggest alcoholic ketoacidosis. 
The concentration of acetone in the blood could be considered as a indicator of 
the development or severity of AKA. Acetone blood levels can increase due to 
intoxication from barbiturates or alcohol, diabetes and hypothermia, metabolic 
ketoacidosis, and isopropanol intoxication. Isopropanol is rapidly oxidized to 
acetone, which can be measured for several days after isopropanol intoxication, 
while the isopropanol will disappear much earlier. Normal values in the serum of 
a living person range from 2.3-3.5 mg/L. In deaths due to diabetic coma the 
acetone level ranges from 16-864 mg/L with most values between 300-400 mg/L. 
(55) In non-diabetic controls acetone values are <10 mg/L. Out of 24 chronic 
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alcoholic cases, nine had acetone levels  ranging from 74-400 mg/L with a mean 
value of 183 mg/L. (55)  
It is generally believed that, in cases of alcoholic ketoacidosis, ethanol is low 
(<10 mg/dL) or absent, the absence of acetone does not preclude ketoacidosis; 
rather, it means that BHB still needs to be measured. Normal levels in post-
mortem blood were reported as less than 52 mg/L, elevated to toxic levels 
ranged from 52 – 260 mg/L, while levels exceeding 260 mg/L are considered 
pathologically significant.(127)  Other studies measured BHB in urine and 
vitreous humour from a range of cases including individuals who were known to 
be alcoholics or diabetics and are summarised in table 1-8. 
Table 1-8:  Levels of BHB Measured in post-mortem Blood, Urine and Vitreous Humour from 
a Range of Case Types. 
Category 
Blood 
(mg/L) 
Urine 
(mg/L) 
Vitreous Humour 
(mg/L) N Ref. 
Elevated/Toxic 52-260 N/A N/A 25 
(127) Fatal >260 N/A N/A 25 
Control Group <52 N/A N/A 69 
Alcoholics with unknown 
cause of death 
N/A 
267 - 850 106 - 850 6 
(133) Alcoholics with known 
cause of death 
N/A 
20 - 2000 0 - 850 6 
Control group N/A <100 <100 36 
Normal N/A 8.5 - 34.7 N/A 30 
(134) 
Diabetic N/A 4.9 - 4520 N/A 20 
 
Analysis of ketone bodies in both AKA and DKA may provide analytical evidence 
to support clinical diagnosis and may possibly provide information about the 
cause of death in the absence of other pathologically significant 
findings.(131;135)  
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1.11.1 Analysis of BHB in Biological Matrices 
The small polar nature of BHB and compounds of similar structure, such as 
gamma-hydroxybutyrate (GHB), make the chromatographic and 
spectrophotometric analysis of this compound complicated. The presence of two 
hydroxyl groups in the structure of BHB makes it suitable for silyl derivatization 
as illustrated in Figure 1-9.  
 
Figure 1-9:  BHB and BHB-TMS-Derivative 
 
Table 1-9 summarises published methods where BHB and related compounds 
were measured in biological matrices.  
The majority of the methods utilised gas chromatography-mass spectrometry 
with electron ionization detection (GC/MS-EI) with full scan mode for ion 
identification. Separation was carried out for most of the GC/MS methods with 
similar types of capillary column and using deuterated internal standards for 
quantification. This combination provides greater specificity and accuracy unlike 
the methods utilising UV spectrometry. Head space-GC/MS has been also used 
for BHB determination however this involves many steps for sample preparation 
and involves conversion of BHB to acetone and a long incubation time. Ideally a 
wide linear range is preferable to eliminate additional work required to dilute 
and re-analyse the higher concentrations found in post mortem samples with 
confirmed AKA or DKA, however only a few methods have a linear range up to 
500 mg/L.   
1.11.2 Gas Chromatography/Mass Spectrometry (GC/MS) 
Gas chromatography uses a gaseous mobile phase to transport the sample 
components through a packed column.  
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Before analysis of the analytes of interest by mass spectrometry, they must be 
converted into gas phase ions. Derivatization, which changes the chemical 
properties of the analytes of interest, is normally used to increase volatilization 
and ionization to promote chromatography, improve peak shape, and increase 
sensitivity and specificity. Analytes of interest are separated from the compound 
mixture by gas chromatography.  The most common ionization techniques in 
GC/MS are electron impact (EI) (figure 1-10) and chemical ionization (CI). 
 
Figure 1-10:  Electron impact ionization.  
 
In electron impact (EI), the parent molecules usually enter the ionization 
chamber in the mass spectrometer ion source and are impacted by an electron 
beam of high energy around 70eV which is enough to ionize the molecules. This 
leads to the formation of positive, negative, and neutral molecular 
fragments.The fragments (usually positive) are introduced to the mass 
quadropole analyser to filter masses and to monitor ions by either scanning them 
in full scan, a selected m/z ratio range, a type of acquisition usually used for 
qualitative analysis or by selected ion(s) monitoring (SIM), a type of ionization 
known to be sensitive and specific. SIM is a scan mode used for quantification. 
(96;136) 
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1.12 Fatty Acid Ethyl Esters (FAEEs) 
FAEEs are non-oxidative products of ethanol metabolism and are formed by the 
esterification of ethanol with free endogenous fatty acids and acyl-CoA/fatty 
acids. These reactions are catalyzed by the two enzymes FAEEs synthase and 
acyl/CoA/ethanol O-acyl-transferase.(142-145) After being synthesized in the 
liver and the pancreas, FAEEs are transported through the blood, while bound to 
lipoprotein and albumin and to the adipose tissue.(146) FAEEs persist in the 
blood for approximately 24 hours after ethanol intake has ceased.(147) Figure 1-
11 illustrates the structure of common FAEEs and deuterated analogues 
commercially available to purchase as analytical standards.  A shorter 
alternative nomenclature is commonly used for FAEEs, including one letter and 
two numbers separated by a colon. This corresponds tothe chain length and 
number of double bonds: for example;  ethyl oleate is (E18:1), with 18 being the 
number of carbons and the number 1 being the number of  double bonds.(148)  
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Figure 1-11:  FAEES and D5-FAEES Structures 
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1.12.1 Sample Selection for the Analysis of FAEEs 
FAEEs can be analysed in variety of biological samples such as blood, plasma, 
hair and meconium. FAEEs in serum correlate well with blood alcohol 
concentrations (BAC) and start to decrease within 2 hours after ethanol 
administration has stopped.(146)  FAEEs persist in the blood for approximately 
24 hours after ethanol intake.(147)  
In patients with a positive BAC, ethyl palmitate (E16:0) was detected in all 
plasma samples. Ethyl stearate (E18:0) was detected in 49% of the patients, 
ethyl oleate (E18:1) in 64%, ethyl linoleate (E18:2) in 13% and ethyl arachidonate 
(E20:4) was found in only 5% of patients. FAEEs were not detected in the control 
group who screened positive for ethanol.(149) 
According to Borucki et al.(124), FAEEs in serum decrease rapidly within 29 hours 
following ethanol intake; then they stabilize at values ranging from 0.007–0.025 
mg/L with no further decrease and remain detectable for long periods of time 
after intake. FAEEs take time to be released from the storage in adipose tissues, 
thus, FAEE determination in serum is limited to detecting recent ethanol 
consumption. 
It has been observed that the total FAEE concentration of ethyl palmitate 
(E16:0), ethyl stearate (E18:0), ethyl oleate (E18:1), and ethyl linoleate (E18:2) 
in the plasma of patients with a history of chronic ethanol abuse was 
significantly higher than in patients with a history of acute ethanol abuse.(149)  
Refaai et al.(150) found good correlation between BAC and FAEEs in the liver 
and between BAC and fat. Ethyl arachidonate (E20:4) is thought to be a highly 
specific marker of premortem alcohol ingestion, and has been detected at 
concentrations greater than 0.066mg/kg in individuals with a positive BAC. 
When ingested, FAEEs are rapidly hydrolysed in the duodenum but remain intact 
in the stomach; therefore, FAEEs may reach the bloodstream after absorption 
from the stomach.(151) It was concluded that kinetics of FAEEs are different in 
heavy drinkers compared with healthy subjects and that FAEEs are of limited 
value for the detection of a prior single ethanol intake.(124)  
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Meconium is a complex composition of greenish mucus material excreted by 
newborns approximately 2–3 three days after birth (may be delayed in 
premature infants). The advantage of meconium is that the collection is easy 
and non-invasive and it is a cumulative matrix in which xenobiotics and 
endogenous substances accumulate from the 13th week of gestation till birth, 
providing a wider window for detection of long-term exposure.(28) All samples 
must be stored immediately after collection in the freezer. 
Although it has been shown that FAEEs do not cross the human placenta unlike 
ethanol, FAEEs can be produced in vivo in the human placenta.(28)  
In a study by Chan et al. 2004, approximately 14% of meconium samples (N=142) 
tested positive for prenatal alcohol exposure with a level greater than 2.0 
nmol/g, equivalent to between 458-666 ng/g of corresponding FAEEs. Ethyl 
oleate, linoleate, palmitate, and arachidonate were detected most often and at 
the highest levels. In 95% of positive samples, a minimum of 3 FAEEs were 
detected.(27) A high correlation was found between FAEEs in meconium 
collected from 124 infants and maternal ethanol. It has also been reported that 
ethyl linoleate (E18:2) and ethyl arachidonate (E20:4) are biomarkers with high 
specificity for detecting prenatal alcohol exposure. Ethyl arachidonate levels 
were significantly higher in the alcohol-exposed groups than in the control 
groups.(152)  
In a separate study, 17 of 682 meconium samples tested positive for significant 
prenatal ethanol exposure (>2.0 nmol/g). The 95% confidence interval of FAEEs 
results that were less than the cut-off was 0.38–0.49 nmol/g [87-163 ng/g] 
versus those that were positive and greater than the cut-off which ranging 
between 7.74–151.28 nmol/g [1772-50376 ng/g].   
Meconium FAEEs analysis demonstrates a fivefold increase in sensitivity over 
self-report–based screening methods for the detection of ethanol-exposed 
pregnancies in a clinical setting.(152)  
The total FAEEs in the study carried out by Moore et al. 2003 (153) was an 
accumulation of 7 FAEE concentrations not including ethyl laurate and ethyl 
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myristate. Cumulative FAEE acid concentration greater than 10,000ng/g may 
indicate that the newborn has been exposed to significant amounts of ethanol 
during the pregnancy. The presence of laurate and myristate ethyl esters in 
meconium is considered non-specific.(153)  
Ethyl linoleate (E18:2) was positive in a meconium specimen of a neonate whose 
mother admitted to an intake of at least 10 drinks per week during the last 
month of gestation. It was also reported in negative cases where the mother had 
less than 3 drinks per week. Ethyl oleate (E18:1) is the most prevalent individual 
ester in meconium, followed by ethyl palmitate (E16:0) and ethyl palmitoleate 
(E16:1); whereas ethyl laurate (E12:0) and ethyl myristate (E14:0) were also 
detected in alcohol-free mothers.(154) 
In addition  It has been reported that ethyl linoleate (E18:2) is the best marker 
of foetal alcohol spectrum disorder FASD.(155)  
Maternal FAEEs in hair has also been recommended as an alternative to 
meconium. The reason behind this is due to the additional cost of developing an 
effective meconium assay with the limitation of providing information on 
maternal drinking only after childbirth, and even then only for the latter two 
trimesters. Also, other research is on-going on a range of other biomarkers, such 
as potential proteomic and metabolic marker.(26)   
1.12.2 Analysis of FAEEs in Biological Matrices 
Kulig et al.(156) utilised GC-MS with a nonpolar dimethylpolysiloxane column to 
analyse FAEEs in plasma. FAEEs analysis methodology includes acetone 
precipitation and extraction with hexane, using amino propyl silica solid phase 
extraction. These methods have been shown to have high sensitivity, specificity 
and accuracy (156) 
The internal standard used was either ethyl heptadecanoate (for several studies 
carried out using LC/MS/MS), or in-house prepared deuterated FAEE standards 
with other analytical techniques such as headspace-gas chromatography mass 
spectrometry (HS-GC/MS) coupled with or without solid-phase microextraction. 
The methods showed high sensitivity, specificity, and accuracy.(157-159)  
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The recommended method to be used for FAEEs determination by the Society of 
Hair Testing (SOHT) is head space (HS)-solid-phase microextraction (SPME) in 
combination with GC/MS with a deuterated internal standard.(160)  
Table 1-10 is a summary of the advantages and disadvantages of using different 
techniques for determining the FAEEs in different matrices. 
Table 1-10:  The Difference of the Techniques Used for the Determination of FAEEs in 
Biological Samples  
Techniques Advantage Disadvantage 
LC/MS/MS  High specificity Many sample preparation steps 
Sensitive High solvent volume used  
Same chromatographic method 
column can be used to detect opiates, 
cocaine, and FAEEs in meconium 
Large sample size  
HS-SPME-GC-MS  Eliminating the need for the organic 
solvent 
Needs optimization of the HS-
SPE 
Minimal sample preparation Equal or less specificity than 
LC/MS/MS 
Obtaining clean extract less matrix 
effect 
Require small amount of sample 
Using deuterated internal standard 
improve the accuracy, sensitivity  
Ideal for routine analysis. 
GC/MS  Alternative method when no 
LC/MS/MS or HS-SPME available in the 
laboratory 
Using CI is better than EI mode 
because EI yields identical fragments 
for various FAEEs  
Less specific than LC/MS/MS 
and less sensitive than 
LC/MS/MS and HS-SPME method  
GC-FID  Can be used as screening method 
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Most techniques used deuterated FAEEs-D5 internal standards prepared in-house 
with HS-SPME-GCMS instruments for analysis of FAEEs in hair and meconium. 
Only recently did four deuterated internal standards become commercially 
available to purchase, namely; ethyl myristate-D5, ethyl palmitate-D5, ethyl 
oleate-D5 and ethyl stearate-D5.  Although HS-SPME-GCMS has more advantages 
as previously indicated in Table 1-10, and is recommended by Society of Hair 
Testing for use when analysing FAEEs in hair, it has also been used for the 
analysis of FAEEs in meconium. Only two LC-MS/MS methods have been published 
for the analysis of FAEEs in meconium and both used a non-deuterated internal 
standard (ethyl heptanoate) as listed in Table 1-11. A summary table of all of 
the different techniques used to analyse FAEEs in different matrices can be 
found in Appendix 1-1. 
1.12.3 Liquid Chromatography Tandem Mass Spectrometry 
(LC/MS/MS) 
A triple quadropole LC/MS/MS consists of an HPLC coupled with a triple 
quadropole mass spectrometry. HPLC uses a suitable liquid mobile phase to 
transport the sample through a column packed with stationary phase material. 
A triple quadrupole mass spectrometer (QQQ) consists of two mass analysers 
(MS1 and MS2) separated by a collision cell arranged in series. The first mass 
analyser allows only the ions of interest (precursor or parent ions) to pass 
through, the ions enter the collision cell where fragmentation takes place and 
produces product or daughter ions which are analyzed in the second mass 
analyser (third quadrupole) and detected by the mass detector using specialist 
software for analysing and processing the data for quantification and 
identification Figure 1-12.(161;162)   
Five scan modes can be used in the triple quadrupole mass analyser. The product 
ion scan to detect all fragments produced by a single precursor, the precursor 
ion scan to detect all precursors producing a common fragment ion, neutral loss 
scan to detect all precursors undergoing a loss of a common neutral moiety, the 
single reaction monitoring (SRM) to detect a specific fragment ion produced from 
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a single precursor, and the multiple reaction monitoring (MRM) to detect 
multiple specific fragment ions produced from a single precursor. Both SRM and 
MRM are the most scan mode used in LC/MS/MS for identification and 
quantification. (161;162) 
 
 
 
 
 
 
Figure 1-12:  Illustration of Triple Quadrupole Mass Spectrometry. 
This figure has been modified and redrawn(161)  
The most common atmospheric pressure ionization techniques (API) in LC/MS/MS 
are electrospray ionization (ESI), atmospheric pressure chemical ionization 
(APCI) and atmospheric pressure photo ionization (APPI). Both ESI and APCI 
provide high sensitivity and specificity for a wide range of analytes(163) 
Electrospray ionization (ESI) is an ionization process whereby ions are formed 
from liquid phase droplets when sprayed through a small tube into a strong 
electrical field in the presence of a flow of warm gas (nitrogen) to assist in 
formation of ions Figure 1-13. As the solvent vaporizes, the droplets disappear, 
leaving highly charged analyte molecules. Nebulisation, desolvation and further 
evaporation are three important steps for transferring sample molecules from a 
liquid to gas phase in the presence of a flow of warm gas (nitrogen) to assist in 
the formation of ions (162;163).  
The first step is nebulisation and charging the sample nebulises through a needle 
at ground potential surrounded with electrodes with a high voltage. The 
potential difference between the nebuliser and the electrode produces a strong 
Electro-
Spray  
Ion 
Bridge 
Q1 
(MS1) 
Q2 
Collision 
Cell 
Q3 
(MS2) 
Detector Data Analysis 
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electric field that charges the surface of the sample droplets. In the second 
step, desolvation occurs by shrinking the charged droplets with a flow of heated 
drying nitrogen. The uncharged material will be carried out of the system. Ion 
evaporation further shrinks the droplets until the analyte ions are desorbed into 
a gas phase and then passed through the sample capillary into a low pressure 
region of the ion source on the mass analysed. (162;163) 
 
(A) 
 
(B) 
Figure 1-13:  Electrospray Ionization (ESI) (A) and (B).  
"(A) This media is in public domain Permission is granted (164)" 
LC 
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1.13 Aims and Objectives: 
From the literature it is clear that there are many variables that must be 
considered when interpreting the presence of volatiles and alcohol biomarkers in 
medico-legal investigations. A better understanding of the stability of these 
analytes in samples collected from the living and at post-mortem, and an 
evaluation of their prevalence in different matrices will greatly aid 
interpretation. The aims of this study and how they will be achieved are listed 
below: 
1. To investigate the prevalence of ethanol and other volatiles (methanol, 
acetone, isopropanol and n-propanol) in different matrices by: 
• Developing a dual-column HS-GC-FID method for the determination of 
ethanol and other volatiles in different biological matrices, involving 
the optimisation of GC conditions and the selection of a suitable 
internal standard; 
• Validating the developed method in accordance with ISO/IEC 17025; 
• Selecting and analysing post-mortem cases where femoral blood, 
urine, vitreous humour and bile samples are available to investigate 
the presence of volatiles in these matrices.  
2. To investigation the stability of volatiles in blood under different conditions 
(temperature and preservative) by: 
• Analysing blank (volatile-free) blood spiked at different volatile 
concentrations, with or without preservative following storage at 
room temperature, in a refrigerator and a freezer;   
• Analysing preserved blood samples collected from individuals arrested 
under section 5 of the Road Traffic Act (1988) after storage at room 
temperature for a time span ranging from 1-5 years; 
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• Analysing paired preserved and unpreserved postmortem blood 
samples following storage in the refrigerator and freezer. 
3. To investigate the role of beta-hydroxybutyrate (BHB) in diagnosing alcoholic 
ketoacidosis by:  
• Developing and validating a GC-MS method for the determination of 
BHB in blood in accordance with ISO/IEC 17025;  
• Quantifying BHB concentrations in postmortem blood samples and 
comparing these findings with case histories and incidence of 
alcoholic ketoacidosis (AKA);  
• Collating all cases on the Forensic Medicine and Science in-house 
database (GUFM) that have been analysed for BHB, ethanol and 
acetone and evaluate the relationship between these analytes, the 
case history, the cause of death and the potential role of AKA. 
4. To investigate the role of fatty acid ethyl esters (FAEEs) as an indicator of 
foetal alcohol exposure by: 
• Developing and validating an LC-MS-MS method for the determination 
of  FAEEs in accordance with ISO/IEC 17025;  
• Analysing meconium samples collected from babies born to mothers 
(some of whom were on a methadone maintenance programme) at the 
Princess Royal Maternity Hospital, Glasgow. 
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Chapter 2 - Evaluation of Common Volatiles in Post-
Mortem Blood by HS-GC-FID 
2.1 Introduction 
Use of a dual-column system is advisable in forensic casework especially when 
analysing highly putrefied samples. This involves using two columns with different 
stationary phases, providing two sets of data and reducing the number of false 
positive results due to other post-mortem volatiles that may be eluting at the 
same retention time as the target analytes.(50) In addition, many forensic 
toxicology laboratories also offer blood alcohol analysis for road traffic cases 
where accuracy and precision are of higher importance than issues relating to co-
elution of volatiles. A summary of published methods for the analysis of volatiles 
in biological matrices is summarised in Appendix 2-1. 
The main aim of this study was to optimise the current FMS in-house method for 
the determination of ethanol, acetone, isopropanol, methanol and n-propanol in 
blood and other body fluids. Method development was achieved by improving 
separation of the volatiles through use of different temperature programmes; to 
evaluate use of two different internal standards (n-propanol and t-butanol) and 
different capillary column stationary phases. The developed method was 
validated and applied to the analysis of real case samples.  
2.2 Materials and Methods 
2.2.1 Statistical methods  
Excel Windows 2003 data analysis was used to calculate average, median, 
standard deviations and regression. The chart wizard was also used for drawing 
histograms, pie charts and bar charts. Minitab software manufactured by Minitab, 
Inc.USA, version 15.1.2 and 15.1.3 and Minitab16 were obtained from the 
University of Glasgow Computing Services. Various statistical tests were used in 
this thesis including paired–t test, regression and correlation calculations, scatter 
plot and bestfit line plots.  
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The P value was also calculated to decide whether there is a significance 
difference between measured and standard amounts.  A statistical test known as 
the significance test can be employed by testing the truth of the hypothesis that 
is known as null hypohesis (H0). The term null is used to imply that there is no 
difference between two sets of data under test. If null hypothesis is rejected the 
difference between the two sets of data is real. Usually the null hypothesis is 
rejected when the probability of difference is less that 1 in 20 (i.e. 0.05 or 5%) in 
such cases the difference is said to be significant at 0.05 (or 5%) level. (165) The 
criteria used to assess the null hypothesis in normally distributed data: 
Calculated value<Tabulated value          Accept null hypotheis 
Calculated value ≥ Tabulated value        Reject null hypothesis 
 
The tabulated t value can be found in t distribution tables in statistics books.  
Calculated value can be calculated manually as following: 
 
In order to decide whether the difference between  (sample mean) and µ (true 
value or population mean) is significant to test the H0. The statistic t is 
calculated, where s= sample standard deviation and n=sample size  
 
In order to decide whether the difference between two sample means 1 and 2 
is significant to test H0: µ1= µ2.  The statistic t is calculated  
 
 
 
 
Paired t tests are used to test whether n paired results are drawn from the same 
population, that is H0: µd= 0, The statistic t is calculated. Paired t-test compare if 
there is a significant difference between the results obtained by two methods. 
The D and SD indicate the mean and standard deviation respectively of D, the 
difference between paired values.  
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2.2.2 Chemicals and Reagents 
Ethanol 99.9% was purchased from Joseph Mills (Denaturants) Limited, Liverpool, 
methanol 99.8% from Sigma Aldrich, acetone 99.9% and n-propanol from BDH-VWR 
International, isopropanol and acetonitrile (HPLC grade) from VWR-PROLAB-BDH 
and t-butanol 99.8% (GC) from Fluka. Sodium chloride (NaCl) was purchased from 
BDH Chemical Ltd (Poole, England). Double distilled water was obtained from the 
in-house Millipore system. 
2.2.3 Preparation of Blank (Volatile-Free) Blood 
Expired packed red blood cell pouches were obtained from the Blood Bank at the 
Western Infirmary Hospital, Glasgow to be used for preparing quality control 
samples. The red blood cells were collected according to the United Kingdom 
Blood Services guidelines,(166;167) and were frozen on receipt within Forensic 
Medicine and Science (FMS). The volume of packed red blood cells was measured 
once fully defrosted and diluted 1:1 with 1% saline solution, which was prepared 
by adding 9.5g sodium chloride into a volumetric flask and dissolving in 1 litre of 
deionized water. 
2.2.4 Preparation of Working Standards and Quality Controls 
Internal standard working solutions were prepared for n-propanol and t-butanol 
at concentrations of 33 and 40 mg/dL respectively by preparing a 10 g/dL w/v 
standard of each and then by adding 3.3 and 4 mL to 1 litre of deionised water, 
respectively. Separate mixed volatile working standard solutions were prepared 
for use with each internal standard, both internal standards stored at room 
temperature for 1 month. 
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Table 2-1:  Preparation of Mixed Working Standard Solutions 
  Method 1 Method 2 
Analyte Final Concentration 
Volume from Stock (10g/dL) 
in 100 mL water 
Ethanol 500 mg/dL 5 5 
Methanol 500 mg/dL 5 5 
Isopropanol 500 mg/dL 5 5 
Acetone 500 mg/L 0.5 5 
n-Propanol 500 mg/dL N/A 5 
 
Preparation of mixed volatile working standard for use with n-propanol: These 
solutions were prepared from stock standards (each at a concentration of 10 g/dL 
w/v) to contain 500 mg/dL of ethanol, isopropanol and methanol and 500 mg/L of 
acetone as summarised in Table 2-1 below. The calibration solutions were diluted 
from the freshly prepared working standard with deionized water. The final 
concentration of the calibration solutions were 10, 25, 50, 80, 100, 200, 300, 400, 
and 500 mg/dL for ethanol, isopropanol and methanol and the equivalent mg/L 
for acetone. The preparation of these calibration solutions is summarised in Table 
2-2.  
Table 2-2:  Preparation of Calibration Standards  
 
 
 
 
 
 
 
Calibrator 
Levels 
Volume of  
working 
standards (mL) 
Volume of 
Water 
(mL) 
[Analytes] 
(mg/dL) 
[Acetone] 
(mg/L) 
BLANK 0 2 0 0 
LEVEL 1 0.02 1.98 5 5 
LEVEL 2 0.04 1.96 10 10 
LEVEL 3 0.1 1.9 25 25 
LEVEL 4 0.2 1.8 50 50 
LEVEL 5 0.32 1.7 80 80 
LEVEL 6 0.4 1.6 100 100 
LEVEL 7 0.8 1.2 200 200 
LEVEL 8 1.2 0.8 300 300 
LEVEL 9 1.6 0.4 400 400 
LEVEL 10 2 0 500 500 
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Preparation of mixed volatile working standard for use with t-butanol: prepared 
as described above but also including n-propanol at a concentration of 500 mg/dL 
as summarised in Table 2-1. The calibration solutions were also diluted as 
described above and their preparation summarised in Table 2-2 
A second set of mixed volatile working standard solutions were prepared as 
described above to make the quality control (QC) samples. QC material was 
prepared in expired (volatile-free) blank blood screened negative for volatiles at 
concentrations of 30, 80, and 300 mg/dL for all volatiles except for acetone, 
which was spiked at 30, 80, and 300 mg/L. The quality control materials were 
aliquoted and transferred to 1.5 mL polypropylene tubes and stored at -22°C. 
Table 2-3 summarises the preparation of the control material. 
Table 2-3:  Preparation of QC Material 
 
 
 
2.2.5 Post-Mortem Case Samples 
One hundred and twenty one preserved post-mortem blood samples were 
selected where there was a history of decomposition as indicated in the post-
mortem report or specimens stored within the laboratory were noted as 
putrefied. All preserved post-mortem blood samples were stored within 
recommended screw-capped vials containing 2 mg/mL of sodium fluoride and 3 
mg/mL of potassium oxalate. 
2.2.6 Instrumentation 
HS-GC-FID analysis was carried out using a Thermo Trace GC 2000 series 
instrument supported with Thermo Co. Chromoquest software version 2.41. The 
instrument has dual column capability connected with a y-splitter and was fitted 
with DB-ALC1 (30 m x 0.53 mm id x 3 µm) and DB-ALC 2 (30 m x 0.53 mm id x 2 
QC 
Points 
Volume of 
working standards 
(mL) 
Volume of 
blood 
(mL) 
[Analyte] 
(mg/dL) 
[Acetone] 
(mg/L) 
QC 1 1.5 23.5 30 30 
QC 2 4 21 80 80 
QC 3 15 10 300 300 
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µm) supplied by J&W Scientific, Agilent technologies, USA. A Compudil 300 
automatic diluter was used for sample preparation. 
2.2.7 Optimisation of GC Conditions 
The FMS in-house method for the analysis of ethanol and acetone using the 
Thermo Trace GC 2000 series achieved separation under isothermal conditions, 
with an oven temperature set at 60°C. In order to achieve optimum separation of 
all six volatiles, several GC program were investigated in combination with 
changes to the flow rate.  
2.2.8 Sample Preparation 
200 µL of blank blood, calibration standard, quality control (QC) or case sample 
was aspirated with 500 µL of internal standard solution using an automatic 
diluter. The mixture was dispensed into a 20 mL head-space vial, then capped 
and loaded onto the HS-GC-FID auto-sampler. 
2.2.9 Method Validation 
Two methods were validated; method 1 involved the use of n-propanol as an 
internal standard, while method 2 involved the use of t-butanol as an internal 
standard. As n-propanol was being used as the internal standard in method 1, it 
was only validated as a volatile of interest using t-butanol as an internal standard 
in method 2.  
Linearity was assessed over a concentration range of 5-500 mg/dL for ethanol, 
methanol, n-propanol and isopropanol and from 5-500 mg/L for acetone. The 
limit of detection (LOD) and limit of quantification (LOQ) were evaluated by 
preparing samples and carrying out a serial dilution of the volatiles in duplicate 
Regression analysis was undertaken, and the LOD and LOQ were calculated in 
accordance with Miller and Miller.(168) 
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LOD was calculated by using Equations 1 and 2: 
YLOD=YB+3SB      Equation 1 
LOD = (YLOD-YB)/m     Equation 2 
 
where YLOD is the standard error, YB is the intercept, and m is the gradient.  
LLOQ values are calculated using the same method of LOD but using 10 times the 
standard error of the regression line. LOQ was calculated using Equations 3 and 4: 
YLOQ=YB+10SB      Equation 3  
LOQ= (YLOG-YB)/m      Equation 4 
         
where YLOQ is the standard error, YB is the intercept, and m is the gradient . 
Intra-day precision (within run precision) was determined at five independent 
preparations of spiked blood control samples at three different concentration 
levels (30, 80, and 300 mg/dL) for ethanol, isopropanol, methanol and n-
propanol, and equivalent in mg/L for acetone. Controls were prepared in 
duplicate and analysed on the same day in the same analyser and same run. The 
percentage coefficient of variance was calculated (%CV), and acceptance criteria 
was set at <15%.(169)  
Inter-day precision (between day precision) was determined at eight independent 
preparations of spiked blood and urine control samples at three different levels 
(30, 80, and 300 mg/dL) for ethanol, isopropanol, methanol and n-propanol, and 
equivalent mg/L for acetone. Controls were prepared in duplicate and analysed 
over eight days. The percentage coefficient of variance was calculated (%CV), 
and acceptance criteria was set at < 15%.(169)  
The recovery and accuracy of the methods were assessed at concentrations of 30, 
80, and 300 mg/dL (n=5) for ethanol, isopropanol, methanol, and n-propanol 
equivalent in mg/L for acetone. Recovery was assessed by calculating the 
percentage of the ratio of the measured value of spiked blood to the measured 
value in water. The accuracy was assessed by calculating the percentage of the 
ratio of measured value of the spiked blood to the expected theoretical value. 
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2.3 Results and Discussion 
2.3.1 Optimisation of GC Conditions 
Table 2-4 summarises the different GC conditions used to optimise the separation 
of the volatiles in both capillary columns. 
Table 2-4: Summary of GC Conditions Used to Optimise Separation of Volatiles 
Conditions 
(1) (2) (3) (4) (5) Final 
RD LD RD LD RD LD RD LD RD LD RD LD 
Oven Temperature 
(˚C) 60 60 40 40 40 40 40 40 40 40 40 40 
 
Right inlet 
Base Temperature  
 (˚C) 
 
200 200 200 200 200 200 200 200 200 200 200 200 
Hydrogen Flow 
(mL/min) 35 35 35 35 35 30 30 35 30 35 30 35 
Air Flow       
(mL/min) 350 350 350 350 350 300 300 350 300 350 300 350 
Right and Left FID 
Base temperature  
(˚C) 
250 250 250 200 250 250 250 250 150 150 250 250 
Split injection mode 
flow rate ( mL/min) 48 48 24 24 20 20 20 20 24 24 24 24 
Carrier gas flow 
rate(mL/min) 16 16 12 12 10 10 10 10 12 12 8 8 
Run Time (min) 6 6 8 8 9 9 10 10 9 9 9 9 
  *RD-Right Detector and LD-Left Detector 
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(C)         (D) 
Figure 2-1:  Separation of Volatiles by HS-GC-FID 
 
Figure 2-1 (A-D) illustrates the separation achieved for each of the volatiles of 
interest in a standard alcohol mixture (water spiked at 300 mg/dL or mg/L for 
acetone) using HS-GC-FID and the final conditions listed in Table 2-4. (A) and (B) 
are chromatograms of the right and the left inlet respectively using n-propanol as 
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an internal standard (method 1). (C) and (D) are chromatograms of the right and 
left inlet respectively using t-butanol as an internal standard (method 2).  (A) and 
(C) were connected to the right inlet with DB-ALC1 while (B) and (D) were 
connected to the left inlet with DB-ALC2.  
Good separation was achieved when using n-propanol as an internal standard 
using DB-ALC1 (Figure 2-1A) and DB-ALC2 (Figure 2-1B). Co-elution of t-butanol 
and acetone could not be resolved with DB-ALC-1 (as illustrated in Figure 2-1C) 
even after adapting the oven and base temperatures, gas and split flow rates and 
trying numerous combinations, as summarised in Table 2-4. 
From the literature, it has been reported that separation of the volatile mixtures 
including t-butanol and acetone can be achieved using RTX-BAC2 (80;95) (30m x 
0.53mm x 2um) and DB-ALC2(170)(see Figure 2-1D) as they are similar stationary 
phases. Separation on RTX-BAC1 (30m x 0.53mm x 3um) was not indicated. 
Although a similar stationary phase to DB-ALC1, the RTX-BAC1 was investigated to 
see if separation of t-butanol and acetone could be achieved, as expected, 
resolution of t-butanol and acetone was not achieved with RTX-BAC1. Separation 
of t-butanol and acetone has been reported using carbowax,(54) in a 6-foot x 1/4 
inch OD glass-packed column.(54)  
Acetonitrile was also included at the start of the project to assess its potential as 
an alternative internal standard but as it also co-eluted with acetone and so no 
further investigation was undertaken.  
The optimised GC parameters are summarised in Table 2-5. The only difference 
(indicated * in Table 2-5) was in relation to the carrier gas flow which was set at 
10 mL/min for method 1 (n-propanol) and 8 mL/min for method 2 (t-butanol). 
This resulted in a slightly different run time of 6 and 9 minutes respectively.   
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Table 2-5:  Optimised GC Parameters used to Evaluate Methods 1 and 2  
Conditions Column 1 Column 2 
GC Parameters 
DB-ALC1 
 (30m x 0.53 mm id x 3µm) 
DB-ALC 2 
 (30m x 0.53 mm id x 2µm) 
Right Detector  Left Detector 
Oven Temperature(˚C) 40ºC 40ºC 
Right Inlet Base Temperature(˚C) 200 200 
Hydrogen Flow (mL/min) 30 35 
Air Flow  (mL/min) 300 350 
Right and Left FID Base temperature(˚C) 250 250 
Post temperature(˚C)/time(minute) 120 for 1 min. 120 for 1 min 
Split/Splitless mode  Split Split 
Split injection mode flow rate ( mL/min) 24 24 
Incubation temperature(˚C) and 
time(minute)  60 for 4 min. 
Carrier gas flow rate(mL/min) 
10* 
8 
10* 
8 
Injection Volume (mL) 2 2 
Run Time (min) 
6* 
9 
6* 
9 
 
2.3.2 Method Validation 
The correlation coefficients (R2) were >0.999 for ethanol, isopropanol, methanol, 
acetone, and n-propanol over the linear range of 10–500 mg/dL (mg/L for 
acetone) using either internal standard, as demonstrated in (Figure 2-2). 
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      (A)                                                              (B) 
Figure 2-2:  Volatile Calibration Curves  
(A) Ethanol, acetone, isopropanol, and methanol using n-propanol as an internal standard 
(Method 1). (B) Ethanol, acetone, isopropanol, methanol and n-propanol using t-butanol as an 
internal standard (method 2). 
 
The LOD for both methods 1 and 2 for ethanol, isopropanol and methanol was 1 
mg/dL and 1 mg/L for acetone for both methods. The LOQ for all volatiles was 
slightly lower when using t-butanol as an internal standard as summarised in 
Table 2-6.  
Table 2-6:  LOD and LOQ for Validated Methods 
Method 
Ethanol 
mg/dL 
Acetone 
mg/L 
Isopropanol 
mg/dL 
Methanol 
mg/dL 
n-propanol 
mg/dL 
LOD LOQ LOD LOQ LOD LOQ LOD LOQ LOD LOQ 
Method 1 
(n-propanol) 1 3 1 4 1 3 1 4 N/A 
Method 2 
(t-butanol) 1 2 1 3 1 2 1 2 1 2 
 
When analysing case samples, results less than 10 mg/dL for ethanol and less than 
10 mg/L for acetone were reported as negative, in accordance with FMS reporting 
criteria. Results of isopropanol, methanol, and n-propanol that were less than the 
LOQ were reported as negative. Determinations greater than the highest 
calibration point were reported as present >500 for all analytes.  A cut-off of 10 
mg/dL was not applied to isopropanol, methanol, and n-propanol to allow a 
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thorough evaluation of the expected concentration range of these analytes in the 
post-mortem blood.  
The intra- and inter-day precision ranged from 1-5% in blood for both methods as 
summarised in Table 2-7.  In general, the %CV when using n-propanol as an 
internal standard, was higher compared with using t-butanol as an internal 
standard. 
Table 2-7:  Intra-day and Inter-day Precision for Volatiles in Blood 
 
Analyte 
 
Internal 
Standard 
30  80  300 
Intraday 
%CV 
(n=5) 
Interday 
%CV 
(n=8) 
Intraday 
%CV 
(n=5) 
Interday 
%CV 
(n=8) 
Intraday 
% CV 
(n=5) 
Interday 
%CV 
(n=8) 
Ethanol       
     
n-propanol 3.17 2.51 3.23 3.34 2.08 3.81 
t-butanol 2.32 1.56 0.77 3.10 1.25 1.15 
Acetone       
     
n-propanol 3.92 3.22 3.91 3.98 1.93 3.86 
t-butanol 3.41 4.49 1.96 2.56 2.81 1.04 
Isopropanol  
  
n-propanol 3.28 2.64 3.39 3.46 1.97 2.87 
t-butanol 2.63 2.07 1.04 2.48 1.95 1.04 
Methanol       
n-propanol 3.48 2.66 3.32 3.41 2.28 4.81 
t-butanol 2.46 2.53 0.80 3.65 1.25 1.23 
n-propanol  t-butanol 2.50 1.22 0.83 2.68 1.64 1.07 
* The unit is mg/dL for all except acetone in mg/L 
The average recovery for spiked blood controls (30, 80, and 300 mg/dL and 
equivalent mg/L in acetone) was 99-107% for method 1 (n-propanol) and 99-109% 
for method 2 (t-butanol). Corresponding accuracy ranged from 95-98% and 95-
101%, for method 1 and 2 respectively. Table 2-8 contains a full list of the 
recovery and accuracy data for each volatile by method.  
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      Table 2-8:  Recovery and Accuracy for Methods 1 and 2 in Blood 
 Method (2)   
t-butanol (%) 
Method (1)  
n-propanol (%) 
BLOOD 
(N=5) 
Control 
mg/dL or 
mg/L 
EtOH ACET IPOL MeOH N-PROP EtOH ACET IPOL MeOH 
Recovery 30 99 104 99 99 99 99 104 99 99 
Accuracy 30 98 96 97 98 98 98 96 97 98 
Recovery 80 102 107 102 101 101 102 107 102 101 
Accuracy 80 95 95 95 96 96 95 95 95 96 
Recovery 300 105 109 103 106 94 105 109 103 106 
Accuracy 300 95 97 97 95 101 95 97 97 95 
 
Although the validation data indicated that t-butanol was marginally better with 
respect to accuracy and precision compared with n-propanol as an internal 
standard, both methods were acceptable for the analysis of volatiles in blood. 
2.3.3 Prevalence of Volatiles in Post-Mortem Blood 
Post-mortem blood samples (n=121) were tested using both methods to evaluate 
the prevalence of each volatile and to compare the results to assess the effect of 
n-propanol present due to post-mortem putrefaction.  
Ethanol was present in 63 samples with concentrations ranging from 10 – 397 
mg/dL (see Table 2-9) and acetone in 46 samples with concentrations ranging 
from 10 – 443 mg/L (see Table 2-10). Methanol and isopropanol were not 
identified in any of the samples tested and n-propanol was present in all samples 
at concentrations ranging from 2 – 14 mg/dL. 
A total of 7 samples were mismatched for ethanol when tested by both methods 
and are highlighted in Table 2-9 and they are in the range from 10-20 mg/dL, 
while ten samples were mismatched for acetone and are highlighted in Table 2-8 
and they are with in the range of 10-12 mg/L.  All mismatched results for ethanol 
and acetone are close to the cut-offs established provide likely explanation for 
the contradictory result.  
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Table 2-9:  Ethanol Concentrations Measured in Post-Mortem Blood by two Methods  
(Methods1=n-propanol; Method2=t-butanol) 
 
 
Table 2-10:  Acetone Concentrations Measured in Post-Mortem Blood two Methods 
Ethanol (mg/dL) 
Case 
Number 
Method 
(1) 
Method 
(2) 
Case 
Number 
Method 
(1) 
Method 
(2) 
Case 
Number 
Method 
(1) 
Method 
(2) 
1 110 100 38 76 75 78 155 162 
2 12 10 39 65 60 82 202 212 
3 10 NEG 40 10 NEG 83 250 257 
5 208 177 43 16 11 86 11 11 
7 13 NEG 45 29 17 87 340 349 
8 297 264 46 20 NEG 93 245 291 
9 NEG 10 47 17 NEG 95 236 241 
10 73 67 50 200 169 96 230 229 
13 60 44 51 73 70 97 265 266 
14 65 61 52 89 92 99 220 234 
15 365 357 54 157 157 101 45 46 
17 173 158 55 162 153 102 28 28 
18 24 23 56 216 210 103 114 117 
20 125 113 58 12 11 109 111 112 
21 30 29 59 233 245 110 78 87 
26 179 172 61 167 191 113 237 152 
27 223 196 62 30 32 115 NEG 11 
28 18 13 64 186 194 116 165 178 
29 19 16 67 296 289 117 380 397 
31 244 216 68 22 22 118 107 115 
33 257 237 72 199 221 121 33 35 
37 12 13 74 185 171  
Acetone (mg/L) 
Case 
Number 
Method 
(1) 
Method 
(2) 
Case 
Number 
Method 
(1) 
Method  
(2) 
Case 
Number 
Method 
(1) 
Method 
(2) 
1 NEG 13 41 NEG 11 83 16 13 
7 14 11 42 NEG 10 86 25 21 
9 405 411 45 296 369 88 21 21 
13 74 59 46 92 134 91 53 36 
14 NEG 11 58 443 372 97 35 40 
21 17 24 60 12 NEG 100 16 13 
22 48 31 62 29 33 102 12 10 
25 NEG 11 64 NEG 10 103 20 17 
26 13 17 65 NEG 11 107 13 12 
31 NEG 11 69 20 21 109 32 34 
32 83 72 70 11 12 110 173 139 
33 NEG 11 71 51 48 111 79 67 
34 36 31 74 11 12 115 48 46 
36 17 18 75 93 64 118 44 38 
37 17 21 76 55 45 121 82 70 
   81 78 79    
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The correlation coefficient (R2) for ethanol was 0.984 (P = 0.084) and 0.954 (P = 
0.536) for acetone. As the P values are greater than 0.05 for both ethanol and 
acetone this indicates that there is no significant difference between the two sets 
of results. 
Figure 2-3 illustrates the correlation between post-mortem blood volatile 
concentrations for ethanol (A) and acetone (B) when measured using n-propanol 
as an internal standard (Result 1) compared with t-butanol (Result 2).  
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Figure 2-3:  Correlation of Ethanol (A) and Acetone (B) concentrations in post-mortem blood 
using n-propanol (Method 1) versus t-butanol (Method 2) as an Internal Standard. 
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Looking more closely at the levels of n-propanol found in post-mortem blood, the 
majority of samples were positive at concentrations close to the LOQ of 2 mg/dL. 
Six cases had elevated n-propanol concentrations ranging from 5 – 14 mg/dL as 
summarised in Table 2-7. 
  Table 2-11:  Elevated Post-mortem Blood n-propanol Concentrations. 
Case 
Number 
Ethanol     
(n-propanol) 
Ethanol     
(t-butanol) 
n-propanol  
(t-butanol) 
Ethanol:               
n-propanol                
Ratio 
18 24 23 5 5 
21 30 29 5 6 
26 179 172 5 34 
72 199 221 9 25 
93 245 291 14 21 
110 78 87 11 8 
 
It has been reported that n-propanol is produced in larger quantities than other 
volatiles and can be detected in postmortem cases when ethanol production is 
suspected. n-propanol concentrations continue to increase even when ethanol 
concentrations have peaked and start to decline. The reason being that n- 
propanol can be produced postmortem from fermentation of amino acids, 
glycerol, fatty acids and could last until the advanced stage of putrefaction.(53)  
It is expected that the presence of n-propanol in putrefied post-mortem blood 
samples will increase the peak area of n-propanol when used as an internal 
standard and this may lead to an underestimate in the calculation of ethanol and 
other volatile concentrations. This is certainly the case with the 3 samples (# 72, 
#93 and #110) in Table 2-7 with higher concentrations of n-propanol. The ethanol 
concentrations are higher by between 11 and 19% when using t-butanol compared 
with n-propanol as an internal standard. However, interpretation of the ethanol 
concentrations in all six cases would not be affected by the presence of n-
propanol due to the putrefaction process.  
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The concentrations in this study are much lower than those reported in previous 
studies, where n-propanol was present in post-mortem blood at concentrations 
ranging from 30 - 70 mg/L. (60;83) However, it should also be noted that there is 
no mention in these publications regarding validation of the methods used to 
quantify n-propanol.   
Nanikawa and Kotoku(171), Nanikawa et al.(172) and Moriya and Hashimoto(97)  
have considered n-propanol as an indicator of post-mortem ethanol production 
and have evaluated the ratio of n-propanol to ethanol in post-mortem blood to 
identify ethanol formation. In these studies, n-propanol was detected in all cases 
of suspected post-mortem ethanol production. Nanikawa and Kotoku(171) also 
suggested that the antemortem ethanol concentration could be estimated from 
the postmortem n-propanol concentration. The authors state that in previous 
studies they found that the potential range of ethanol produced postmortem was 
20 times the amount of n-propanol produced.  
Moriya and Hashimoto(97) concluded that n-propanol cannot be used as an 
internal standard for post-mortem blood samples unless a screen has first been 
conducted to confirm its absence from the specimen.  
Ziavrou et al.(173) suggested that due to significant variability, no valid 
estimation of antemortem ethanol production can be made from the postmortem 
n-propanol and ethanol concentrations. In another study of the relationship 
between ethanol and n-propanol in 62 post-mortem cases, only 17 of the cases 
samples had a detectable level of n-propanol. This finding is in variance with 
Nanikawa et al.(172) whose study indicated that n-propanol could be used as an 
indicator for ethanol formation and further showed that all positive results for 
ethanol were also positive for n-propanol. (83)  
The ratios were calculated for the cases with elevated n-propanol concentrations 
in this study and are summarised in Table 2-7. The ratios range from 5 to 34 but 
with conflicting evidence on the suitability of this ratio for estimating post-
mortem production of ethanol, no further conclusions can be made.  
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Although studies have concluded that n-propanol is produced in all specimens 
along with ethanol(171;172;174), it may in fact be detected in only a small 
percentage of postmortem cases. Further, Schuberth(99) and Kronert et al.(175) 
identified n-propanol in living subjects along with other common volatiles at 
concentrations below the limit of quantitation (10 mg/dL) utilised by many 
forensic toxicology laboratories today.  
The majority of samples in this study had n-propanol concentrations below 5 
mg/dL and must be interpreted with caution as the presence of n-propanol in 
these cases may or may not be as a result of post-mortem production. 
2.4 Conclusion 
Two methods have been developed and validated for the quantitative analysis of 
common volatiles (methanol, ethanol, isopropanol, n-propanol and acetone) 
utilising dual-column HS-GC-FID and two internal standards, namely n-propanol 
and t-butanol. Both methods demonstrated excellent linearity, precision and 
accuracy. The analysis of real case samples to evaluate the meaning of the 
presence of n-propanol in putrefied blood samples found no significant effect 
with levels in this study much lower than previously reported in the literature. 
The correlation between both methods was excellent and although the presence 
of elevated levels of n-propanol resulted in lower ethanol concentrations, the 
decreases had no impact on the interpretation of ethanol in the cases.  
It is however recognised that this study looked at a relatively small data set 
(N=121) and that a much larger study is required to investigate the prevalence of 
n-propanol in putrefied post-mortem blood samples. The findings in this study do 
not support the findings reported by other authors that n-propanol should not be 
used as an internal standard. n-propanol is an ideal internal standard for use with 
the dual-column system used in this study and when applied to the analysis of 
ethanol in blood from living subjects, e.g. road traffic arrests. Although using n-
propanol as an internal standard in post-mortem cases may result in an 
underestimate of the concentration of other volatiles, the risk associated with 
this appears to be minimal with the majority of samples in this study having n-
propanol concentrations close to the LOQ and therefore negligible. It is 
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impractical to consider screening all post-mortem blood samples for the presence 
of n-propanol prior to its use as an internal standard, as has been suggested by 
other authors, but further investigations are required into the prevalence and 
range of concentrations of n-propanol to fully assess the risks associated with the 
use of this volatile as an internal standard to quantify volatiles in post-mortem 
blood.   
The use of ethanol to n-propanol ratio to determine whether ethanol formation 
has occurred is unlikely to be an effective indicator and other criteria must be 
considered, including the case history, condition of the specimens, distribution of 
ethanol in different matrices, presence or absence of ethanol in different 
specimens of the case sample, presence of volatile compounds and the 
concentration of ethanol. (83)  
The internal standard t-butanol offers an effective alternative internal standard 
for the quantification of volatiles in post-mortem blood, including the ability to 
measure n-propanol. However, co-elution with acetone when using DB-ALC1 or 
RTX-ALC1 rules out the use of this internal standard with these types of columns. 
It has also been reported that the level of t-butanol as an internal standard may 
decrease when the fat content of the sample analysed increases. The fat content, 
as well as protein and salt, may affect the accuracy of the head-space method. 
Increased concentrations of ethanol may be a consequence of the stronger 
affinity of isobutyl alcohol when used as an internal standard for fatty aqueous 
slurry. The peak height of t-butanol decreases as the amount of fat in the sample 
analysed is increased.(94)  
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Chapter 3 - Application of a Validated Method for 
the Analysis of Volatiles in Biological Matrices  
3.1 Introduction 
Following validation of a method for the analysis of common volatiles (ethanol, 
methanol, isopropanol, n-propanol and acetone) with t-butanol as an internal 
standard (detailed in Chapter 2), the method was utilized to investigate: 
• The stability of volatiles in blood; 
• The prevalence and correlation of volatiles measured in different 
biological matrices; 
• The evaluation of a commercially available enzymatic assay for screening 
ethanol in blood. 
 
The aims of the stability study were three-fold; to evaluate the effect of 
preservative and antioxidant on the stability of volatiles at different 
concentrations during short-term storage at different temperature conditions; to 
evaluate the stability of ethanol and acetone in paired preserved and 
unpreserved post-mortem blood samples, and to evaluate the stability of ethanol 
in preserved blood after long-term storage at room temperature. 
The aims of the study involving the analysis of volatiles in different biological 
matrices were; to assess the prevalence of volatiles in femoral blood, vitreous 
humour, urine and bile and to evaluate the correlation between the different 
matrices for ethanol and acetone.  
The final study aim was to evaluate the performance of the enzymatic assay 
manufactured by Immunalysis Corporation as a semi-quantitative screening 
method for ethanol in blood, in comparison to the validated method utilising HS-
GC-FID. 
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3.2 The Effect of Preservative and Antioxidant Reagents 
on the Stability of Volatiles in Blood 
3.2.1 Introduction 
An evaluation of the stability of common volatiles in blood was carried out by 
spiking blood at two concentrations with ethanol, isopropanol, acetone, 
methanol and n-propanol and adding different amounts of preservative and 
antioxidant. Spiked samples were stored at room temperature (25±2ºC), 
refrigerated (4±2ºC), and frozen (-22±2ºC). Tests were carried out at regular 
time intervals over a period of 50 days.  
3.2.2 Sample Preparation 
Two 250 mL class A volumetric flasks were labelled (A) and (B). To flask (A), 0.5 
mL of each volatile stock standard (10% w/v) and 0.05 mL of acetone stock 
standard (10% w/v) were added for a final concentration of 20 mg/dL for 
ethanol, isopropanol, n-propanol and methanol, and 20 mg/L for acetone in 
blood.  
To Flask (B), 2 mL of each each volatile stock standard (10% w/v) and 0.2 mL of 
acetone stock standard (10% w/v) were added for a final concentration of 80 
mg/dL for ethanol, isopropanol, n-propanol and methanol, and 80 mg/L for 
acetone.  Each flask was further sub-divided into five 50 mL class A volumetric 
flasks. The flasks were labeled as groups 1, 2, 3, 4, and 5, containing varying 
amounts of preservative (sodium fluoride) and antioxidant (sodium 
metabisulfite) as summarised in Table 3-1. 
         Table 3-1:  Preservative and Antioxidant Concentrations by Group 
Groups PRESERVATIVE (Sodium Fluoride) 
ANTIOXIDANT 
(Sodium Metabisulfite) 
GROUP 1 NO NO 
GROUP 2 0.2% NO 
GROUP 3 0.2% 0.2% 
GROUP 4 1% NO 
GROUP 5 1% 0.2% 
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The concentration of sodium fluoride (NaF) at 0.2% was selected to be 
representative of the commercially available specimen containers submitted to 
Forensic Medicine and Science (FMS) for blood alcohol analysis. From each 
group, 1 mL aliquots were placed into labeled 1.5 mL polystyrene screw cap 
tubes. The aliquots for each group were stored under three different conditions; 
at room temperature (RT) at 25±2 ºC, in the refrigerator at 4±2ºC, and in the 
freezer at -22 ±2ºC as illustrated in Figure 3-1. Temperatures were monitored by 
using a certified calibrated thermometer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1:  Stability Study Design and Spiked Sample Preparation Guide 
 
3.2.3 Results and Discussion 
Figure 3-2 illustrates the changes observed in volatile concentrations for blood 
spiked at 80 mg/dL (mg/L for acetone) and stored at room temperature 
(25±2°C).  
 Stability Study Design  
 
20 and 80 mg/dL for all in mg/L for acetone  
Groups NaF    ANTIOXIDANT  
G 1 NO NO 
G 2 0.2% NO 
G 3 0.2% 0.2% 
G 4 1% NO 
G 5 1% 0.2% 
G1 
20 mg/dL  
G2 G3 G4 G5 
 RT@25±2ºC    
4±2ºC    
  
-20Cº±2
  
 -22±2ºC 
 
50 mL 
G2 G3 G4 G5 G1 
80 mg/dL  
50 mL  
DAY  
[1] [4] [7] [10]  
[15] [23] [30]  
[40] [50] 
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(A) Ethanol, (B) Acetone, (C) Isopropanol related to figure 3-2 continued next page 
Stability of Volatiles Spiked in Blood at Room Temperature (25 ±2°C)  
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Key: 
—•—   (No preservative)  
—■—    (0.2%  NaF)                                 —♦—   (0.2%  NaF + antioxidant)      
—▲—   (1%     NaF)                          —►—  (1%     NaF + antioxidant) 
 
Figure 3-2:  Stability of Volatiles Spiked in Blood at Room Temperature (25 ±2°C)  
(Spiked at 80 mg/dL and equivalent mg/L for acetone for (A) Ethanol, (B) Acetone, (C) 
Isopropanol, (D) n-propanol and (E) Methanol). 
 
The corresponding figures and tables summarizing the changes observed in 
volatile concentrations for blood spiked at 20 and 80 mg/dL (mg/L for acetone) 
following storage at different temperatures are summarized in Appendix 3-1.  
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Ethanol levels initially increased and then decreased when stored in the 
refrigerator or at room temperature with or without preservative. The observed 
increase was greater at room temperature when no preservative or antioxidant 
was present as illustrated in Figure 3-2 A. The subsequent ethanol decrease is 
most likely due to oxidation of ethanol to acetaldehyde. However, the improved 
stability of ethanol in the presence of the sodium fluoride preservative was 
unaffected by the presence or absence of the antioxidant sodium 
metabisulphite.  
At room temperature, acetone concentrations increased and isopropanol levels 
decreased from the start of the stability study for all groups. This inversely 
proportional relationship between acetone and isopropanol is most likely 
explained by the oxidation of isopropanol to acetone. This is further supported 
by the less-pronounced increase in acetone concentrations for the samples 
containing the antioxidant, sodium metabisulphite as illustrated in Figures 3-2 B 
and 3-2 C. 
n-Propanol mirrored the same profile as that observed with isopropanol, namely 
a decreasing concentration as seen in Figure 3-2D. The decrease was less 
pronounced when the samples were stored in the refrigerator or freezer and 
when both sodium fluoride and sodium metabisulphite were present. 
Methanol was stable under all conditions and was the only volatile of those 
studied whose stability was unaffected by temperature, preservative or 
antioxidant as illustrated in Figure 3-2 E. 
All volatiles were stable in blood over the study period of 50 days when stored in 
the freezer (-22±2ºC) whether preservative or antioxidant was present or not. 
Samples spiked at 20 mg/dL (mg/L for acetone) had a similar pattern to samples 
spiked at 80 mg/dL (mg/L for acetone).  
The stability study was also carried out using method 1 (n-propanol as an 
internal standard and not an analyte of interest). Similar results were also 
observed and are summarized in Appendix 3-2. 
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3.3 Stability of Ethanol and Acetone in Paired Preserved 
and Unpreserved Post-Mortem Blood 
3.3.1 Introduction 
Post-mortem examinations carried out in the West of Scotland requiring 
toxicological investigation are routinely tested for alcohol and drugs. Femoral 
blood samples are collected and submitted as both preserved and unpreserved 
samples. The preserved samples are stored within screw cap vials containing 2 
mg/mL of sodium fluoride and 3 mg/mL of potassium oxalate. Following 
submission to the toxicology laboratory within FMS, the preserved sample is 
tested for alcohol and may also be tested for known labile drugs, e.g. cocaine, 
while the unpreserved blood sample is tested for a wide range of prescription 
and illicit drugs. Samples are stored in the refrigerator for approximately 1 to 2 
months while investigations are on-going before being moved to a freezer for 
long-term storage.  
The analysis of paired preserved and unpreserved post-mortem samples from a 
range of cases will provide an insight into the role of the preservative on the 
stability of ethanol and acetone in real cases.  
3.3.2 Methodology 
Seventy-one paired preserved and unpreserved post-mortem blood samples were 
re-analyzed after storage in the refrigerator for six months and a further 10 
months following storage at -22 ±1ºC. The selection criteria required paired 
preserved and unpreserved post-mortem blood, stored in the refrigerator for 6 
months with a selection of cases that were positive and negative for ethanol in 
post-mortem blood.   
The initial analysis was carried out by FMS Technical Staff in accordance with 
the ISO/IEC 17025 accredited method for the analysis of ethanol in post-mortem 
blood and urine. Acetone was quantified in these cases using a positive control 
and the calibration curve for ethanol which was linear over the range of 0-400 
mg/dL.  
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The first re-test of the preserved blood and paired unpreserved blood six months 
later was carried out using the validated method described in Chapter 2 utilising 
n-propanol as internal standard. The second re-test after a further 10 months 
was carried out using the validated method described in Chapter 2 utilising t-
butanol as internal standard including n-propanol as an analyte. 
3.3.3 Results and Discussion 
Table 3-2 and 3-3 summarizes the results of the paired samples positive for 
ethanol and/or acetone. All samples with volatile concentrations lower than 10 
mg/dL (or 10mg/L for acetone) were classified as negative. A total of ten cases 
were negative for all volatiles. The stability of methanol, isopropanol and n-
propanol could not be assessed as too few samples were positive for these 
volatiles. Four cases were positive for methanol, two for isopropanol and two for 
n-propanol at low concentrations ranging from 11 to 29 mg/dL.  
The results for the original test of the preserved blood sample (OP) are included 
for ethanol and acetone along with subsequent analysis (after 6 months 
refrigeration) of both preserved and unpreserved blood (P1, UP1) and re-analysis 
(after a further 10 months in the freezer) of both the preserved and unpreserved 
blood (P2, UP2). 
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Table 3-2:  Ethanol Concentrations in Paired Post-Mortem Blood Samples. 
Ethanol (mg/dL) 
Case  
Number OP P1 P2 UP1 UP2 
Case 
Number OP P1 P2 UP1 UP2 
1 158 73 70 141 120 37 374 340 349 412 355 
2 136 89 92 118 131 38 N N N N N 
3 N N N 11 10 39 N N N 11 11 
4 186 157 157 128 142 41 N N N N N 
5 223 162 153 222 228 42 16 N N N 10 
6 220 216 210 196 209 43 260 245 291 212 272 
7 N N N N N 44 26 N N N N 
8 23 12 11 24 23 45 325 236 241 N N 
9 280 233 245 286 340 46 226 230 229 222 237 
10 N N N 22 15 47 308 265 266 149 153 
11 323 167 191 256 270 48 40 N N N N 
12 71 30 32 45 54 49 191 220 234 49 52 
14 246 186 194 223 211 50 17 N N N N 
15 N N N N N 51 20 45 46 80 94 
17 362 296 289 365 377 52 70 28 28 73 81 
18 44 22 22 43 46 53 128 114 117 126 138 
19 N N N N N 54 N N N 21 24 
20 N N N N N 57 N N N N N 
21 N N N N N 58 N N N 21 30 
22 231 199 221 172 189 59 134 111 112 138 145 
24 278 185 171 256 264 60 131 78 87 126 157 
25 17 N N 24 21 61 N N N N N 
26 N N N N N 62 N N N N N 
27 N N N 17 17 63 174 237 152 169 173 
28 187 155 162 141 146 64 N N N N 10 
29 N N N N N 65 23 N 11 53 56 
31 N N N N N 66 212 165 178 185 185 
32 236 202 212 14 46 67 391 380 397 406 436 
33 297 250 257 268 277 68 N 107 115 33 36 
34 10 N N 21 24 71 54 33 35 30 27 
36 19 11 11 N N       
(OP - Original results for the preserved sample; (P1 & P2) preserved blood retested after 6 months and 
a further 10   months; (UP1 & UP2) corresponding unpreserved blood samples). 
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Table 3-3:  Acetone Concentrations in Paired Post-Mortem Blood Samples 
Acetone (mg/L) 
Case 
Number 
OP P1 P2 UP1 UP2 Case 
Number 
OP P1 P2 UP1 UP2 
1 N N N 15 15 37 N N N N N 
2 N N N N N 38 N 21 21 10 11 
3 N N N N N 39 N N N N N 
4 N N N 10 12 41 43 53 36 70 55 
5 N N N 23 N 42 N N N N N 
6 N N N N N 43 N N N N N 
7 N N N 16 11 44 N N N N N 
8 260 443 372 310 258 45 N N N 10 12 
9 N N N N N 46 N N N N N 
10 N 12 N 10 11 47 N 35 40 41 42 
11 N N N N N 48 N N N N N 
12 93 29 33 N N 49 N N N N N 
14 N N 10 10 11 50 N 16 13 162 101 
15 N N 11 14 18 51 N N N N N 
17 N N N N N 52 N 12 10 N N 
18 N N N N N 53 N 20 17 17 19 
19 N 20 21 11 12 54 N N N N N 
20 N 11 12 22 18 57 N 13 12 10 11 
21 N 51 48 54 50 58 N N N N N 
22 N N N N N 59 N 32 34 25 29 
24 N 11 12 N N 60 N 173 139 24 32 
25 30 93 64 40 31 61 94 79 67 70 73 
26 N 55 45 40 43 62 N N N 19 10 
27 N N N N N 63 N N N N N 
28 N N N N N 64 N N N N N 
29 N N N 21 18 65 38 48 46 46 49 
31 63 78 79 107 75 66 N N N N 10 
32 N N N N N 67 N N N N N 
33 N 16 13 13 15 68 N 44 38 N N 
34 N N N N N 71 N 82 70 13 15 
36 28 25 21 32 27       
(OP - Original results for the preserved sample; (P1 & P2) preserved blood retested after 6 months 
and a further 10   months; (UP1 & UP2) corresponding unpreserved blood samples). 
 
 
3.3.3.1 Ethanol Stability in Preserved Blood After 6 Months Refrigeration 
and 10 Months in the Freezer 
The mean ethanol concentration of the original results (OP) was 109 mg/dL. The 
mean ethanol results for preserved and unpreserved samples stored for 6 months 
refrigeration and 10 months in the freezer were 90, 92, 90 and 96 for P1, P2, 
UP1 and UP2 respectively. The percentage of mean loss ranged between 22-27% 
of preserved and unpreserved samples.  
A total of 40 preserved blood samples originally tested (OP) positive for ethanol. 
Following re-analysis after a period of 6 months in the refrigerator, 90% (N=36) 
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had lower levels of ethanol (P1), indicating loss of ethanol during the six-month 
storage period. A loss of greater than 20% was evident in 58% (N=21) of these 
samples. Ethanol production was also evident in five cases: four samples had 
higher levels of ethanol (#46, #49, #51 and #63), while case #68, originally 
negative had an ethanol concentration of 107 mg/dL when retested. This 
concentration increased further to 115 mg/dL after an additional 10 months 
storage in the freezer (P2). Thirty cases were negative for all tests, indicating no 
ethanol formation.  
The correlation coefficient (R2) was calculated when comparing the different 
data sets and fitted line plots were plotted as illustrated in Figure 3-3 (A-D) for 
ethanol and Figure 3-4 (A-D) for acetone. A summary of the values are listed in 
Table 3-3 along with the P values.  
An assessment of the correlation between the results generated for the original 
preserved blood ethanol concentrations (OP) compared with those measured in 
the same preserved blood sample after 6 months (P1) and a further 10 months 
(P2) storage are summarized in Table 3-3. Although the values for the original 
test (OP) versus P1 and P2 were 92.6% and 92.9%, respectively, the P values 
were less than 0.05 at the 95% confidence interval, indicating significant 
differences between the initial analysis and the two subsequent analyses.  
Figure 3-3A illustrates the correlation between the ethanol concentrations in the 
original preserved blood (OP) and the reanalysis after 6 months in the 
refrigerator. Although ethanol loss was observed in most of the cases over the 
initial 6 months refrigeration, no significant differences in ethanol concentration 
were observed following a further 10 months storage in the freezer (P1 versus 
P2,  = 98.5%, p = 0.993). 
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Table 3-4:  Summary of Correlation Data for Ethanol in Blood. 
 Ethanol Acetone 
  Regression Equations 
P 
value  
Regression 
Equations 
P 
value 
OP vs. P1 0.926 OP=8.353+1.110P1 0.00  0.724 OP=-1.528+0.5136P1 0.006 
OP vs. P2 0.929 OP=8.398+1.088P2 0.00  0.738 OP = - 2.081 + 0.6196P2 0.005 
P1 vs. P2 0.985 P1=0.754+0.9743P2 0.334  0.993 P1=-0.8029+1.192P2 0.037 
P1 vs. UP1 0.766 P1=11.38+0.8500UP1 0.947  0.696 P1 =  1.256 + 1.108 UP1 0.422 
P2 vs. UP2 0.775 P2=9.366+0.8436UP2 0.570  0.787 P2=-0.577+1.220UP2 0.330 
UP1 vs. UP2 0.984 UP1=-1.291+0.9580UP2 0.334  0.973 UP1=-1.053+1.220UP2 0.075 
(P value of paired preserved (P) post-mortem blood and  unpreserved(UP). OP: Original   
preserved blood.  P1: Preserved blood retested after 6 months in fridge. P2: Preserved 
blood retested after additional 10 months in freezer. 
 
3.3.3.2 Ethanol Stability in Unpreserved Blood after 10 Months in the Freezer 
An excellent correlation (R2= 98.4%) was observed (see Figure 3-3D) for the 
unpreserved blood ethanol concentrations measured following 10 months of 
storage in the freezer (UP1 versus UP2) with a P value of 0.334 indicating no 
significant differences. The unpreserved blood samples were not analysed at the 
same time as the original preserved blood so no assessment of the stability of 
ethanol in unpreserved blood following 6 months refrigeration can be 
undertaken.  
3.3.3.3 Ethanol Stability in Preserved Blood versus Unpreserved Blood 
When comparing the unpreserved blood (UP) ethanol concentrations with those 
of the original preserved samples (OP), 70% (N=28) of preserved samples and 60% 
(N=24) of unpreserved samples had lower levels of ethanol, with about 54% 
(N=15) of these samples recording a loss of greater than 20% over the six-month 
period. Ethanol production was also evident in 18 and 23 cases respectively for 
both UP1 and UP2 with 7 of these cases originally negative having ethanol 
concentrations ranging from 10 to 36 mg/dL when retested. 
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As would be expected, the preserved samples demonstrated less variability than 
the unpreserved samples regarding formation of ethanol; however, both 
preserved and unpreserved samples had significant loss of ethanol over the 
period of six months when stored in a refrigerator. There are a number of 
factors that must also be considered when interpreting the data. The 
unpreserved samples are commonly retained within Forensic Medicine and 
Science for analysis of a range of analytes and as such the vials are opened and 
closed on numerous occasions depending on the number of tests carried out, 
increasing the risk of ethanol loss due to evaporation. In addition, the 
circumstances surrounding the cases were not considered (i.e., body badly 
decomposed).  
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(D) 
Figure 3-3:  Fitted Line Plots of Ethanol concentrations in Paired Blood Samples. 
(A) Original [EtOH] in preserved blood(OP) versus preserved blood [EtOH](P1) after 6 
months in the refrigerator (B) Preserved blood [EtOH]  versus unpreserved [EtOH]  following 
16 months storage(6 months fridge+ 10 months freezer). (C) preserved blood [EtOH](P1) 
versus preserved blood [EtOH](P2) after 10 months storage in freezer. (D) Unpreserved 
blood[EtOH] (UP1) versus Unpreserved blood [EtOH](UP2) after 10 months storage in 
freezer.  
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Figure 3-4:  Fitted Line Plots of Acetone concentrations in Paired Blood Samples. 
(A) Original [Acetone] in preserved blood(OP) versus preserved blood [Acetone](P1) after 6 
months in the refrigerator (B) Preserved blood [Acetone]  versus unpreserved [Acetone]  
following 16 months storage(6 months fridge+ 10 months freezer). (C) preserved 
blood[Acetone](P1) versus preserved blood [Acetone](P2) after 10 months storage in 
freezer. (D) Unpreserved blood[Acetone EtOH] (UP1) versus Unpreserved blood [Acetone 
EtOH](UP2) after 10 months storage in freezer. 
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3.3.3.4 Acetone Stability in Preserved Blood versus Unpreserved Blood 
The mean acetone concentration of the original results (OP) was 11 mg/L. The 
mean acetone results for preserved and unpreserved samples stored for 6 
months refrigeration and 10 months in the freezer were 24, 21, 21 and 18 for P1, 
P2, UP1 and UP2 respectively.   
Acetone was detected in 35 cases at concentrations ranging from the LOQ to 443 
mg/L, however acetone was not present in all of the paired samples. The 
correlation between the original acetone concentration (OP) and the re-analysis 
after 6 months (P1) and 10 months (P2), as illustrated in Figures 3-4 A and C 
respectively, was greater than 70% but with significant differences (p<0.05) in 
the measured concentrations. However, the linear range and LOQ of the original 
analysis were not comparable with the current method developed and reported 
here. As a consequence, further comparison of the significance of the results in 
relation to stability of acetone is not possible. 
When comparing acetone concentrations in preserved blood (P1 versus P2) and 
unpreserved blood (UP1 versus UP2) after a period of 10 months storage in the 
freezer, 17 preserved and 13 unpreserved samples showed acetone loss of on 
average 20% and 26%, respectively. Acetone production was evident in 7 
preserved samples and 17 unpreserved samples with gains in the range of 9-14%.  
The values for P1 versus P2 and UP1 versus UP2 were 99.3% and 97.3% 
respectively with corresponding P values >0.05 indicating that there is a good 
correlation between the two results. This in turn means that acetone 
concentrations may not increase or decrease significantly when samples are 
stored for over 10 months in the freezer. 
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3.4 Stability of Ethanol in Preserved Blood Following 
Long-Term Storage at Room Temperature 
3.4.1 Introduction 
Blood samples collected from individuals arrested under section 5 of the Road 
Traffic Act 1988 (United Kingdom) are regularly submitted to Forensic Medicine 
and Science for quantitative analysis of ethanol. Prior to 2007, on completion of 
the case, the samples were removed from cold storage and kept at room 
temperature as no disposal process was in place. This provided an ideal study to 
evaluate the stability of ethanol in preserved blood samples that were stored in 
crimped cap vials containing sodium fluoride and potassium oxalate at 
concentrations ranging from 1 to 2%.   
3.4.2 Methodology 
Two hundred and nineteen preserved blood samples collected from individuals 
arrested under section 5 of the Road Traffic Act 1988 (United Kingdom) were 
analysed for the presence of alcohol on receipt within the laboratory of Forensic 
Medicine and Science (Result 1). The blood samples were refrigerated until the 
case was heard in court (approximately 1 month after analysis). Following 
completion of the court case the samples were removed from the refrigerator 
and stored at room temperature for varying periods of time spanning 5 years. 
The blood samples were removed from long-term storage at room temperature 
and re-analysed (Result 2).  
The initial analysis (Result 1) was carried out by FMS Technical Staff prior to 
attaining ISO/IEC 17025 accreditation for the analysis of ethanol in blood. 
Acetone was quantified in these cases using a positive control and the 
calibration curve for ethanol (linear over the range of 0-400 mg/dL). 
The re-test (Result 2) of the blood was carried out using the validated method 
described in Chapter 2 utilising n-propanol as internal standard and HS-GC-FID. 
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3.4.3 Results and Discussion  
Preserved blood samples (N=219) collected from individuals arrested under 
section 5 of the Road Traffic Act were initially tested following short-term 
storage (Result 1) in a refrigerator and then re-tested after long-term storage of 
between 1 and 5 years (Result 2) at room temperature. The correlation 
coefficient (R2) between the ethanol concentrations measured was 0.85 as 
illustrated in Figure 3-5 with a P value of <0.05. Out of the 219 samples tested, 
208 when retested were positive at concentrations >10 mg/dL. The mean and 
median ethanol concentration of the original results were 102 and 88 
respectively and for retested results the mean and median were 71 and 60 
respectively. The vast majority (85%) had an ethanol recovery greater than 50% 
as summarized in Figure 3-6.  
Five samples were negative for ethanol at both the initial and second analysis 
times. Only 1% (N=3) of samples demonstrated ethanol formation Figure 3-7. One 
sample was originally negative for ethanol but when retested had an ethanol 
concentration of 76 mg/dL and two samples positive for ethanol at 
concentrations of 19 and 65 mg/dL after the initial analysis had significant gains 
when retested with ethanol concentrations of 46 (247%) and 138mg/dL (212%) 
respectively. This is most likely as a result of a lack of sufficient preservative in 
the collection vial or the blood in the collection vial was not mixed appropriately 
with preservative and anticoagulant powder.   
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Figure 3-5:  Correlation Between Road Traffic [Ethanol] following Long-Term Storage  
(Result 1 versus Result 2) 
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Figure 3-6:  Road Traffic Preserved Blood Percentage Recovery of Ethanol  
(Result 1 versus Result 2). 
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Figure 3-7:  Road Traffic Preserved Blood - Percentage Recovery of Ethanol following Long-
Term Storage at Room Temperature. 
 
 
With the exception of the two samples with excessively high gains in ethanol 
concentration, the average recovery of ethanol was 71% with a standard 
deviation of 48.3, following long-term storage from between 1 and 5 years. As 
can be seen in Figure 3-7 the variation in recovery increases in proportion with 
the increasing number of years in storage. Only 23% of the samples retested 
after more than 3 years in storage at room temperature had recoveries of 
greater than 50% of the initial ethanol concentration.   
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3.5 Evaluation of the Prevalence of Volatiles in Urine, 
Vitreous Humour and Bile and their Correlation with 
Femoral Blood. 
3.5.1 Introduction 
Interpretation of alcohol concentrations in post-mortem cases is more 
challenging if there is insufficient information about the type of death, the stage 
of the ethanol distribution in the body, incubation period, storage conditions and 
temperature of the specimens. Analysis of other body fluids, mainly vitreous 
humour, bile and urine, in addition to blood samples, may help with 
interpretation. Ethanol distributes throughout other tissue or fluids according to 
their water content. The body fluids and tissues containing more water will 
contain more alcohol. Even within the blood, there may be differences in 
ethanol concentrations depending on the stage of absorption.(46)  
Samples of blood and urine are regularly submitted to FMS for the determination 
of volatiles, with ethanol and acetone most commonly identified but vitreous 
humour and bile are only submitted in a small proportion of cases. The sample 
database within FMS was used to extract all cases where alternative matrices 
(vitreous humour and bile) were analysed for volatiles in addition to femoral 
blood. The prevalence of volatiles in these cases was evaluated and any 
correlations between urine, vitreous humour, bile and femoral blood 
investigated. 
3.5.2 Methodology 
The method used for the analysis of ethanol and acetone was fully validated, 
robust, and sensitive and was carried out by FMS Technical Staff. Acetone was 
quantified in these cases using a positive control and the calibration curve for 
ethanol (linear over the range of 0-400mg/dL).(132)  
Paired vitreous humour and blood (N=109), bile and blood (N= 20) and urine and 
blood (N=942) post-mortem case samples were analysed using HS-GC-FID.   
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Comparisons between the paired matrices were carried out by calculating the 
correlation coefficient (R2) and P values to evaluate if there were significant 
differences between the volatile concentrations in both matrices.  
The ratio of the ethanol and acetone concentrations in vitreous humour, bile and 
urine versus those in femoral blood were calculated. The ratio range, at a 95% 
95% confidence interval (95% CI), were also calculated for both ethanol and 
acetone. The calculated ratios were compared with those published in the 
literature.  
3.5.3 Volatile Standards 
n-Propanol was used as the internal standard as described in section 2.2.3. 
Certified solutions of ethanol were purchased from LGC Standards (Teddington, 
UK) at concentrations of 10, 25, 50, 80, 100, 200, 300 and 400 mg/dL. Quality 
control (QC) samples were purchased from Medichem (Germany) at 
concentrations of 30, 80 and 300 mg/dL. Acetone was quantified in these cases 
using a positive control (water spiked at 250 mg/L) and extrapolated using the 
ethanol calibration curve. 
3.5.4 Results 
3.5.4.1 Comparison of Ethanol Concentrations in Paired Blood and Vitreous 
Humour Samples 
Of the 109 paired blood and vitreous humour (VH) samples, 89% of the pairs 
were positive (N=43) or negative (N=54) for ethanol in both matrices as 
summarised in Table 3-5. The remaining 12 paired case samples were negative in 
vitreous humour and positive in blood with ethanol concentrations ranging from 
12-70 mg/dL. The P value for VH versus blood was >0.05 with a value of 94.4% as 
summarised in Table 3-6 and illustrated in Figure 3-8. The mean ratio of VH:BAC 
in this study was 1.13 with a range of 1.00-1.26 in comparison with published 
ratios ranging from 0.63 – 1.75 (n=672) with mean value 1.19, median 1.18.(71) 
in another study the ratio ranged from 1.0 to 2.20(n=209) mean value 1.24, 
median 1.19.(73). 
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Figure 3-8:  Comparison of Ethanol Concentrations in Paired Blood and Vitreous Humour 
Samples  
 
 
Table 3-5:  Comparison of Positive and Negative Results for Ethanol in BloodVersus 
Vitreous Humour 
ETHANOL 
N= 109 Positive Vitreous Humour 
Negative Vitreous 
Humour 
Positive Blood 43 12 
Negative Blood 0 54 
 
 
Table 3-6:  Summary of Mean Ethanol Ratio and Correlation for Blood in Comparison to 
Vitreous Humour (VH), Bile and Urine. 
Ethanol 
Ratio 
Mean 
Ratio/(n)  
Median St Dev. SE 
Mean 95% CI 
Regression Equations  
 P value 
VH/Blood 1.13 (n=43) 1.11 0.4319 0.0659 
1.00-1.26 EtOH _Blood =  7.584 + 
0.8449 EtOH_VH 94.4 0.356 
Bile/Blood 1.04 (n=13) 1.07 0.469 0.135 
0.74-1.33 EtOH _Blood =  7.30 + 
0.7739 EtOH_Bile 92.0 0.122 
Urine/Blood 1.35 (n=461) 1.31 1.0917 0.0491 
1.25-1.44 EtOH _Blood =  0.559 + 
0.7607 EtOH_Urine 90.0 0.0001 
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3.5.4.2 Comparison of Ethanol Concentrations in Paired Blood and Bile 
Samples 
Of the 20 paired blood and bile samples, 80% of the pairs were positive (N=13) or 
negative (N=3) for ethanol in both matrices as summarised in Table 3-7. The 
remaining 4 paired case samples were negative in blood and positive in bile with 
ethanol concentrations ranging from 10-39 mg/dL.  
The P value for bile versus blood was >0.05, this indicates no significant 
difference between the ethanol concentrations in blood and bile.  The value of 
92% as summarised in Table 3-6 and illustrated in Figure 3-9. The mean ratio of 
bile to blood in this study was 1.04 with a range of 0.74-1.33 in comparison with 
published ratios ranging from 0.32 -2.91.(75) 
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Figure 3-9:  Comparison of Ethanol Concentrations in Paired Blood and Bile Samples 
 
Table 3-7:  Comparison of Positive and Negative Results for Ethanol in Blood Versus Bile 
ETHANOL 
N = 20 Positive Bile Negative Bile 
Positive Blood 13 0 
Negative Blood 4 3 
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3.5.4.3 Comparison of Ethanol Concentrations in Paired Blood and Urine 
Samples 
Of the 942 paired blood and urine samples, 85% of the pairs were positive 
(N=461) or negative (N=338) for ethanol in both matrices as summarised in Table 
3-8. Of the remaining paired case samples, 34 were negative in urine and 
positive in blood with ethanol concentrations ranging from 10-303 mg/dL, and 
109 were negative in blood and positive in urine with ethanol concentrations 
ranging from 10-174 mg/dL. The P value for urine versus blood was <0.05 with a  
value of 90% as summarised in Table 3-6 and illustrated in Figure 3-10. The mean 
ratio of urine to blood in this study was 1.35 with a range of 1.25-1.44 in 
comparison with published ratios ranging from 0.53 -2.17.(61;67;68). In another 
study the first void ethanol mean ratio was 1.34 with the range of 1.68-1.75 and 
the second void ethanol urine to blood ratio was 1.22 with a range of 1.43-1.47. 
(61) 
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Figure 3-10:  Comparison of Ethanol Concentrations in Paired Blood and Urine Samples 
 
Table 3-8:  Comparison of Positive and Negative Results for Ethanol in Blood Versus Urine 
ETHANOL 
N = 942 Positive Urine Negative Urine 
Positive Blood 461 34 
Negative Blood 109 338 
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3.5.4.4 Comparison of Acetone Concentrations in Paired Blood and Vitreous 
Humour and Paired Blood and Bile Samples 
Tables 3-9 and 3-10 summarise the results for acetone in paired blood and 
vitreous humour samples and paired blood and bile samples respectively. Of the 
104 paired blood and vitreous humour samples, 100% of the pairs were positive 
(N=2) or negative (N=102) for acetone in both matrices, while 84% of the paired 
blood and bile samples were positive (N=3) or negative (N=13) for acetone in 
both matrices. Of the remaining paired blood and bile samples, 2 were negative 
in bile but positive in blood with acetone concentrations of 44 and 62 mg/L. One 
case was negative in blood <10 mg/L but positive in bile with an acetone 
concentration of 15 mg/L.  
Table 3-11 summarises the ratios and correlations values for both vitreous 
humour and bile acetone concentrations versus blood acetone concentrations. 
The P values for both were >0.05 for both which indicates that there is no 
significant difference between two sets of results (VH-Blood and Bile-blood). The 
mean ratio values which was 2.61 for VH: blood acetone concentrations and 0.54 
for bile: blood acetone concentrations.  
Table 3-9:  Comparison of Positive and Negative Results of Acetone in Blood versus 
Vitreous Humour 
ACETONE 
N = 104 Positive Vitreous Humour 
Negative Vitreous 
Humour 
Positive Blood 2 0 
Negative Blood 0 102 
 
Table 3-10:  Comparison of Positive and Negative Results of Acetone in Blood Versus Bile 
ACETONE 
N = 19 Positive Bile Negative Bile 
Positive Blood 3 2 
Negative Blood 1 13 
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Table 3-11:  Summary of Mean Acetone Ratio and correlation for Blood in Comparison to 
Vitreous Humour (VH), Bile and Urine. 
Acetone 
Ratio 
Mean 
Ratio/(n)  Median St Dev. 
SE 
Mean 95% CI 
Regression Equations 
 
 P value 
VH/Blood 2.61  (n=2) 
2.61 1.85 1.31 0-19.27 
Acetone 
_Blood=0.2351+0.3820 
Acetone_VH 
74.4 0.248 
Bile/Blood 0.54  (n=3) 
0.64 0.281 0.126 0-1.08 
Acetone _Blood 
=6.083+1.749 
Acetone_Bile 
0.41 0.064 
Urine/Blood 2.11 (n=70) 
1.56 2.262 0.270 1.57-2.65 
Acetone _Blood 
=1.101+0.5021 
Acetone_Urine 
0.69 0.0001 
 
3.5.4.5 Comparison of Acetone Concentrations in Paired Blood and Urine 
Samples 
Of the 934 paired blood and urine samples, 96% of the pairs were positive (N=70) 
or negative (N=828) for acetone in both matrices as summarised in Table 3-12. 
Of the remaining paired case samples, 7 were negative in urine and positive in 
blood with acetone concentrations ranging from 56-339 mg/L, and 29 were 
negative in blood and positive in urine with acetone concentrations ranging from 
25-861 mg/L.  There were three samples not included in the calculation and 
were considered as outliers and they were at concentrations of 1482 mg/L in 
urine with a corresponding negative blood), 2879 mg/L in urine and 
corresponding negative blood) and 1581 mg/L in urine and 117 mg/L 
corresponding in blood). (The P value for urine versus blood was <0.05 with a 
value of 68.6% as summarised in Table 3-11 and illustrated in Figure 3-11. The 
mean ratio of urine to blood in this study was 2.11 with a range of 1.57-2.65.  
9008007006005004003002001000
700
600
500
400
300
200
100
0
-100
A c e t o ne _ur ine
A
ce
to
n
e
-B
lo
o
d
R-S q 68.9%
Ac eto n e-B lo o d  =   1 .1 0 1  +  0 .5 0 2 1  Ac eto n e_ u rin e
 
Figure 3-11:  Comparison of Acetone Concentrations in Paired Blood and Urine 
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Table 3-12:  Comparison of Positive and Negative Results for Acetone in Blood Versus Urine 
ACETONE 
N = 934 Positive Urine Negative Urine 
Positive Blood 70 7 
Negative Blood 29 828 
 
 
3.5.5 Discussion 
Ethanol concentrations in vitreous humour and bile samples were not 
significantly different from the blood ethanol concentrations. The ratio of VH 
ethanol concentration to blood ethanol concentration  was reported to be higher 
during the post absorption phase as a result of the higher percentage of water in 
VH than in blood.(73) The mean ratio of VH/Blood in this study was 1.13 which is 
in agreement with published ratios as previously indicated.  It was also observed 
that 12 of the 109 case samples were negative for ethanol in VH but positive in 
the paired blood sample. The most likely explanation for this is neo formation of 
ethanol in blood by microorganisms or that the death occurred before 
equilibrium was achieved.  
The bile to blood ratio range of ethanol concentration obtained from this study 
was within the published range. Four bile samples were positive for ethanol but 
negative in paired blood samples. A possible reason behind this could be that the 
sample was collected during the post-absorption phase after ethanol was 
eliminated from the blood. There was a significant difference between urine and 
blood ethanol concentration, although the R2 was approximately 90% and the 
ratio of urine to blood was in agreement with published ratios. 34 out of 942 
case samples were negative for ethanol in urine but positive in blood. This may 
be due to several factors, such as formation of ethanol in blood due to bacterial 
action; or death occurred in the pre-absorption phase; or the urine may be 
diluted or contaminated. It could also be due to loss of ethanol from the urine 
sample due to microorganisms especially in non-preserved samples or the 
container may not have been sealed properly or was an unsuitable size. Another 
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reason might be that there is still a residue of negative urine in the bladder that 
diluted the urine after alcohol consumption.  
A total of 109 urine samples were positive for ethanol in urine but negative in 
blood. This could be due to the sample being collected in the post-absorption 
phase, formation of ethanol due to microorganism action in the urine sample or 
if the sample was collected and stored in unpreserved samples.  
The P values were > 0.05 for acetone concentrations in vitreous humour and bile 
paired with blood, indicating that there is no significant difference in these 
matrices. However, a large proportion of the samples tested were negative and 
as such any conclusions from this study must be made with caution and it is 
recommended that a much larger study be carried out with more positive paired 
samples.  
The two samples that were negative for acetone in bile but positive in blood 
could be because the sample was collected in the pre-absorption phase, due to 
acetone formation or as a result of oxidation of isopropanol to acetone.  
A significant difference was indicated between acetone concentrations in blood 
and urine. Seven cases were negative for acetone in urine but positive in blood 
and this may be due to formation of acetone in blood due to microorganisms, or 
due to oxidization of isopropanol to acetone. Twenty nine cases were positive 
for acetone in urine but negative in blood. This may be due to the samples being 
collected after elimination of acetone from blood or due to loss of acetone due 
to evaporation. There are no published ratios for acetone in body fluids versus 
blood to make any further comparison with those calculated in this study. 
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3.6 Evaluation of the Immunalysis Ethyl Alcohol 
Enzymatic Assay as a Semi-Quantitative Test in 
Comparison to HS-GC-FID 
3.6.1 Introduction 
Testing each sample received in the forensic laboratory by complicated methods 
and instrumentations will need more manpower, time, and high cost especially 
when the workload is high. The purpose of the immunoassay screening tests is to 
eliminate the negative samples from the more lengthy confirmation testing 
process. There are different types of immunoassays including radioimmunoassay 
(RIA), fluorescence polarization immunoassay (FPIA), enzyme multiplied 
immunoassay technique (EMIT), and enzyme linked immunosorbant assay (ELISA). 
Several biological matrices can be tested with immunoassays, including blood, 
hair, oral fluid, plasma, post-mortem blood, serum, urine, and sweat. Sample 
pre-treatment is required before applying the samples to the microplate.  
The basic principle is that immunoassays can be used to screen biological 
samples for an antigen, such as a drug of interest. Establishing the cut-off point 
in an enzymatic method is important in order to distinguish between positive 
and negative results and provide a balance between false positive and false 
niegative results.  
Cross-reactivity may occur in tested specimens with structurally similar 
compounds or due to interference from the matrix. In terms of result 
interpretation, a false negative result means that it was negative by 
immunoassay and positive with a confirmatory test. A false positive result means 
that the screening was positive and the confirmatory test was negative. 
The signal changes associated with binding to form a labelled "antibody and 
drug–derivative immune complex" can be measured either qualitatively or semi-
quantitatively. The qualitative mode is used as a screening test to identify the 
presence or absence of the analyte of interest relative to the cut-off value. The 
semi-quantitative mode is conducted by comparing the signal value of a known 
sample to a calibration curve to estimate the concentration of in the sample.  
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The Immunalysis ethyl alcohol assay is an enzymatic method used for the semi-
quantitative analysis of ethyl alcohol in human blood. Positive alcohol results 
generated from using the enzymatic method should be confirmed with an 
alternative non-enzymatic method such as head space gas chromatography flame 
ionization detection (HS-GC-FID).(176)  
Enzymatic assays used for the detection of ethanol in humans are based on the 
same reaction that occurs in-vivo (see Figure 3-12). Ethanol is converted to 
acetaldehyde in the presence of alcohol dehydrogenase (ADH) with the 
accompanying formation of the nicotinamide adenine dinucleotide reduced form 
(NADH). NADH is then measured spectrophotometrically at a wavelength of 340 
nm.(176;177) 
 
Figure 3-12:  Enzymatic Alcohol Reaction 
 
3.6.2 Chemicals and Reagents 
Certified ethanol standard solutions were purchased from LGC Standards 
(Teddington, UK). The concentrations were: 25 mg/dL 50 mg/dL, 80 mg/dL, 100 
mg/dL, 200 mg/dL, 300 mg/dL, and 400 mg/dL. The Enzymatic Kit for alcohol 
determination in blood was manufactured by the immunalysis Corporation 
(Pomona, CA, USA) and contained one bottle of 0.5 N perchloric acid, Reagent A 
(RA) containing 0.6 M tris buffer, and Reagent E (RE) containing ADH and NAD in 
tris buffer as a stabilizer. Both RA and RE contain 0.1% sodium azide 
preservative. Other materials included 96-well flat-bottom polysterene 
microtiter plates; pipettes with volumes of 10, 20, and 100 µL with disposable 
tips, disposable 1.5 polypropylene conical bottom centrifugal tubes with caps, 
and a timer. 
+ 
(ADH) 
Alcohol dehydrogenase 
+ 
NAD+ 
+ 2H+ + 2e¯ 
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Chapter 3  102 
3.6.3 Methodology 
A total of 60 post-mortem blood samples, 50 preserved in 0.2% sodium fluoride 
(NaF) and 10 unpreserved were analysed for ethanol, acetone, isopropanol, and 
methanol utilizing a validated HS-GC-FID as described in Chapter 2. The same 
samples were screened for ethanol using the enzymatic assay.(176)  
The cut-off point used to distinguish positive from negative utilizing HS-GC-FID 
was 10 mg/dL for ethanol and 10 mg/L for acetone. Although the LOD was 
established by the immunalysis manufacturer at 10 mg/dL, the cut-off point 
used for the ethanol results generated from the enzymatic method was 25 
mg/dL, equivalent to the lowest point of the calibration curve.  
A tabulated cross-match between the positive and negative results was carried 
out in addition to evaluating any correlation between the two tests.  
3.6.3.1 Enzymatic Ethyl Alcohol Assay 
An aliquot of 100 µL of the standard, sample or quality control material was 
added with 400 µL 0.5N perchloric acid to each centrifuge tube. The tubes were 
vortexed and left at room temperature for 5 minutes. All tubes were centrifuged 
at 4000 RPM for 5 minutes. A 10 µL aliquot of the clear solution was transferred 
to a microplate well in duplicate and 100 µL each of RA and RE added to each 
well. The plate was covered and placed in the dark for 30 minutes, then the 
plate was read at 340nm using microplate RXM reader.  
3.6.3.2 HS-GC-FID 
The validated method utilizing HS-GC-FID and n-propanol as internal standard 
was carried out as described in chapter 2. 
3.6.4 Method Validation 
For the enzymatic assay, validation was carried out by the Immunalysis 
manufacturer as per the manufacturers insert package instructions.(176) The 
linearity was assessed by preparing the calibrators at 0, 20, 100, 200, and 400 
mg/dL. Intra-assay (within-run) and inter-assay (between-run) precision was 
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obtained by preparing 8 replicates of treated samples at concentrations of 0, 20, 
100, 200, and 400 mg/dL. In terms of accuracy, two sets of data (n=50) 
generated from the HS-GC-FID and enzymatic method were compared and the R2 
was calculated. Specificity was assessed with various structurally similar organic 
compounds tested at different levels, such as acetaldehyde, acetone, n-butane, 
ethylene glycol, isopropanol, methanol, n-propanol, and urea. The linearity was 
assessed by preparing a concentration range of 25-400 mg/dL for ethanol. The 
cut-off point used in this method was at the concentration of the first calibrator 
(25 mg/dL).  
3.6.5 Results and Discussion 
The cross-reactivity studies were carried out by the manufacturer and were 
reported as low for all volatiles assessed: n-butanol (9%), ethylene glycol (2.5%), 
isopropanol (6.5%) and n-propanol (11.5%). 
Linearity was assessed using certified standards and ranged from 25-400 mg/dL 
with an >0.997 (Figure 3-13). 
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Figure 3-13:  Calibration Curve for Ethanol using the Enzymatic Assay 
 
 
Table 3-13 summarises the semi-quantitative results for the samples tested using 
the enzymatic assay and the quantitative results following analysis by HS-GC-
FID. Of the 60 samples, 24 (21 preserved and 3 unpreserved) samples were 
positive in both methods, while 31 (26 preserved and 5 unpreserved) were 
negative in both. These results are summarised in Table 3-14 and highlight four 
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samples (3 preserved and 1 unpreserved) that were positive by HS-GC-FID but 
negative by the enzymatic assay, and 1 unpreserved blood sample that was 
negative by HS-GC-FID but positive by the enzymatic assay. 
Table 3-13:  Ethanol Results for HS-GC-FID versus Enzymatic Assay highlighted 
mismatched cases in yellow 
 UP-Unpreserved 
Case 
No. 
Enz 
(mg/dL) 
GC 
(mg/dL) 
Case 
No. 
Enz 
(mg/dL) 
GC 
(mg/dL) 
Case 
No. 
Enz 
(mg/dL) 
GC 
(mg/dL) 
1 33 73 16 <25 <10 34 <25 <10 
1UP 57 141 16UP <25 <10 35 <25 <10 
2 48 89 17 355 296 36 <25 11 
3 <25 <10 18 25 22 36UP <25 <10 
4 118 157 19 <25 <10 37 366 340 
5 109 162 20 <25 <10 38 <25 <10 
5UP 161 222 21 <25 <10 39 <25 <10 
6 187 216 22 231 155 40 <25 <10 
7 <25 <10 23 <25 <10 41 <25 <10 
8 <25 12 24 <25 <10 42 <25 <10 
8UP <25 24 25 <25 <10 43 351 245 
9 226 233 26 370 199 44 <25 <10 
10 <25 <10 27 <25 <10 45 319 236 
11 166 167 28 329 185 45UP <25 <10 
12 <25 30 29 <25 <10 46 259 230 
13 <25 <10 30 <25 <10 47 342 265 
13UP <25 <10 31 <25 <10 48 <25 <10 
14 213 186 32 362 202 49 321 220 
15 <25 <10 32UP 134 14 50 <25 <10 
15UP <25 <10 33 247 250 50UP 29 <10 
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Table 3-14:  Ethanol in Blood (Enzymatic-v-HS-GC-FID) 
Ethanol in Blood GC vs. Immunoassay Method 
N = 60 Positive (Enzymatic) 
Negative 
(Enzymatic) 
Positive (GC result) 24 4 
Negative (GC result) 1 31 
 
The correlation coefficient (R2) between the two sets of the results was 87.6% as 
illustrated in Figure 3-14). The P value was 0.056, indicating that there is no 
significant difference between the results of the two methods. 
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Figure 3-14:  Blood Ethanol Correlation between HS-GC-FID and the enzymatic method 
 
Table 3-15 highlights the five unmatched ethanol results. The first four samples 
were all positive by HS-GC-FID and negative by the enzymatic assay, however 
the different cut-off points used for each method provide an explanation for the 
difference in these results. Although the manufacturer's cut-off was 10 mg/dL 
for ethanol and 10 mg/L for acetone and because the immunoassay method used 
for the purpose of comparison with HS-GC-FID, validation of this method has not 
been carried out. Instead the lower point used for the immunoassay calibration 
curve which are 25 mg/dL for ethanol and 25 mg/L for acetone was used as a 
cut-off for the immunoassay method. 
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Table 3-15:  Mismatched Ethanol Results (Enzymatic versus HS-GC-FID)  
Case 
No. 
Sample 
Condition 
Acetone 
HS-GC-FID  
(mg/L) 
Ethanol 
HS-GC-FID 
(mg/dL) 
Ethanol 
Enzymatic Method 
(mg/dL) 
8 Preserved 443 (POS) 12 (POS) (2) <25 (NEG) 
8 Unpreserved 310 (POS) 24 (POS) (9) <25 (NEG) 
12 Preserved 29 (POS) 30 (POS) (22) <25 (NEG) 
36 Preserved 25 (POS) 11 (POS) (11) <25 (NEG) 
50 Unpreserved 162 (POS) <10 (NEG) (29) (POS) 
 
One sample, number 50, was negative using HS-GC-FID and positive using the 
enzymatic method. Two possible explanations are that as the sample contains no 
preservative and there was a delay between the initial test by HS-GC-FID and the 
enzymatic assay, the formation of ethanol may have taken place, or it may be 
due to interference from other volatile compounds that were present in the 
sample. The cross-reactivity of acetone was not reported by the manufacturer so 
this may provide an explanation. However, acetone was also present in the other 
samples and is a particularly high concentration in both preserved and 
unpreserved samples of case 8 with corresponding negative enzymatic assay 
response. 
3.7 Conclusion 
All volatiles investigated in this study, with the exception of methanol, had 
improved stability when stored in containers with preservative (0.2 or 1% sodium 
fluoride) and antioxidant (0.2% sodium metabisulphite). Storage at -22°C is 
preferred for optimal stability rather than at room temperature (25°C) or in the 
refrigerator (4°C). Isopropanol concentrations decreased and acetone 
concentrations increased over the 50-day testing period, confirming oxidation of 
isopropanol to acetone. The oxidation process for both isopropanol and n-
propanol was significantly reduced with the addition of the antioxidant, sodium 
metabisulphite.  
Blood samples collected following suspected drink-driving offences which 
contain both preservative and antioxidant were stored at room temperature for 
a period of between 1 to 5 years following initial tests for ethanol. Recoveries of 
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50% or more of the original ethanol concentration were achieved in 85% of the 
samples tested. However, recoveries decreased with increasing number of years 
of storage with only 23% of the samples retested after more than 3 years with 
recoveries achieving 50% or more.  
Over a period of six months refrigerated storage, significant loss and formation 
of ethanol occurred in both preserved and unpreserved paired post-mortem 
blood samples from cases submitted to the toxicology laboratories of Forensic 
Medicine and Science. However, further losses were not significant following an 
additional storage period of 10 months in the freezer at -22°C. 
Further investigations are needed to evaluate the effect of anti-coagulant in 
terms of anti-oxidation and to investigate the optimum antioxidant 
concentration with the additional evaluation of a longer period of storage to 
optimize the conditions required to prevent loss or formation of volatiles.  
These findings support the conclusions of the author of a 2007 report who 
highlighted the importance of understanding the stability of analytes of interest 
and ultimately interpretation for medico-legal casework.(178)  
Several different specimens should be collected from different sites of the body, 
mainly vitreous humour, or bile and urine if they are available for better 
interpretation of alcohol results. Many other factors might be useful for better 
interpretation of alcohol results (e.g. the circumstances of the death and the 
peri-mortem status, medical history of the deceased if any ante-mortem dilution 
occured due to transfusions of blood or fluids at the hospital, contamination of 
specimen by diffusion from the stomach to surrounding organs in case of trauma, 
or stage of absorption in the body, post- mortem decomposition and embalming 
effect). Collection of post-mortem samples for alcohol analysis should be under 
hygienic procedures, with proper storage in a container that includes a suitable 
preservative and is stored at a low temperature. These measures may help to 
eliminate the alteration of the alcohol level from the time of collection until 
analysis, however this will not prevent the action of microorganisms between 
death and time of sample collection, especially in cases of advanced 
decomposition.  
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Although femoral blood is recommended for the analysis of alcohol, this sample 
is not always available. In this study, the comparison showed a correlation 
between bile, vitreous humour and blood, which may indicate that the 
distribution in the majority of the case samples was in post-absorption. Vitre 
Humor, urine and bile/blood ratios were within the published range with the 
urine alcohol results significantly different with blood for both ethanol and 
acetone. Vitreous humour and bile seem to be more reliable than urine as 
alternative samples in a post-mortem casewoek for alcohol and acetone analysis. 
A wide range of data needs to be analysed for alcohol and acetone with 
consistent sample conditions in order to confirm this conclusion; also many 
factors (as mentioned previously) that may affect the alcohol level should be 
considered when using urine as an alternative sample. More investigation needs 
to be carried out in relation to acetone such as: cut of points in the post-mortem 
formation, stability and the ratio between blood and other body fluids. Analysis 
of ethanol biomarkers may help with interpretation. 
The enzymatic assay demonstrated good correlation with HS-GC-FID. Further 
evaluation and optimization of the LOD and LLOQ is required. However, its 
application to post-mortem or criminal toxicology is of limited value. 
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Chapter 4 - Determination of β-Hydroxybutyrate 
(BHB) in Post-mortem Blood and Urine Using Gas 
Chromatography -Mass Spectrometry (GC-MS) 
4.1 Introduction 
β-Hydroxybutyrate (BHB) has the potential as a biomarker for sudden deaths in 
chronic alcoholics caused by alcoholic ketoacidosis (AKA). The aim of this study 
was to develop and validate a method for the determination of BHB in 
postmortem blood and urine using GC-MS following silyl derivatisation. The 
validated method was then applied to the analysis of real case samples to 
investigate the prevalence of BHB in medico-legal cases. 
A further database study of all samples tested for BHB, ethanol and acetone 
within Forensic Medicine and Science (FMS) was carried out to evaluate the 
relationship between BHB, ethanol, and acetone levels in post-mortem blood 
and urine.  
4.2 Method Development 
4.2.1 Materials 
4.2.1.1 Chemicals and Reagents  
The internal standard used was deuterated γ-hydroxybutyrate (GHB-d6, 1 
mg/mL) purchased from LGC Standards (Teddington, UK). β-Hydroxybutyrate 
(BHB) and o-bis (trimethylsilyl) trifluoroacetamide (BSTFA) with 1% 
trimethylchlorosilane (TMCS) were sourced from Sigma-Aldrich. (Basingstoke, 
England). Acetonitrile (ACN), methanol (MeOH) and ethyl acetate (EtOAc) were 
all HPLC grade, sulphuric acid was 98% and were all purchased from VWR 
International Ltd. Disodium hydrogen orthophosphate anhydrous (Na2HPO4; MW 
141.96) and sodium dihydrogen orthophosphate monohydrate (NaH2PO4H2O; MW 
137.99) were sourced from BDH. Sodium chloride 99+% was sourced from Aldrich. 
Ammonia solution 35% was sourced from Fisher Scientific. ZSGHB20 Clean Screen 
SPE column size 200 mg/10 mL were purchased from United Chemical Company 
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UCT, USA. Distilled water came from the Millipore purification system within 
FMS.  
4.2.1.2 Preparation of Blank (Drug and Volatile-Free) Blood and Urine 
Prepared using expired packed red blood cell pouches and 1% saline solution as 
described in section 2.2.2. Blank urine was obtained from a healthy adult 
volunteer with no history of alcohol consumption. Triplicate samples of each 
blood and urine were screened for BHB and the level was less than the LOD 
limits.  Preparation of Standards and Quality Controls 
Two separate stock standard solutions (A) and (B) were prepared at 
concentrations of 2 g/L. Stock standard solution (A) was used to prepare the 
standards for the calibration curve. The calibrator points were prepared in blood 
and urine as summarised in Table 4-1 from the stock standard to give final BHB 
concentrations of 0, 5, 10, 25, 50, 100, 200, 300, 400, 500 mg/L. 
Table 4-1:  Preparation of BHB Calibration Standards 
Calibrator 
Concentrations  
(mg/L) 
Calibration 
Level 
Volume of 
Stock A 
Added 
(µL) 
Final 
Volume 
Blood/Urine 
(mL) 
0 Level 1 0 5 
5 Level 2 12.5 5 
10 Level 3 25 5 
25 Level 4 62.5 5 
50 Level 5 125 5 
100 Level 6 250 5 
200 Level 7 500 5 
300 Level 8 750 5 
400 Level 9 1000 5 
500 Level 10 1250 5 
 
Stock solution (B) was used for preparing the quality control samples as 
summarised in Table 4-2. Quality control material was prepared in blood and 
urine at concentrations of 50 and 300 mg/L and then aliquoted and transferred 
to 1.5mL polypropylene tubes and stored at -22±2°C.  
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Table 4-2:  Preparation of BHB Quality Control Samples 
Concentrations  
(mg/L) 
QC's 
level 
Volume of 
Stock B 
Added 
(µL) 
Final 
Volume 
Blood/Urine 
(mL) 
0 Level 1 0 5 
50 Level 5 125 5 
300 Level 8 750 5 
 
The working internal standard (GHB-D6) was prepared at 10 mg/L in methanol 
from a stock solution of (1 mg/mL). This was achieved by adding 1 mL of the 
stock internal standard solution (1 mg/mL) to a 100 mL volumetric flask and 
diluting with methanol.  
4.2.1.3 Preparation of Solutions 
0.1M monobasic sodium phosphate was prepared by weighing and transfering  
2.76g of sodium dihydrogen orthophosphate monohydrate (NaH2PO4H2O; MW 
137.99) to a 200 mL volumetric flask, dissolving in 100 mL deionized water and 
then making up to the mark with water. The solution was mixed and then 
transferred to a labelled clean glass bottle to be stored for 1 month at 5±1ºC. 
0.1M dibasic sodium phosphate was prepared by weighing and transferring  2.84g 
of disodium hydrogen orthophosphate anhydrous (Na2HPO4; MW 141.96) to a 200 
mL volumetric flask, dissolving in 100 mL deionized water and then making up to 
the mark with water. The solution was mixed and then transferred to a labelled 
clean glass bottle to be stored for 1 month at 5±1ºC. 
0.1 M phosphate buffer (pH 6) was prepared by dissolving 1.7g disodium 
hydrogen orthophosphate anhydrous (Na2HPO4) and 12.14g sodium dihydrogen 
orthophosphate monohydrate (NaH2PO4H2O) in 800 mL of water. The pH was 
adjusted to pH 6±0.1 with 0.1M monobasis sodium phosphate (lowers pH) or 0.1M 
dibasic sodium phosphate (raises pH) and made up to 1 litre with water. The 
buffer was mixed and then transferred to a labelled clean glass bottle to be 
stored for 1 month at 5±1ºC. 
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Methanol (CH3OH)/Ammonia NH4OH (99:1) was prepared by measuring 99 mL of 
methanol using a measuring cylinder and was then transferred to a clean 
labelled reagent bottle and 1 mL of ammonia added and mixed. This solution 
was prepared fresh daily    
A solution of 0.025M H2SO4 was prepared by dissolving 0.695 mL of concentrated 
(18 M) sulphuric acid in approximately 200 mL of deionized water and then made 
up to the mark (500 mL volumetric flask) with water.  The solution was stored at 
room temperature after being transferred to a clean labelled bottle. 
4.2.2 Instrumentation 
Gas chromatography-mass spectrometry (GC-MS) was carried out using a 
Thermoquest, CE Instrument Trace GC with X-calibur software coupelled with 
Finnigan Trace MS and AS 800 autosampler purchased from (Thermo Fisher 
Scientific, UK). The column used was a DB-5 capillary column (5% phenyl/95% 
methylsiloxane, 30m x 0.25 mm I.D. 0.25 mm film thickness) purchased from 
Agilent Technologies Ltd, UK.  
4.2.2.1 GC/MS Conditions 
Optimization of the GC conditions was carried out by comparing two programs:  
Initial GC program - Initial oven temperature of 60ºC was held for two minutes 
and then ramped to 180ºC at 15ºC/min, followed by a further ramp to 300ºC at 
50ºC/min and held for 5 minutes. The total run time was 10 minutes. The source 
temperature was 200ºC; the transfer line temperature was 250ºC; the injector 
base temperature was 250ºC using splitless mode and the carrier gas flow rate 
was 1.2 mL/min. The mass detector multiplier voltage was 500 volts and the 
scan range was 40-300 amu.  
Final GC program - Initial oven temperature of 60ºC was held for two minutes 
and then ramped to 180ºC at 20ºC/min, followed by a further ramp to 250ºC at 
50ºC/min and held for 1 minute. The total run time was 10 minutes. The source 
temperature was 200ºC; the transfer line temperature was 250ºC; the injector 
base temperature was 250ºC using splitless mode and the carrier gas flow rate 
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was 1.2 mL/min. The mass detector multiplier voltage was 500 volts and the 
scan range was 40-300.  
Data was collected in full scan mode and the ions monitored were: m/z 233, 
191, and 117 for BHB and m/z 239 and 240 for the internal standard GHB-d6. The 
bolded underlined ions were used for quantification. 
4.2.3 Method Evaluation 
Methods previously developed by other authors(179-181) were modified slightly, 
including optimisation of the extraction, derivatization and GC-MS conditions 
and were then applied to blood and urine samples. The three methods involved: 
(A) clean screen solid-phase extraction (SPE); (B) liquid-liquid extraction (LLE) 
and (C) protein precipitation. A summary of the methods are listed in Table 4-3. 
Table 4-3:  Methods Evaluated for the Determination of BHB in Blood and Urine.  
Method Conditions Extraction Solvent Derivatization Conditions 
A (SPE) Original(181) 
Acetone, pH 6 
Phosphate buffer  
MeOH: 
Ammonia 99:1 
100 µL EtOAc:100 µL of 
BSTFA+1%TMCS at 70ºC for 30 
minutes 
B (LLE) 
Original(179) EtOAc 75 µL ACN: 25 µL BSTFA+1% TMCS at 60ºC for 60 minutes 
Condition 1 EtOAc 75 µL ACN: 25 µL BSTFA+1% TMCS at 60ºC for 60 minutes 
Condition 2  EtOAc 50 µL  EtOAc: 50 µL BSTFA+1% TMCS at 70ºC for 30 minutes 
Condition 3  EtOAc 25 µL  EtOAc: 75 µL BSTFA+1% TMCS at 70ºC for 30 minutes 
C (PP) Original(180) ACN 75 µL BSTFA+1% TMCS, at 90ºC for 10  
 
SPE - Solid Phase Extraction, LLE - Liquid-Liquid Extraction, PP - Protein Precipitation, 
EtOAc - Ethyl Acetate and ACN - Acetonitrile  
 
Two of the methods (A and C) were originally used for analysing GHB in different 
post-mortem matrices and were applied to the detection of BHB in blood and 
urine due to the similarity of their chemical structure.  
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Peak shape, reproducibility, time of extraction, linearity range and the 
cleanliness of the derivative were evaluated when comparing the above 
methods. The LLE extraction method (B) was also used to evaluate and optimize 
different derivatization conditions (incubation temperature and time and volume 
of derivatising agent) as summarised in Table 4-3.  
4.2.3.1 Method A – CLEAN SCREEN SPE 
The CLEAN SCREEN SPE is a mixed-mode cartridge packed with hydrophobic and 
phenyl/ propylsulfonic acid, which is a strong cationic exchange sorbent.(182) It 
was designed to be used for filtration and extraction of GHB. Isolation of BHB 
from blood and urine was achieved using acetone, after adding 100 µL of 
internal standard (GHB-D6) as follows; after vortexing for 15 seconds and 
centrifugation at 1500 rpm for 5 minutes, the upper layer was collected and 
transferred to a clean vial and evaporated at 70ºC to dryness with nitrogen. The 
dried extract was dissolved in 200 µL of 0.1M phosphate buffer (pH 6.0) and was 
vortex mixed for 10 seconds. The reconstituted extract of the samples was 
applied to the conditioned SPE columns. Clean test tubes were added to the rack 
and then 1 mL of methanol/ammonia (99:1) was added to the original sample 
test tube, vortex mixed and then decanted onto the SPE column. The extract 
was collected, removed from the vacuum manifold and evaporated at 70ºC to 
dryness with nitrogen. For the derivatization step, 100 µL of ethyl acetate and 
100 µL of BSFTA +1% TCMS were added to all samples, mixed, and heated at 70ºC 
for 30 minutes. Samples were transferred to GC vials and 2 µL injected onto the 
GC-MS.  
4.2.3.2  Method B – Liquid-Liquid Extraction (LLE) 
A 100 µL aliquot of blood or urine was extracted by adding 100 µL of internal 
standard (GHB-d6), 1 mL ethyl acetate and 100 µL 0.025 M sulphuric acid. After 
mixing in the sample shaker for 10 minutes, the samples were centrifuged at 
1500 rpm for 5 minutes. The upper layer was collected and transferred to a 
clean vial and evaporated to dryness with nitrogen then derivatized with BSFTA 
+1% TCMS. Evaporation and derivatization was carried out at different 
temperatures and using different ratio mixtures of ethyl acetate and BSFTA +1% 
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TCMS as per Table 4-3. Samples were transferred to GC vials and 2 µL injected 
onto the GC-MS. 
4.2.4 Results and Discussion 
Good separation was achieved between BHB and the internal standard (GHB-D6) 
in blood and urine using the “Final GC Program” conditions as illustrated in 
Figures 4-1 and 4-2 respectively. 
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Figure 4-1:  Chromatogram and Spectra for BHB and GHB-D6 from a Blood Control (50 
mg/L) 
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Figure 4-2:  Chromatogram and Spectra for BHB and GHB-D6 in Post-Mortem Urine (300 
mg/L) 
 
Poor peak shape was observed with Method B (LLE) using derivatisation 
conditions (1): 75 µL ACN and 25 µL BSTFA+1% TMCS at 60ºC for 60 minutes as 
illustrated in Figure 4-3.  
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Figure 4-3:  BHB and GHB-D6 Extracted Ions for Spiked Blood using LLE and derivatization 
Conditions (1) 
 
 
This may be due to the long derivatization time or as a consequence of 
incomplete derivatisation due to the low volume of the derivatizing reagent. 
Symmetric peak shapes were observed when using derivatisation conditions (2) 
and (3). Figure 4-4 illustrates the excellent peak shapes achieved with the LLE 
method and derivatisation conditions (3). The derivatisation time was shorter 
and the volume of BSTFA+1%(TMCS) greater. 
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Figure 4-4:  BHB and GHB-D6 Extracted Ions for Spiked Blood using LLE Method and 
Derivatisation Conditions (3).  
 
 
The correlation coefficient (R2) and linearity ranges are summarized in Table 4-
4. The linearity of BHB using the SPE method (A) was up to 200 mg/L and 100 
mg/L in blood and urine, respectively. The values were not always > 0.99 when 
the experiment was repeated and the sample preparation was found to be time-
consuming. The main limitations of the SPE method were: the number of steps 
involved with sample preparation and the linear range only extended to 200 and 
100 mg/L in blood and urine, respectively. The upper limit of quantification 
(ULOQ) was not high enough and would therefore require reanalysis and dilution 
of real case samples in order to achieve accurate quantitative results within the 
linear range. Also interference from uric acid is another problem and this is also 
observed by telepchak, et al. 2004.(183)  
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Table 4-4:  R2 and Linear Range of BHB for Different Methods 
Method Conditions Matrix BHB ( R2) Linear Range (mg/L) 
A (SPE) Original 
Blood 0.9878  LOQ-200 
Urine 0.9335 LOQ-100 
B (LLE) 
Original N/A Poor peak shape 
Condition 1 N/A Poor peak shape 
Condition 2 
Blood 0.9877 LOQ-500 
Urine 0.9877 LOQ-500 
Condition 3 
Blood 0.9991 LOQ-500 
Urine 0.9987 LOQ-500 
C (PP) Original 
Blood 0.9994 LOQ-500 
Urine 0.9983 LOQ-400 
 
Although the linearity using the LLE method (B) was up to 500 mg/L using both 
derivatizing conditions 2 and 3, the value was better using conditions (3). The 
limitation of derivatisation conditions (2) was that the derivative, following 
extraction of the blood sample, was brownish in colour and the presence of uric 
acid interfered with the urine extraction.  
Using the protein precipitation method (C) the linear ranges in blood and urine 
for BHB were LOQ-500 mg/L and LOQ-400 mg/L, respectively. The ULOQ in the 
published method was 300 mg/L for GHB. Interference with uric acid in urine 
samples was a problem with this method. Comparing the protein precipitation 
methods with LLE, the protein precipitation method in blood was more robust 
and used less solvent. The final derivatised blood extract was cleaner, the 
sample preparation was faster due to fewer and shorter steps. However, using 
this method to extract urine was problematic, due to high interference with uric 
acid crystals in the final derivative.  
The SPE method (A) using clean screen SPE column was not selected due to the 
narrow linear range and the interference with uric acid which was also reported 
by Telepchak.(183) The LLE method (B) with condition 3 was selected for the 
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extraction of BHB from urine as the final extract was cleaner than the protein 
precipitation method with a linear range up to 500 mg/L. The protein 
precipitation method (C) was used for the extraction of BHB from post-mortem 
blood because it was more robust, the final derivatised extract was cleaner 
compared with the LLE method and the linear range was up to 500 mg/L while 
using less solvent. The sample preparation was fast due to the fact that it 
contained fewer and shorter steps. Method validation was carried out for both 
selected methods as summarised in Table 4-5.  
Table 4-5:  Summary of Blood and Urine Extraction Methods for the Analysis of BHB 
 
 
4.3 Method Validation 
4.3.1 Linearity 
Calibration standards were prepared by spiking blank blood and urine with BHB 
at concentrations ranging from 50-500 mg/L as detailed in section 4.2.1.3. The 
peak area ratio of the BHB to internal standard (GHB-D6) was calculated, and the 
calibration curve was generated by plotting the area ratio against the 
concentration. The equation of line and correlation of coefficient (R2) was 
measured and should be greater than 0.99.  
Matrix 
Step 1 Step 2 Step 3 Step 4 
Sample 
 Volume 
GHB-d6 
(10 mg/L) 
Extraction Derivatization Conditions 
Blood  100 µL   100 µL   
0.5 mL ACN 
 Vortex mix 30s 
Centrifuge @ 1500 rpm 
Evaporate @ 45ºC±1 to 
dryness 
75 µL BSTFA+1% TMCS, 
at 90ºC for 10 minutes 
Urine 100 µL   100 µL   
100 µL 0.025 M H2SO4  
+ 1 mL EtOAc 
Vortex 30s 
Centrifuge @ 1500 rpm 
Evaporate @ RTºC±1 to 
dryness 
25 µL  EtOAc: 75 µL 
BSTFA+1% TMCS at 
70ºC for 30 minutes 
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4.3.2 Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The LOD and LOQ were determined by diluting the spiked samples with 
decreasing concentrations of BHB within the expected range of the LODs (1.25–
25 mg/L). Regression analysis was undertaken and the LOD and LOQ were 
calculated was explained in chapter 2 section 2.2.9 in accordance with Miller 
and Miller.(168)  
Case samples for BHB at concentrations that are above or below the linear range 
(50-500 mg/L) were reported as less than the LOQ (<50 mg/L) or greater than 
the highest calibrator (>500 mg/L). 
4.3.3 Precision and Accuracy 
Intra-day precision (within-day precision) was evaluated with urine (N=6) and 
blood (N=8) spiked controls, prepared at two different concentrations (50 and 
300 mg/L) and extracted in a batch with case samples. Inter-day precision 
(between-day precision) was evaluated with urine and blood spiked controls, 
prepared at two different concentrations (50 and 300 mg/L) and extracted in 
batches with case samples on different days (N=8). The percentage of 
coefficient of variance (%CV) acceptance criteria was <20%. Accuracy was 
assessed by preparing and extracting triplicate spiked blood and urine control 
samples at concentrations of 50 and 300 mg/L. The accuracy was determined by 
comparing the calculated amount extracted to that of the theoretical expected 
concentration of both control levels.  
4.3.4 Recovery and Matrix Effect 
The recovery of BHB from blood and urine was assessed by preparing spiked 
blood and urine controls at concentrations of 50 and 300 mg/L. The controls 
were extracted as described above however, 100 µL of the internal standard 
(GHB-D6) at a concentration of 10 mg/L was added prior to evaporation after 
extraction. The recovery was determined by comparing the extracted BHB:GHB-
D6 ratio to that of the unextracted standards at the same concentration. All 
analyses were carried out in triplicate and the average calculated. The absolute 
recovery was calculated by comparing the peak area ratio of extracted sample 
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when the internal standard was added at the beginning of the extraction versus 
the unextracted standards at the same concentration. 
The relative recovery was obtained by extracting water spiked at concentrations 
of 50 and 300 mg/L, calculating the BHB: GHB- D6 ratio and comparing that to 
the ratio calculated for blood and urine, expressed as a percentage. All analyses 
were carried out in triplicate and the average calculated. The relative recovery 
was carried out to check the matrix effect and the absolute recovery to check 
the efficiency of the method. 
4.3.5 Stability  
Two small studies were carried out to assess the stability of the derivatized 
extracts and to assess the stability of BHB in blood. The stability of the 
derivatized extract was evaluated by repeatedly injecting the same two levels 
(50 and 300 mg/L) of processed samples for 4 days following derivatization and 
storage at room temperature (22±2°C).  
The stability of BHB in blood was assessed by extracting replicate spiked samples 
(50 and 300 mg/L) from the same quality control lot stored at 2-5ºC and 
analysed at time intervals of days 1, 3, 11, 13 and 15. The percentage recovery 
was calculated from the mean concentration of QC samples injected in days 3, 
11, 13 and 15 and compared as a percentage to day one (normalised as 100%). 
The 95% confidence interval (CI) from the mean concentration (n=6) for day one 
was calculated and stability was assumed when the percentage of the mean of 
the QC samples was within 80-120%.(169)  
4.3.6  Case samples  
Post-mortem blood (N=13) and urine (N=12) were selected from fourteen cases 
where the cause of death was not known and there was a history of alcohol 
abuse. Preserved samples (0.2% sodium fluoride) were analysed in preference to 
unpreserved samples but these were not available for all cases. All unpreserved 
and preserved samples were stored at 4±1ºC until analysis.   
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4.3.7 Results and Discussion 
Both methods for blood and urine were linear over the range of 50-500 mg/L and 
resulted in average coefficients of correlation (R2) > 0.99 as illustrated in Figure 
4-5). The LOD was 2 mg/L in blood and urine, while the LOQ was 6 and 7 mg/L 
respectively for urine and blood. Although the LOQ is lower than the first 
calibrator point (50 mg/L), this point was used as a cut-off point to distinguish 
between positive and negative results. The endogenous level in serum has been 
reported in healthy adults as being 30-60 mg/L.(133) Urinary endogenous levels 
of BHB in healthy humans ranged 8.51-34.7 mg/L (mean is 18.4 mg/L), it has 
been also observed that the urinary endogenous levels of BHB is approximately 
20 times higher than its related compounds such as GHB.(134) Triplicate samples 
of blood and urine were screened for BHB to be used to spike quality conrol 
samples and the results were less than LOD of the method also they very low 
compared to the cut-off points (50 mg/L). Urine and blood blanks were included 
in each calibration curve to take into account any endogenous BHB.   
             (A)          (B) 
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Figure 4-5:  Calibration Curves for BHB in Blood (A) and Urine (B) 
 
 
The inter-day and intra-day precision was measured by coefficients of variation 
(%CV) for blood and urine and ranged from 1.40 to 12.41% for quality control 
samples spiked at level of 50 and 300 mg/L as summarised in Table 4-6. 
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Table 4-6:  BHB Intra day and Interday Precision in Blood and Urine 
Matrix 
Intraday Precision 
(%CV) 
Interday Precision 
(%CV) 
Accuracy 
(%) 
50 mg/L 300 mg/L 50 mg/L 300 mg/L 50 mg/L 300 mg/L 
Urine 6.75 (N=6) 
5.23 
(N=6) 
12.16 
(N=8) 
6.03 
(N=8) 
111 
(N=3) 
100 
(N=3) 
Blood 4.94 (N=8) 
1.40 
(N=8) 
12.41 
(N=8) 
6.79 
(N=8) 
97 
(N=3) 
99 
(N=3) 
 
Table 4-7 summarises the recovery of BHB from blood and urine. The recovery of 
BHB from blood was greater than or equal to 82% while the relative recovery 
(matrix effect) was 129% and 106% at concentrations of 50 and 300 mg/L, 
respectively. The recovery of BHB from urine was 134 and 105% at 
concentrations of 50 and 300 mg/L, respectively.  The efficiency (Absolute 
recovery) for both urine and blood were all within the range of 88-106% at both 
concentrations except in urine at 50 mg/L (135%). The high % recoveries may be 
explained by matrix effects, e.g. interference from uric acid in urine, but can 
also be affected by poor extraction or the fact that the internal standard, (GHB-
D6) although structurally related to BHB is not the same. 
Table 4-7:  BHB Recovery and Matrix Effect Data 
Method 
Matrix effect 
(Relative Recovery) % 
Efficiency 
(Absolute Recovery) % Recovery % 
50 mg/L 300 mg/L 50 mg/L 300 mg/L 50 mg/L 300 mg/L 
Urine 101 131 135 89 134 105 
Blood 129 106 106 88 82 83 
 
 
 
Table 4-8 summaries the stability data for BHB in blood over a period of 15 days 
and a separate study following derivatization and storage for 4 days.  
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Table 4-8:  BHB Stability Data for Spiked Blood Stored at 2-5ºC for 15 Days 
 (A) BHB stability in spiked blood stored at 2-
5º for 15 days 
n=3 Recovery %[Measured value mg/L] 
Day 50 mg/L 300 mg/L 
1 100 [55] 100 [297] 
3 103 [56] 117 [348] 
11 106 [58] 105 [313] 
13 98  [53] 106 [315] 
15 77  [42] 100 [298] 
Range 
[Mean of 
day 1±SD 
52-57 262-332 
 
 (B) BHB stability in processed samples 
stored at room temperature for 4 days 
n=3 Recovery % Measured value mg/L] 
Day 50 mg/L 300 mg/L 
1 100 [61] 100  [330] 
2 109 [66] 112  [369] 
3 102 [62] 99   [327] 
4 113 [69] 99   [326] 
Range 
[Mean of 
day 1±SD 
56-66 283-378 
 
(A) and (B) for Derivatised Extracts Stored at Room temperature for 4 Days 
 
Although there was some variation in the measured concentrations, BHB remains 
stable in blood spiked at a concentration of 300 mg/L for 15 days when stored 
within a refrigerator (2-5°C). There was some loss of BHB in the control samples 
spiked at 50 mg/L on day 15 and a longer stability study is required to 
investigate this further. BHB remains stable for approximately four days at room 
temperature after derivatization.  
Fourteen case samples(details summarised in Table 4-9) consisting of blood 
(N=13), urine (N=12) and vitreous humour (N=1) samples were analysed for BHB. 
The cause of death as reported by the pathologist is also included. 
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Table 4-9:  BHB Summary of Case Results  
No. 
BHB mg/L Acetone mg/L Ethanol mg/dL 
History /Cause of Death 
Blood Urine VH Blood Urine VH Blood Urine VH 
1 205 >500  145* 431 152 19* 81 30 Alcoholic/fatty liver, cause of death undetermined 
2 343 >500  35* 452 41 NEG* NEG NEG Fatty liver 
3 239 429  694* 780  30* NEG  Diabetic/possible ketoacidosis or drug/alcohol related 
4  >500   201 325  12 25 Known alcohol abuse 
5 <50 >500  20* 164  12* 58  Chronic alcohol abuse 
6 203 >500  40* 54  NEG* NEG  Fatty liver 
7 328   387*   NEG*   Diabetic/possible ketoacidosis or drug/alcohol related 
8 214* >500  19* 89  NEG* NEG  Alcoholic/Fatty liver, cause of death undetermined 
9 198* 432  194* 342  12* NEG  Alcohol abuse 
10 138* 323 341 76* 103 71 67* 88 72 Undetermined cause of death, fibrosis 
11 233 307  157* 225  340* 538  
Liver failure, known alcoholic, 
smell of alcohol, micronodular 
cirrhosis, heart disease 
12 211   311*   NEG*   
Suspected drug related 
death/alcohol abuse but no smell 
of alcohol 
13 246 252  50* 76  297* 347  Found dead in his room 
14 267* >500  250* 314  NEG* NEG  Fatty degeneration of the liver, chronic alcohol abuse, fatty liver 
*Indicates preserved samples. 
 
BHB and acetone are reported in mg/L while ethanol is reported in mg/dL. 
Results are reported with no decimal places. Blood BHB results for alcoholics 
above 260 mg/L or 2500 µmol/L are considered to be consistent with alcoholic 
ketoacidosis (AKA).  
The cases were selected on the basis of high acetone levels and the cause of 
death was either undetermined or the deceased had a history of chronic alcohol 
abuse. Two of the fourteen cases were known diabetics (Cases #3 and #7), but in 
all cases the deceased had a history of alcohol abuse and post-mortem findings 
included fatty degeneration or fibrosis of the liver. 
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BHB levels in post-mortem blood ≥260 mg/L have been associated with fatalities 
attributed to alcoholic ketoacidosis.(127) BHB was elevated within the toxic or 
fatal ranges in blood for all the cases investigated except one (case sample #5) 
where the BHB level was normal <50 mg/L. The range of BHB in urine in all 12 
cases was between 252 to >500 mg/L. 
Figures 4-6 illustrates a chromatogram and spectra for BHB and the internal 
standard GHB- D6 extracted from a case with both blood and urine samples. 
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Figure 4-6:  Post-mortem Case Samples with BHB in (A) Blood (343 mg/L) and (B) Urine 
(>500 mg/L) 
 
 
Blood acetone levels were elevated in all cases although, in five cases, acetone 
levels were ≤ 50 mg/L. Ethanol levels in all case samples were low or less than 
the LOD, except for case samples # 11 and 13, where the ethanol level for both 
urine and blood samples was high. 
The relationship between BHB, acetone and ethanol levels requires further 
investigation with a larger data set. 
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4.4 Study Investigating the Relationship between β-
hydroxybutyrate (BHB), Acetone and Ethanol in Post-
Mortem Cases 
4.4.1 Introduction 
A reduced blood pH (ketoacidosis) from the production of ketone bodies as a 
result of alcoholic ketoacidosis (AKA) or diabetic ketoacidosis (DKA) can feature 
in many fatalities and analytical evidence can be used to support a pathological 
diagnosis, or provide a possible cause of death in the absence of other 
pathologically significant findings. Existing beliefs concerning the relationship of 
BHB concentrations, acetone and ethanol needs to be re-examined by the 
analysis of these analytes in a range of different post-mortem cases. BHB, 
acetone and ethanol concentrations measured in post-mortem blood will be 
grouped according to whether or not the deceased had a history of alcohol abuse 
or diabetes. 
The method developed and described earlier in the chapter for the 
determination of BHB in blood was adapted and revalidated using a newer 
instrument from a different manufacturer. Acetone and ethanol were analysed 
with a dual–column head space gas chromatography flame ionisation detector 
(HS-GC-FID) in accordance with the FMS ISO/IEC 17025 accredited method.(132)  
The existing belief that in cases of AKA, ethanol is always low (<10 mg/dL) or 
absent will be evaluated in addition to whether the absence of acetone will 
preclude a high BHB (>250 mg/L). The levels of BHB measured in this study will 
be categorised according to the published data indicating endogenous levels are 
<50 mg/L, toxic levels are within the range of 51–249 mg/L and pathologically 
significant levels are >250 mg/L. 
4.4.2 Methodology 
4.4.2.1 Instrumentation 
GC-MS analysis was carried out using an Agilent 7890A GC system coupled with a 
5975 mass spectrometry detector (MSD) and ChemStation software (Agilent, UK). 
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A DB-5+ DG capillary column (30m x 0.25 mm I.D., 0.25 µm film thickness) was 
purchased from Agilent Technologies Ltd., UK.  
The conditions optimised using the Thermo instrument and described in 4.2.2 
were used on the Agilent instrument with only one alteration. Due to the 
sensitivity of the newer Agilent instrument the samples were injected in split 
mode as opposed to splitless mode.  
4.4.2.2 Summary of Validation 
The validation was carried out as described in sections 4.3.1 to 4.3.4 above. In 
summary, BHB in both blood and urine was found to have a linear response over 
the concentration range of 10-500 mg/L as illustrated in Figure 4-7.  
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   (A)           (B) 
Figure 4-7:  BHB Calibration Curves for Blood (A) and Urine (B) using the Agilent GC-MS. 
 
 
The LOD and LOQ was 2 and 6 mg/L respectively for blood and 1 and 2 
respectively for urine. An overlay of chromatograms for BHB in samples of spiked 
blood and urine at concentrations of 2, 5, 10, and 50 mg/L in comparison to a 
blank sample is illustrated in Figure 4-8. 
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Figure 4-8:  BHB Overlaid Chromatograms for Spiked Blood (A) and Spiked Urine (B) at 
Different Concentrations. 
 
 
The intra and inter-day precision was less than 20%. Although the recovery was 
between 50-61% for BHB in blood and urine, the efficiency of the method was 
between 93-137% and its accuracy between 84-98%. Table 4-10 summarises the 
validation data for BHB in blood and urine.  
50mg/L 
5mg/L 
2mg/L 
Blank  
10mg/L 
2mg/L 
5mg/L 
50mg/L 
10mg/L 
Blank  
(A) 
(B) 
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Table 4-10:  BHB Intraday, Interday Precision, Accuracy and Recovery  Data 
 
 
Intraday 
precision 
CV%  (n=6) 
Interday 
precision 
CV% (n=10) 
 
Accuracy % 
 
Recovery % 
 
Efficiency % 
Matrix 50 mg/L 
300 
mg/L 
50 
mg/L 
300 
mg/L 
50 
mg/L 
300 
mg/L 
50 
mg/L 
300 
 mg/L 
50 
mg/L 
300  
mg/L 
Urine  7.5 4. 6 13.2 5.8 84 98 61 50 137 105 
Blood  1. 3 1. 4 2.8 5.3 95 97 56 60 100 93 
 
Quality control samples (QC’s) were prepared at two different concentrations 
(50 and 300 mg/L) and were then extracted with each batch and injected on 
different days. QC’s were evaluated according to the acceptable range which is 
the mean ± 2 standard deviations. Quality control charts were used to record 
and monitor the acceptability of each batch and are included in Appendix 4-1. 
QC results were within the acceptable range for all batches. 
4.4.2.3 Case Samples 
Post-mortem blood (N=120) and urine (N=82) from 122 cases were identified 
within the FMS in-house database to be tested for BHB. The cases had already 
been analysed for volatiles and had varying causes of death recorded. BHB had 
not been tested routinely within FMS prior to this study and as such the cause of 
death was determined by the pathologist without knowledge of the BHB 
concentrations. Preserved case samples were analysed in preference to 
unpreserved samples but were not available for all cases; namely case numbers 
99, 101, 102, 104, 105, 108 and 109. Full details of each case are listed in 
Appendix 4-2. “Preserved” blood samples were blood samples collected and 
stored in commercially available vials containing a preservative (0.2% sodium 
fluoride). All unpreserved and preserved samples were stored at 4ºC ±1 until 
analysis.  
4.4.3 Results and Discussion 
The majority of the cases (72%, N=79) have blood BHB levels between 0 and 50 
mg/L with 10% of cases having blood BHB levels >250 mg/L as illustrated in 
Figure 4-9.   
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Figure 4-9:  Prevalence of BHB at Different Concentrations in Post-Mortem Blood 
 
The cases were grouped according to the cause of death and the level of BHB 
present in blood. Twelve cases were excluded on the basis that the cause of 
death was not known (N=11), as these were carried out by external pathologists 
or only urine was available (N=1). Table 4-11 summarises the number cases 
categorised by cause of death and blood BHB concentration, while Figure 4-10 
illustrates the percentage of cases at each blood BHB concentration by cause of 
death.  
Table 4-11:  Post-Mortem Cases Classified by Cause of Death and Blood BHB Level   
  Cause of Death 
BHB N Natural Alc Drug Accident Suicide Homicide Unasc. 
0-50 79 18 6 23 9 16 3 4 
51-150 16 6 5 1 3 0 0 1 
151-250 6 3 2 1 0 0 0 0 
>250 9 3 6 0 0 0 0 0 
Alc: alcohol-related; Drug: drug-related; Unasc.: unascertained/undetermined 
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Of the 79 cases with blood BHB levels at 50 mg/L or below, 27 cases (34%) were 
negative (<10 mg/L) for BHB in blood. The positive blood samples ranged from 
10 to 48 mg/L with a mean and median of 22 and 19 mg/L respectively. The 
cause of death in these cases was predominantly un-related to alcohol (92%) but 
it was not possible to determine from the case files whether there was a history 
of alcohol misuse or diabetes in these cases. 
Although the number of cases with blood BHB levels ranging between 51-150 
mg/L, was considerable smaller, there was observed, an increase in the 
percentage of alcohol-related deaths in this group. 
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Figure 4-10:  Percentage of Cases with Varying Blood BHB Concentrations by Cause Death  
 
 
Table 4-12 summarises details of the six cases with elevated levels of BHB 
ranging from 165 - 249 mg/L. The cause of death in two cases was alcohol-
related. A history of alcohol misuse was recorded for one of the four cases 
where the cause of death was not related to alcohol.  
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Table 4-12:  Post-Mortem Cases with Blood BHB Concentrations Between 151-250 mg/L 
 
Case 
# 
 
Gender Age 
BHB          
(mg/L) 
Acetone    
(mg/L) 
Ethanol   
(mg/dL) Cause of Death 
Blood Urine Blood Urine Blood Urine 
16 M 73 195  50 56 NEG NEG 
1a- Ischaemic heart 
disease 
1b- Coronary artery 
atheroma 
30 F 66 237 452 15 26 NEG NEG 
1a- Acute hepatic 
necrosis; 
 1b- paracetamol Toxicity 
73 M 71 208 308 67 84 NEG NEG 1a- Acute pyelonephritis; 1b- Possible hypothermia 
81 F 40 249 498 121 145 NEG 66 
1a- Fatty degeneration of 
the liver                                    
1b- Chronic alcoholic 
abuse 
100 M 80 215 497 82 111 23 14 1a-Hypothermia 
113 F 36 165  40  NEG  
1a. Fatty  degeneration of 
the Liver;  
1b. Chronic Alcohol 
Abuse 
F: female, M: male, NEG: negative 
 
Table 4-13 summarises the cases where blood BHB concentrations are >250 mg/L 
which is associated with pathological findings and considered a marker for 
ketoacidosis.  Three deaths (#17, 89, 112) were categorised as natural and the 
cause of death in each of these was related to insulin dependent diabetes 
mellitus (IDDM) and was specifically recorded as diabetic ketoacidosis in two 
cases (#17. 89). In both cases, the pathologist had requested BHB analysis, while 
in the third case (#112) BHB analysis was not requested even though the 
individual had a history of diabetes and alcohol misuse. 
The remaining six cases were all alcohol-related and in all cases the individual 
had a history of chronic alcohol misuse. However, alcoholic ketoacidosis was not 
recorded as a contributing factor to the cause of death. The role of alcoholic 
ketoacidosis should be considered in these cases and those listed in Table 4-12 in 
light of the elevated blood BHB concentrations. 
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Table 4-13:  Post-Mortem Cases with Blood BHB Concentrations >250 mg/L 
 
Case 
# 
 
Gender Age 
BHB          
(mg/L) 
Acetone     
(mg/L) 
Ethanol   
(mg/dL) Cause of Death 
Blood Urine Blood Urine Blood Urine 
5 F 44 >500 >500 167 224 NEG 16 
1a- Fatty degeneration of 
the liver                                    
1b- Chronic alcoholic 
17 F 18 >500 >500 >400 >400 NEG NEG 
1a- Diabetic ketoacidosis; 
1b. Insulin Dependent 
Diabetic Mellitus 
89 M 34 >500 >500 297 >400 NEG NEG 
1a- Drowning ; 1b- Diabetic 
ketoacidosis;  
1c. Insulin Dependent 
Diabetic Mellitus 
98 M 67 383 358 72 85 338 392 1a. Alcohol related death 
104 M 61 263 >500 42 147 193 286 
1a. Ischaemic heart 
disease and gastro 
intestinal haemorrhage 
from erosive oesophagitis.  
2a. Fatty degeneration of 
the liver 
105 F 56 396  177  34  
1a. Fatty degeneration of 
the liver due to;  
1b. chronic alcohol abuse. 
110 F 57 >500 >500 399 620 NEG NEG 
1a-Alcoholic Stetosis  and 
Ischaemic heart disease; 
1b Fatty degeneration of 
the liver;  
1c- Chronic Alcoholic 
112 M 42 >500  469  30 NEG 
1a-Ischaemic heart disease  
1b- Coronary artery 
atheroma  
2a- Insulin dependent 
diabetes mellitus 
122   >500  169 247 NEG NEG 
1a. Fatty  degeneration of 
the Liver;  
1b. Chronic Alcohol Abuse 
F: female, M: male, NEG: negative 
 
Alcoholic ketoacidosis is commonly associated with high blood BHB 
concentrations, elevated blood acetone concentrations and low alcohol 
concentrations. 
Figure 4-11 illustrates the concentrations of acetone found relative to the blood 
BHB concentration. In all cases with blood BHB >250 mg/L, acetone was >10 
mg/L. In two cases (# 98, 104) the acetone concentrations were below 100 mg/L 
(42 and 72 mg/L respectively) with corresponding BHB >250mg/L. 
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Figure 4-11:  Acetone Concentrations in Post-Mortem Blood Relative to BHB Levels  
Note: The scale of y axis has been reduced to 15 instead 100 to show the case number in 
lower scale  
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Figure 4-12:  Ethanol Concentrations in Post-Mortem Blood Relative to BHB Levels 
 
 
In five of the nine cases with blood BHB >250 mg/L, no ethanol was detected. 
Two cases had low ethanol concentrations of 30 and 34 mg/dL, however the 
remaining two cases had high ethanol concentrations of 193 and 338 mg/dL, as 
illustrated in Figure 4-12. 
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4.5 Conclusion 
A robust and sensitive method for the analysis of BHB in postmortem blood and 
urine was validated. The method was utilised to investigate the stability of BHB 
in blood and to investigate the potential of BHB as a biomarker for AKA. BHB was 
found to be stable in blood for 15 days when stored in the refrigerator and initial 
findings support the use of BHB as a biomarker for AKA. The majority of samples 
analysed were preserved, there were not enough unpreserved results to evaluate 
the affect of preservative on BHB.  AKA does not always equate to low or 
negative ethanol levels. High levels of ethanol were reported in case samples 
with blood BHB levels >250 mg/L, which is in agreement to other 
studies.(55;184) In all case samples with high blood BHB level (>250 mg/L), the 
acetone concentration was high. Acetone can be used as an initial biomarker for 
AKA but the concentrations measured are not well correlated to BHB. Acetone is 
volatile and may be unstable in the blood and the production of other volatiles 
may interfere with it due to putrefaction, (55;127) therfore, its  absence does 
not preclude  a pathologically significant ketoacidosis (BHB >250 mg/L). 
Therefore, BHB should still be analysed in case samples associated with a history 
of chronic alcoholism, even if acetone is low or absent. From the literature, 
vitreous humour could be an alternative substitute for blood.(125) 
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Chapter 5 - Application of the Method Validated for 
the Analysis of β-Hydroxybutyrate (BHB) to the 
Analysis of γ-Hydroxy-butyrate (GHB) and β-
Hydroxy-β-Methylbutyrate (HMB) 
5.1 Introduction 
Due to the similarity of the structures of β-hydroxy-β-methylbutyrate (HMB) and 
γ-hydroxybutyrate (GHB) to β-hydroxybutyrate (BHB), as illustrated in Figure 5-
1, the method validated for the analysis of BHB (as described in Chapter 4) was 
applied to the analysis of GHB in blood and urine, and the analysis of HMB in 
plasma and urine.  
CH3 O
OH OH
           OH
O
C H 3
CH 3 O H
        
OH
OH
O
 
β-hydroxybutyrate     β-hydroxy-β-methylbutyrate     γ-hydroxybutyrate 
(BHB)              (HMB)                    (GHB) 
 
 
Deuterated γ-hydroxybutyrate sodium salt 
(GHB-D6) 
Figure 5-1:  Chemical Structures of BHB, HMB, GHB and GHB-D6 
 
This chapter has two parts, the first part will summarise the validation of the 
BHB method for the analysis of GHB in postmortem blood and urine. The aims of 
this study are to develop a robust method for the determination of GHB in post-
mortem blood and urine, to identify GHB-related fatalities, and to evaluate the 
level of GHB in post-mortem bodies that are not associated with a history of GHB 
intoxication. These results will then be compared with the published data. 
The second part of the chapter will summarise the validation for the analysis of 
all three analytes (BHB, GHB & HMB) in plasma and urine. The aims of this study 
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were to develop and validate a method for the determination of HMB in plasma 
and urine in normal individuals at baseline and after oral administration of a 
dose of 3 grams of HMB. 
5.2 Determination of GHB in Post-Mortem Blood and 
Urine using GC-MS 
5.2.1 Introduction 
GHB is a minor metabolite of γ-aminobutyric acid (GABA) which is an inhibitory 
neurotransmitter, and is a central nervous system depressant. The two main 
metabolic precursors of GHB are γ-butyrolactone (GBL) and 1,4-butanediol 
(1,4B) Figure 5-2. 
 
Figure 5-2: In vivo metabolism of GHB, GABA, GBL and 1,4BD 
[Redraw from Marinetti(185)] 
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Chapter 5  141 
GHB was therapeutically used as an anaesthetic and antidepressant agent. It 
causes relaxation and has the capacity to induce euphoria, short-term amnesia, 
and sedation at high concentrations.(185)  In the USA, has been used in the form 
of a sodium oxybate under the name of Xyrem to treat narcolepsy. It is also used 
in the treatment of alcohol withdrawal syndrome. (185) Misuse of GHB is 
common among body builders, as it is believed that GHB stimulates the release 
of the growth hormone; it is also used by dance club attendees, for its sedative 
and muscle relaxant effects and has been detected in drivers and victims of 
drug-facilitated sexual assault.(186) The use of GHB has been associated with 
fatalities when administered alone or in combination with other drugs. GHB is 
commonly referred to as a "date-rape drug", with street/slang names for GHB 
including "scoops," "liquid ecstasy," "easy lay," "salt water," "vita G," "Georgia 
home boy," "grievous bodily harm" and "great hormones at bedtime." (185) 
The slang name "liquid ecstasy" used for GHB is often confused with MDMA. 
"Ecstacy," or “XTC” is the slang name commonly associated with methylene-
dioxymethamphetamine (MDMA), which is not in the same classification as GHB. 
(185)  MDMA scheduled as class A and GHB as Class C.(187)  
5.2.2 Prevalence of GHB in Biological Matrices 
GHB is a small molecule. It behaves similar to ethanol due to being highly 
solubility in water and lacking the ability to bind to plasma protein. As expected 
GHB concentrations are higher in plasma than blood due to a higher percentage 
of water in plasma than blood. The distribution ratio between blood and serum 
is probably similar to ethanol which is 1.6:1. The fatal concentration of GHB in 
plasma ranged between 250-280 mg/L and therefore it is expected that whole 
blood GHB concentration will be around 16% lower in plasma. [Cited by 
Kugelberg, et al. 2008 (188) from Iffland et al 1999]. Due to the endogenous 
nature of GHB, the interpretation of GHB levels in biological matrices is a 
challenge in forensic toxicology.(188) 
In living individuals, toxicological analysis of exogenous GHB in body fluids is 
time critical, since GHB disappears very quickly from the body after ingestion. 
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The cut-off time for detection in blood is approximately 8 hours post-ingestion 
and 12 hours and not more than 48 hours after offence in the urine.(189) 
An elevation of the urinary levels of GHB has been reported in the case of a 
genetic disorder called GHB aciduria, due to a deficiency of succinic 
semialdehyde dehydrogenase. This leads to an accumulation of GHB in the urine. 
The reported level of GHB in this type of disorder was around 200 mg/L in 
urine.(184;190-192)  
Characteristics of GHB toxicity include euphoria, dizziness, visual disturbances, 
vomiting, nausea, bradycardia, hypotension, confusion, agitation, hypothermia, 
coma, respiratory depression, and death.(185)  
In postmortem blood samples, GHB is frequently detected at levels that range 
from physiological to pharmacological concentrations, even in cases when GHB 
use is not suspected. Stephens et al. (1999) (193) observed a relatively minimal 
formation of GHB in blood samples stored in a refrigerator without sodium 
fluoride. It has been reported GHB detected in the blood of corpses could be due 
to production during the interval between death and autopsy, rather than during 
sample storage at 4°C.(194)   
GHB concentrations may increase after death in the case of advanced 
decomposition or when the sample is heart blood. The common cut-off level of 
urinary GHB used in several studies to differentiate endogenous from exogenous 
is 10 mg/L. This can be applied to the samples that were properly stored but 
excludes cases of GHB aciduria.(134;192;195) Some laboratories use a cut-off 
concentration of 50 mg/L in the case of post-mortem cardiac blood.(186) In 
another study, the cut-off concentration of GHB for reporting positive results in 
post-mortem femoral blood and urine was 30 mg/L.(188)  
It is expected that the concentrations of GHB produced in vitro during storage 
will be more prevalent in post-mortem than in antemortem material. No levels 
of GHB above 3 mg/L were found in antemortem serum specimens, whereas in 
post-mortem blood, GHB levels up to 100 mg/L were reported, followed by a 
subsequent drop to unmeasurable values. (196) GHB production is less likely in 
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post-mortem urine samples and therefore collection and analysis of urine could 
provide an ideal control for the analysis of GHB in suspected drug related death. 
Freezing or preservation of specimens with sodium fluoride may improve 
stability of GHB from the time of the collection until the time of analysis.(196)  
It has been suggested that enzymatic conversion of succinic acid, GABA and 
putrescine are probably responsible for endogenous GHB production. In addition, 
glycolysis by bacteria may enhance endogenous GHB production.(185) Bacteria 
can metabolize glucose to succinic acid via phosphoenolpyruvate and 
oxaloacetate. Succinic acid is converted to succinic semialdehyde that can be 
reduced to GHB by succinic semialdehyde reductase.(185) Table 5-1 summarises 
published GHB levels in both living and post-mortem samples. 
Table 5-1:  GHB Published Levels in the Living and Post-Mortem 
Reference Matrix Population/Status GHB  (mg/L) N 
Endogenous GHB 
Elian, 2002.(197) Urine Ante mortem urine 0.34-5.75 670 
Fieler, Coleman and Baselt,  
1998.(198) Blood Postmortem 3.2-168 20 
Rahbeeni et al. 1994; Divry  
 et al. 1983; Elliott, 2003. 
(190-192) 
Urine Patients with GHB aciduria 200 6 
Exogenous GHB 
Kavanagh, Kenny and Feely, 
2001(199) Urine 
Volunteers  after 10 
hours after administration 
of 1 gram GHB 
 
4 1 
Jones, Holmgren and 
Kugelberg, 2008. (200) Blood 
People arrested for 
driving under the 
influence of GHB 
Mean=89, 
highest 340 
548 
Fatal GHB level 
Kugelberg et al. 2010. (188) Blood Postmortem In excess of 300 49 
 
5.2.3 Analysis of GHB 
Several techniques have been used to analyse GHB in biological samples, such as 
GC-MS, high performance liquid chromatography with UV detection (HPLC-UV) 
and liquid chromatography tandem mass spectrometry (LC/MS/MS). Appendix 5-1 
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lists a summary of the published methods for the analysis of GHB and related 
compounds in different biological matrices. 
The method originally developed and validated for the analysis of BHB in post-
mortem blood and urine(138) as described in Chapter 4, was adapted and 
revalidated for the determination of GHB in post-mortem blood and urine and 
this validation is described below.  
5.2.4 Materials 
The internal standard used was deuterated gamma hydroxybutyrate (GHB-D6      
1 mg/mL), purchased from Cerilliant Corporation (Round Rock, TX) and gamma-
hydroxybutyrate (GHB) was obtained from Sigma-Aldrich Co. Ltd. (Basingstoke, 
England). All other materials used are as described in sections 4.2.1.1 – 4.2.1.4. 
Drug and volatile-free blood and urine blanks used for preparing quality controls 
and calibrators were tested for endogenous interference.  
Post-mortem blood (N=120) and urine (N =64) samples selected from the same 
cases analysed for BHB (as described in section 4.5.2.3) were also analysed for 
GHB. Basic demographic information is also summarised in Appendix 5-2 for 
these cases, including gender, age, other drugs detected at post-mortem and 
the cause of death. This information was not always available for every case as 
the post-mortem was carried out for some cases by a forensic pathologist who 
was not based within Forensic Medicine and Science. These cases are indicated 
as “External Case”. 
5.2.5 Methodology 
The instrumentation, GC conditions utilised and extraction methods developed 
and validated in Chapter 4 for the analysis of BHB were also used for the analysis 
of GHB in blood and urine. Data was collected in full scan mode and the ions 
monitored were m/z 233, 117, and 204 for GHB and m/z 239 and 240 for the 
internal standard GHB-D6. The underlined ions were used for quantification. 
Chapter 5  145 
5.2.6 Method Validation 
Method validation for GHB in post-mortem blood and urine was carried out as 
previously described in Section 4.3 for the validation of BHB in blood and urine. 
5.2.7 Results and Discussion 
Figures 5-3 and 5-4 illustrate typical chromatograms and spectra for GHB and the 
internal standard GHB- D6 extracted from blood and urine, respectively. 
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Figure 5-3:  Chromatogram and Full-Scan Spectrum o
(50 mg/L). 
[(A) GHB-TMS extracted ion chromatogram, (B) GHB-
extracted ions chromatogram. (C) and (D) Full-scan s
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Figure 5-4:  Chromatogram and Full-Scan Spectrum of GH
(50 mg/L). 
[(A) GHB-TMS extracted ion chromatogram, (B) GHB-TMS
extracted ions chromatogram. (C) and (D) Full-scan spec
respectively] 
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GHB was linear over the concentration range of 10-500 mg/L in both blood and 
urine as illustrated in Figure 5-5. 
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Figure 5-5:  GHB Calibration Curves for Blood and Urine 
 
The LOD of GHB in urine and blood was 1 mg/L and the LOQ was 2 and 4 mg/L 
respectively. Figure 5-6 involves a series of overlaid chromatograms for GHB 
spiked in blood and urine at low concentrations (blank, 2, 5 and 10 mg/L) to 
demonstrate that there was no interference from the matrix due to endogenous 
GHB. GHB levels in the blank samples were less than the LOD in both matrices. 
The intra-day and inter-day precision were less than 10% as summarised in Table 
5-2. QC results were within the acceptable ranges as illustrated in Appendix 5-3.  
    Table 5-2:  GHB Intra-day and Inter-day Precision for Blood and Urine 
 
 
 
 
 
Intra-day 
precision %CV 
(n=6) 
Inter-day 
precision %CV 
(n=10) 
Matrix 50 (mg/L) 
300 
(mg/L) 
50 
(mg/L) 
300 
(mg/L) 
Urine 1.7 1.5 2.9 2.7 
Blood 2.3 3.1 3.3 5.6 
Chapter 5  149 
8.18 8.19 8.19 8.20 8.20 8.21 8.21 8.21 8.22 8.22 8.23 8.23 8.24 8.24 8.25 8.26 8.26
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
220000
240000
Time-->
Abundance
Ion 233.00 (232.70 to 233.70): 2009-06-14-006.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-011.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-012.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-014.D\data.ms
 
 (A) 
 
8.18 8.19 8.19 8.20 8.20 8.21 8.21 8.21 8.22 8.22 8.23 8.23 8.24
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
Time-->
Abundance
Ion 233.00 (232.70 to 233.70): 2009-06-14-028.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-032.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-034.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-036.D\data.ms
 
       (B) 
Figure 5-6:  GHB Extracted Ion Chromatograms for Blank Blood (A) and Urine (B)  
[Spiked at Concentrations of 2, 5 and 10 mg/L] 
 
Recovery of GHB ranged from 40-50% in blood and urine. The efficiency 
(absolute recovery) of the method was between 83 and 99% and the accuracy 
was between 89 and 104%, as summarised in Table 5-3.  
10 mg/L 
2 mg/L 
5 mg/L 
Blank 
Blank 
5 mg/L 10 mg/L 
2 mg/L 
Chapter 5  150 
Table 5-3:  Recovery, Efficiency and Accuracy of GHB  
 Recovery (%) Efficiency (%) Accuracy (%) 
Matrix 50     (mg/L) 
300     
(mg/L) 
50 
(mg/L) 
300 
(mg/L) 
50 
(mg/L) 
300 
(mg/L) 
Urine 40 41 99 96 95 89 
Blood 47 50 86 83 95 104 
 
Although the recovery of GHB was low (40 and 50%) in blood and urine, the 
efficiency (absolute recovery) of the method was between 83 and 99%, and the 
accuracy was between 89 and 104%.  
Appendix 5-2 summarises the 120 cases tested for GHB and included five cases 
(case # 36, 103, 106, 108 and 118) with high levels of GHB in post-mortem blood 
and urine (where available). These five specific cases are summarised in Table 5-
4 and Figure 5-7 illustrates the chromatograms and spectra for the high levels 
GHB detected in blood and urine samples from Case number 36. 
Table 5-4:  Case Samples with High/Toxic Levels of GHB in Post-Mortem Blood and Urine  
Case No. Gender Age GHB (mg/L) Background/ Cause of Death Blood Urine 
36 Male 34 >500 >500 1a- GHB intoxication 
103 Male  369  Suspected GHB/GBL intoxication (External Case) 
106 Male  300  Suspected GHB/GBL intoxication (External Case) 
108 Female  >500 >500 Suspected GHB/GBL intoxication (External Case) 
118 Female 37 264  Suspected GHB/GBL intoxication (External Case) 
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Figure 5-7:  Chromatograms (A) and (C) and Full-Scan Spectra (B) and (D) for GH
from Blood and Urine, respectively, from Case # 36 at Levels >500 mg/L. 
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of GHB in urine was 4 mg/L, the majority of the results were negative. 
Concentrations of 50 mg/L in postmortem blood and less than 10 mg/L in urine 
may be due to endogenous levels of GHB, but this is not sufficient by itself to 
distinguish between natural endogenous levels and exogenous use. 
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Figure 5-8:  GHB Levels in Post-Mortem Blood and Urine in Cases with no History of GHB 
and/or GBL Misuse. 
 
Earlier observations suggested that GHB was present in postmortem blood of 
non-GHB related fatalities, it was therefore suggested that the presence of GHB 
in urine could indicate the exogenous ingestion of GHB before death.(198) A 
study detected GHB in postmortem blood and urine in non GHB related fatalities 
with higher levels in blood than urine.(193) The exact source of the GHB in such 
instances has not as yet been identified. 
Although some studies indicated that the GHB concentration due to formation 
postmortem may reach 409 mg/L(186) and 168 mg/L,(198) Berankova et al.(196) 
found levels up to 100 mg/L of GHB concentration in postmortem blood. The 
exogenous increase of GHB levels in post-mortem blood was only temporary, 
reaching the maximum with a subsequent drop to immeasurable values. Another 
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study reported that 43 mg/L was the highest GHB level in postmortem 
blood.(194) 
The levels of GHB in postmortem blood and urine that were associated with 
GHB/GBL intoxication in this study had high or fatal levels of GHB ranging from 
264 to >500 mg/L. A high GHB concentration ranging from( was also reported in 
case samples where there was no evidence of GHB and or GBL exposure.Fieler et 
al.1998 reported that GHB post-mortem blood can be detected at concentration 
ranges between (3.2-168 mg/L)in post-mortem femoral blood. According to a 
study carried out by Kintz et al. 2004 (186) seventy one autopsy cases were 
reported where cardiac blood GHB concentrations were >50 mg/L with range of 
(0.4-409 mg/L).This makes the interpretation more difficult to distinguish 
between endogenous and exogenous levels of GHB. Analysis of other biological 
fluids postmortem, such as vitreous humour or femoral blood, in addition to the 
knowledge of the circumstances surrounding the death may help in interpreting 
the results.  Additionaly information relating to the post-mortem interval, the 
time of sample collection and the condition of storage of the corpse may also 
provide supportive information for result interpretation. Elliott, 2001(184;201) 
reported that GHB in urine was elevated in GHB unrelated fatalities and 
suggested that the presence of GHB in urine does not necessarily indicate GHB 
ingestion. Furthermore in living subjects although urine was an accepted 
specimen in most of drug-facilated sexual abuse (DFSA) at a cut off 10 mg/L, it 
has been reported by Le Beau et al. 2006.(202) that there is potential for an 
artificial increase in GHB concentrations in urine and reported results from 31 
volunteers who never used GHB thought to occur during storage in refrigerator at 
5ºC without preservative for a period over 6 months.   
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5.3 Simultaneous Determination of HMB, BHB and GHB 
in Plasma and Urine using GC/MS 
5.3.1 Introduction 
β-Hydroxy-β-methylbutyrate (HMB), or β-hydroxyisovaleric acid (β-HIV), has 
recently been considered a promising dietary supplement; the claim is that it 
increases strength and muscle mass and that it is the sixth most commonly used 
supplement. In 1999, the International Olympic Committee’s medical advisory 
board categorized HMB as a legal substance.(203) It was patented by Iowa State 
University Research Foundation in 2000. HMB has been found useful for reducing 
cholesterol levels and improving low lipoprotein density (LDL), enhancing the 
immune response of mammals (204), and it may lead to increase muscle mass 
and decrease muscle break down and proteolysis. It is considered an 
anticatabolic agent(204). It has been proposed that the HMB nutritional 
supplement may increase the strength and lean mass in humans involved in 
resistance training programs.(205) HMB can be synthesised through oxidation of 
diacetone alcohol in a free acid form which is then converted to the salt.(204) 
Other studies indicate that HMB can be produced through the conversion of β—
methylbutyric acid by the action of bacteria (Galactomyces reesii). (205)  HMB 
doses used in research was between 1.5 to 3.0 grams per day. (206) It has been 
concluded from review studies carried out by Slater and Jenkins, 2000 (203) that 
supplementation of HMB at doses of 1.5 to 3 g/day may enhance gains in 
strenghth and lean body associated with resistance training and there may be a 
reduction in skeletal muscle damage. The mechanism by which this may occur is 
unknown. It has been suggested that the further controlled studies to confirm 
this finding.  
HMB is a metabolite of the essential amino acid (leucine). Transamination of 
leucine is through branched chain acid transaminase to produce alpha-
ketoisocaptoate (KIC). KIC is involved in the formation of β-hydroxyisovalorate 
(β-HIV or HMB) in 3 different ways. The first way is through the action of 
cytosolic α-ketoisocaproate oxygenase. The second way is through 
decarboxylation of the branched chain ketoacid dehydrogenase to isovaleryl-
CoA, which is partially hydrolyzed to isovalerate and then oxidized to HMB. The 
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third way is through further oxidization of isovaleryl-CoA to β-methyl crotonyl-
CoA by isovaleryl-CoA-dehydrogenase and by hydration, followed by enoyl-CoA 
hydratase, followed by hydrolysis of β-hydroxyisovaleryl-CoA. β-methyl crotonyl-
CoA is metabolized to acetyl CoA and ketone bodies via β-methylglutaconyl-CoA 
and β-hydroxy-β-methylglutaryl-CoA(206).as illustrated in Figure 5-9. 
Approximately 2–10% of leucine oxidation is converted to HMB.(207) 
 
 
Figure 5-9:  Leucine Metabolism and Formation of β-hydroxy-β-methylbutyrate (HMB) 
[(A) Branched chain amino acid transaminase, (B) branched chain ketoacid dehydrogenase, 
(C) isovaleryl-CoA, (D) enoyl-CoA hydratase, (E) β-methylcrotonyl-CoA carboxylase,(F) β-
methylglutaconyl-CoA hydratase, (G) cytolic α-ketoisocaporate oxygenate, (H) β–hydroxy 
butyric acid dehydrogenase.  [Redraw from Yu et al  (206)and Landaas(208)] 
 
Leucine hypoglycaemia and maple-syrup urine disease (MSUD) are known to be 
the only inborn error disease related to leucine metabolism. Several studies have 
indicated that a new genetic disorder related to leucine metabolism has been 
discovered in which the defect of leucine metabolism results in the 
accumulation of isovaleric acid, HMB and β-methylcrotonyl aciduria.  (206;209-
212) It was reported that the urinary increase of HMB in the inborn error disease 
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could be due to the defect of enzymes involve in the degradation of 
leucine.(209) 
In ketoacidosis, usually characterized by the accumulation of ketone bodies 
(acetone, acetoacetate and BHB), this may occur with several clinical disorders 
in which fatty acids replace glucose for energy. Production of acetyl CoA is as a 
result of fatty acid oxidation. Acetyl CoA has an important role in 
ketogeneis.(208) Landaas reported the urinary increase of HMB in all ketotic 
patients and a positive correlation between HMB and BHB. High levels of BHB 
and acetoacetate and increased oxidation of fatty acids may influence the 
degradation of leucine, which may lead to increased HMB levels.(208) 
In 1975, Landaas(213) reported that in ketoacidosis, a close relationship was 
demonstrated between the excretion of HMB in urine and the degree of 
ketoacidosis. He also indicated that another two hydroxy acids (β-
hydroxyisobutyric acid and 2-methyl-3-hydroxybutyric acid) increased, in 
addition to HMB. Two possibilities have been considered in relation to the 
formation of HMB during ketoacidosis. The first one indicates that either the 
leucine might be the precursor or the increased pool of 3-hydroxy-3-
methylglutaryl-CoA(3-HMG-CoA) might give rise to metabolites.(213) 
According to the study of Weimin, et al.(206), it is also known that type 1 
diabetes mellitus (insulin deficiency) may accelerate the breakdown of proteins, 
leading to enhanced leucine metabolism, and the same effect might occur in 
cases of diabetes melitus type 2 (insulin resistance). It was also reported that 
urinary levels of HMB and serum leucine were higher in ketotic patients than in 
nonketotic patients. The amount that HMB increases in nonketotic patients 
depends on the degree of hyperglycemia. It has also been observed that the 
leucine levels in nonketotic patients was almost the same as in the control 
group. This study leads to the conclusion that urinary HMB levels in diabetes 
mellitus might be useful in the evaluation of protein metabolism even in the 
absence of ketosis and marked hyperglycemia. 
Weimin, et al.(206) calculated the HMB and BHB urinary concentrations listed in 
Table 5-5 were from the ratio of the HMB peak area to that of the internal 
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standard and expressed as µg per mg creatinine as a correction for urinary 
dilution or concentration by kidneys which may affect endogenous HMB 
concentrations.  
Table 5-5:  Urinary Levels of HMB, BHB and Serum Leucine in Diabetic and Non-Diabetic 
Patients(206) 
Group Urinary HMB Urinary BHB 
Serum leucine 
µmol/L N 
Diabetic with 
ketosis 
27.1-87.5 ug/mg 
creatinine 
0-1274 ug/mg 
creatinine 
212-260 9 
Diabetic without 
ketosis 
21.7-51.3 ug/mg 
creatinine 
undetectable 141-187 12 
Control Group 
4.1-16.3 ug/mg 
creatinine 
undetectable 135-168 21 
 
5.3.2 Analysis of HMB  
Analysis of HMB has been conducted using a variety of different analytical 
techniques such as GC/MS and LC/MS/MS as summarised in Table 5-6.  
Table 5-6:  Summary of the Published Methods for the Analysis of HMB. 
Ref. Analyte Matrix 
Extraction and 
Internal Standard 
Technique Ions/identification 
(206) HMB, BHB, MMA Urine serum 
PP for serum 
(n-heptadecanoic acid). 
LLE for urine then SPE 
(MMA D3) 
GC/MS-SIM 
HMB (247) 
MMAD3 (250) 
 
 
(208) HMB, BHB and Lactate 
Urine 
serum 
PP for serum 
LLE for urine 
(2-HIV). 
 
GLC/MS Retention Time/Mass spectra 
(214) HMB Plasma 
LLE 
(MMA D3) 98% pure 
synthesized from 
acetone D6 and acetic 
acid 
GC/MS 
HMB (117,175, 217) 
HMB-D6 (181) 
 
 
(162) 
Amino acid, Fatty 
acids Organic 
acids 
Blood 
Sample dissolve in 
water and organic 
solvent then 
derivatized. 
LC/MS/MS Different scan mode depends on analytes 
PP (Protein precipitation), LLE (Liquid Liquid Extraction), MMA D3 (Deuterated methyl malonic acid), 2-
HIV (2- Hydroxy isovaleric acid), HMB-D6 (Deuterated HMB) 
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The method originally developed and validated for the analysis of BHB and GHB 
in post-mortem blood and urine,(212) as described in Chapter 5, was further 
adapted and revalidated for the determination of HMB in plasma and urine as 
described below.  
5.3.3 Materials 
β-hydroxyisovaleric acid (HMB), liquid form, purity, ≥97% was purchased from 
Sigma Aldrich Co. (St Louis, USA). Blank plasma was obtained from the blood 
bank at the Western Infirmary Hospital, Glasgow. Blank urine was obtained from 
a healthy adult volunteer. Both blank plasma and urine were tested in triplicate 
for the presence of HMB, BHB and GHB. The internal standard used was 
deuterated gamma hydroxybutyrate (GHB-d6, 1 mg/mL), purchased from 
Cerilliant Corporation (Round Rock, TX). All other materials used are as 
described in Sections 4.2.1.1 – 4.2.1.4. Drug and volatile-free plasma and urine 
blanks used for preparing quality controls and calibrators were tested for 
endogenous interference.   
One hundred and forty five plasma and 201 urine samples were received from 
the Center for Human Toxicology, University of Utah, USA as part of 
collaboration. The samples were collected from subjects (N=8) as part of a 
clinical study, at time zero (baseline), and after 2 hours for plasma and between 
0–4 hours for urine after oral administration of 3 grams of HMB. All samples were 
tested for HMB, BHB and GHB. Results less than the LOQ were reported as <LOQ. 
Samples greater than the ULOQ were diluted in water and reanalysed, then 
multiplied by the dilution factor after analysis. All samples were stored at -
20±2ºC during the time of analysis. 
A statistical calculation of mean, standard deviation and 95% confidence 
intervals (CI%) was calculated at baseline and after 2 hours for plasma and at 0–4 
hours for urine for all analytes (HMB, BHB and GHB). 
The method was applied to two post-mortem cases in which the results of initial 
analysis using the previous method indicated a high BHB level in one case and 
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high GHB level in the other case. Whole blood and urine for both cases were 
analysed using this method.  
5.3.4 Methodology 
The instrumentation, GC conditions utilised and extraction methods developed 
and validated in Chapter 4 and section 5.2 for the analysis of BHB and GHB were 
also used for the analysis of HMB in plasma and urine. Data was collected in full-
scan mode and the ions monitored were: for HMB m/z 247, 131 and 205; BHB 
m/z 233, 117 and 191; GHB m/z 233,117 and 204 and m/z 239 and 241 for the 
internal standard GHB-d6. The bold underlined ions were used for quantification. 
A 50µL aliquot of plasma or urine calibrators, QCs and samples were transferred 
to 2 mL snap top polypropylene microcentrifuge tubes and extracted using the 
same blood method described in section 4.2.4 and Table 4-5.  
5.3.5 Method Validation 
Method validation for HMB, BHB and GHB in plasma and urine was carried out as 
previously described in Section 4.3 for the validation of BHB in blood and urine, 
with the exception of the assessment of stability which is summarised below. 
The assessment of the long-term stability of HMB, BHB and GHB in plasma and 
urine at two concentrations (50 and 300 mg/L) was carried out by re-analysing 
three sets of QC samples stored for 12 months at -20±2ºC. The percentage 
recovery was calculated by dividing the mean peak area ratio of the extracted 
QC samples versus the mean peak area ratio of the same spiked QC samples 
extracted and analysed 12 months previously. Analytes were considered as 
stable when the percentage recovery was between 90-110% of control samples 
and the 95% confidence interval (CI) was within 80-120% of the mean of the 
control samples.(169)  
5.3.6 Results and Discussion 
Figure 5-10 illustrates a typical chromatogram and spectra of an unextracted 
derivatized standard for HMB, BHB, GHB and internal standard GHB-D6. 
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analytes in plasma and urine respectively. The retention time of all analytes, 
including the internal standards was between 6-8 minutes.  
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The correlation coefficients (R2) were >0.99 for HMB, BHB and GHB over the 
linear range of 10–500 mg/L as illustrated in figure 5-13. Table 5-7 summarises 
the linearity data for each analyte in both matrices and also includes the LOD 
and LOQ. Due to the endogenous nature of HMB (212), BHB and GHB, the first 
point of the calibration curve was used as the lower limit of quantitation (LLOQ). 
Results less than 10 mg/L were reported as negative and results above 500 mg/L 
were reported as >500 mg/L. 
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Figure 5-13:  HMB, GHB and BHB Calibration Curves for Urine (A) and Plasma (B) 
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Table 5-7:  LOD, LOQ and Linearity for HMB, BHB and GHB 
Matrix Analyte LOD 
(mg/L) 
LOQ 
(mg/L) 
Linearity 
(mg/L) 
R2 
Urine 
HMB 2.3 7.7 10-500 0.994 
GHB 1.0 3.3 10-500 0.999 
BHB 2.2 7.3 10-500 0.999 
Plasma 
HMB 2.3 7.8 10-500 0.990 
GHB 1.5 5.1 10-500 0.999 
BHB 0.9 2.9 10-500 0.998 
 
Inter-day and intra-day precision was less than 10% for all three analytes in both 
matrices. The average accuracy ranged from 98-102% and recovery from 42-77% 
in spiked controls as summarized in Table 5-8. 
Table 5-8:  HMB, BHB and GHB, Intraday and Interday Precision, Recovery and Accuracy  
 
 
The quality control samples were analysed on several occasions as illustrated in 
Appendix 5-4 and although some variation was noted, specifically in the lowest 
QC level of 10 mg/L, the majority of the QC results were within the acceptable 
limit of the mean ± 2 standard deviations (±2SD).  
Matrix Analyte QC conc. (mg/L) 
Intraday 
%CV 
(n=5) 
Interday 
%CV 
(n=12) 
Accuracy 
(%) 
Recovery 
(%) 
 
Urine 
HMB 50 
(300) 
3.7 
(1.7) 
12.4 
(8.5) 
120 
(102) 
75 
(77) 
GHB 50 
(300) 
3.2 
(1.8) 
5.5 
(5.2) 
98 
(100) 
67 
(74) 
BHB 50 
(300) 
1.8 
(1.5) 
11.1 
(5.3) 
100 
(99) 
64 
(68) 
 
Plasma 
HMB 50 
(300) 
6.2 
(9.2) 
9.5 
(7.9) 
100 
(101) 
42 
(53) 
GHB 50 
(300) 
0.9 
(3.6) 
2.9 
(4.0) 
100 
(102) 
73 
(74) 
BHB 50 
(300) 
8.9 
(2.8) 
3.4 
(4.4) 
98 
(101) 
57 
(66) 
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HMB, GHB and BHB were all stable when stored for over 12 months at -20±2ºC 
with recoveries of greater than 91% achieved for the 300 mg/L QC as summarised 
in Table 5-9.  
Table 5-9:  HMB, GHB and BHB Concentrations Measured in Spiked Plasma and Urine 
[following (A) Initial tests and (B) after 12 months storage at -20°C].  
 
GHB concentrations increased across both matrices and at the two 
concentrations investigated. The recoveries for BHB were lower for the 50 mg/L 
QC in both plasma and urine although still greater than 85% after 12 months. The 
%CV was much higher for the 50 mg/L QC when retested for both plasma and 
urine and may account for this variability. However, this does not explain the 
considerable decrease in HMB concentration for the 50 mg/L spiked urine QC 
sample (56%) however this is not reflected in the recoveries at 300 mg/L urine 
QC sample or either of the plasma samples which are all greater than 91%.  
Figures 5-14 and 5-15 provide examples of HMB identified in plasma and urine 
respectively in both spiked and real case scenarios when compared with blank 
matrices. Full scan spectra are also provided.  
The method was applied to two post-mortem cases where both whole blood and 
urine were analysed. The first case (Figure 5-16) had high concentrations of BHB 
in blood and urine and elevated levels of GHB, while the second case (Figure 5-
   
PLASMA  
(mg/L) 
URINE  
(mg/L) 
 Sample 
Conditions 
Conc. 
(mg/L)   HMB GHB BHB HMB GHB BHB 
A 
50                    
(n=12) 
Mean 50 50 49 60 49 50 
SD 4.26 1.78 2.54 8.14 2.96 5.03 
%CV 8.51 3.54 5.17 13.59 6.05 10.02 
300                 
(n=12) 
Mean 304 305 304 307 299 296 
SD 26.96 13.71 14.26 44.53 10.34 10.97 
%CV 8.87 4.49 4.68 14.51 3.46 3.71 
B 
50                 
(n=6) 
Mean 47 56 43 33 54 43 
SD 6.53 1.62 6.78 4.90 1.70 5.77 
%CV 13.77 2.90 15.61 14.73 3.16 13.54 
300                 
(n=6) 
Mean 282 334 296 279 358 316 
SD 21.68 14.83 18.35 14.09 9.91 7.40 
%CV 7.68 4.44 6.20 5.06 2.77 2.34 
         
% 
Recovery 
50  95 111 88 56 110 85 
300  93 109 97 91 120 107 
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17) had high concentrations of GHB in blood and urine and low levels of BHB. In 
both cases HMB was less than the LOQ.  
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Figure 5-14:  Chromatogram and Full-Scan Spectrum for HMB Extracted from a Plasma Case 
Sample (37 mg/L) Versus the Spiked Plasma Control at 50 mg/L and Blank Plasma.  
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Figure 5-15:  Chromatogram and Full-Scan Spectrum for HMB extracted from a Urine Case 
Sample (500 mg/L) versus the Spiked Urine Control at 50 mg/L and Blank Urine.  
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Figure 5-16:  (A) Chromatogram 
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of HMB at a concentration of 50 mg/L was less than 50%, but the accuracy was 
between 98% and 102%. 
Table 5-10 summarises the mean and range of HMB, GHB and BHB at baseline 
and after administration of 3 g of HMB. Baseline concentrations for HMB in 
plasma and urine were less than the LOQ (<10 mg/L) before drug administration.  
Following administration of the 3g dose of HMB, plasma and urine were positive 
respectively. 
Table 5-10:  HMB, GHB and BHB level in urine and plasma at baseline and after 0-4  
hours(urine) and 2hours(plasma) following 3g  dose of HMB   
 
 
5.4 Conclusion 
A robust and sensitive method for the analysis of gamma-hydroxybutyrate (GHB) 
in postmortem blood and urine was validated. The method was utilised to 
investigate GHB intoxication in postmortem case samples. In all case samples, 
there are no data to support GHB exposure with the exception of five cases. 
Concentrations of GHB less than the proposed published cut-off point of 50 mg/L 
in postmortem blood may be due to endogenous levels of GHB, but this is not 
sufficient by itself to distinguish between natural endogenous levels and 
exogenous use. Other matrices, such as vitreous humour, femoral blood, urine 
and hair, must also be considered when interpreting postmortem GHB levels, as 
recommended by Kintz et al. (186)Knowledge of the time intervals from the 
Matrix Analyte 
Baseline 
(mg/L) 
0-4 hours (urine) or 2 hours 
(plasma) after 3g oral HMB 
(mg/L) 
Mean Median 95% CI Mean Median 95% CI 
Urine 
(n=8) 
HMB 4 4 1-7 123 111 52-194 
GHB 0 0 0-1 0 0 0-1 
BHB 5 4 1-9 1 0 0-3 
Plasma 
(n=7) 
HMB 0 0 0 20 23 17-24 
GHB 0 0 0 0 0 0 
BHB 6 0 0-15 0 0 0-1 
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time of death until the time of sample collection and the condition of the 
storage of the corpse before collection of the samples might also provide some 
information for better interpretation of the results. 
It is important to evaluate the effect of HMB on the body because it is the sixth 
most commonly used dietary supplement and because it is legal.(203) There was 
a significant increase of HMB levels in urine and plasma 20–30 times more than 
the baseline level after consumption of 3 grams of HMB. No increase of BHB and 
GHB was observed. There was no correlation between the HMB levels and BHB or 
GHB in plasma and urine after administration of the HMB drug. 
The use of GC-MS provides a specific and selective technique for determining 
HMB and structurally related compounds such as BHB and GHB in biological 
samples. Dilution of the urine and plasma samples with blank plasma provided a 
cleaner extract minimising the interference from urea in urine samples. A rapid, 
specific and robust method was developed for the simultaneous determination of 
HMB, BHB and GHB in plasma and urine. This method was successfully applied to 
post-mortem blood and urine, and plasma and urine from healthy subjects. For 
long-term storage, samples should be stored at -20±2ºC to minimise degradation 
of HMB, BHB or GHB.  
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Chapter 6 - Fatty Acid Ethyl Esters 
6.1 Introduction 
 
Fatty acid ethyl esters (FAEEs) are non-oxidative metabolites of ethanol which 
are currently used as biomarkers for direct ethanol consumption in different 
biological matrices including, hair, blood and skin surface lipids. Elevated FAEEs 
in meconium, the infant’s first bowel movement, have also been reported as a 
biomarker for the detection of heavy prenatal ethanol exposure.  The aim of this 
project was to develop and validate a method for the determination of FAEEs in 
meconium using liquid chromatography tandem mass spectrometry (LC-MS/MS). 
Commercially available deuterated internal standards were used for the first 
time for the detection of FAEEs using LC/MS/MS. The validated method was then 
applied to the analysis of eighty- four meconium case samples collected from 
babies born at the Princess Royal Maternity Hospital, Glasgow to investigate 
neonatal exposure to alcohol in the absence of maternal drinking history.  
6.2 Materials and Methods  
6.2.1 Chemicals and Reagents 
Ethyl laurate 99.5% GC grade (E12:0), ethyl myristate (E14:0) 99% GC grade, 
ethyl palmitate 99% GC grade (E16:0), ethyl stearate (E18:0) 99% GC grade, ethyl 
oleate 98% GC grade (E18:1), ethyl linoleate 99% GC grade (E18:2), ethyl 
linolenate (E18:3) minimum 98%, and ethyl arachidonate 99% (E20:4) esters were 
obtained from Sigma Aldrich Company Ltd., Dorset, UK. The deuterated internal 
standards (IS) ethyl myristate-D5 99%, ethyl palmitate– D5 99%, ethyl oleate– D5, 
and ethyl stearate-D5 were obtained from LGC Standards, Teddington,UK. Ethyl 
heptadecanoate (E:17) >97 % GC, ethyl palmitoleate (16:1) >99%, and the methyl 
esters standards were all obtained from Sigma Aldrich Company Ltd., Dorset, 
UK. The methyl esters included, methyl arachidonate (99% GC grade), methyl 
heptadecanoate (99% GC grade), methyl linoleate (minimum 99%), methyl 
lenolenate, methyl myristate (99% GC grade), methyl oleate (≥ 99% GC grade), 
methyl palmitate (≥ 99% GC grade), methyl palmitoleate (99% GC grade), methyl 
stearate (99%) and methyl laurate (99.5% GC grade).  
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The deuterated internal standards purchased from LGC Standards were not 
available at the start of this project and so deuterated internal standards were 
initially prepared in-house, the details of which are summarised in Appendix 6-1. 
Cyclohexane, acetone, acetonitrile and 2-propanol were all purchased from VWR 
International Ltd; ultrapure water was obtained from the in-house Millipore 
purification system. Amino propyl-silica solid phase extraction (SPE) columns 
(100 mg sorbent amount, 1 mL volume, 40µm particle size) were obtained from 
Sigma Aldrich Company Ltd., Dorset,UK. 
6.2.2 Instrumentation  
Analysis was carried out using an Agilent 6410 LC/MS/MS triple quadropole 
(Agilent, USA) coupled with an Agilent 1200-series binary pump, high 
performance autosampler, and thermostated column compartment. An 
electrospray ionization (ESI) source was used in positive ionization mode. The 
column used was Eclipse XDB-C8 column (150 x 4.6mm, 5µm) with a guard 
column of the same packing material (4.6 x 12.5) from Agilent Technologies, 
USA. An LC/MS/MS LCQ DECA XP Plus ion trap instrument from Thermo Finnigan 
(San Jose, CA) was used to tune the analytes of interest for collision energy 
optimization and product ion optimization to compare with the triple quadropole 
LC/MS/MS instrument. 
6.2.3 LC-MS-MS Operating Conditions 
Isocratic elution was chosen using a mobile phase with the ratio of water: 
isopropanol: acetonitrile of 20:40:40, v/v/v, at a flow rate of 0.7 mL/min. The 
total run time was 25 minutes with a column temperature maintained at 30ºC. 
The source parameters to obtain optimum sensitivity and specificity were the as 
follows capillary voltage, 4500v, source temperature 120ºC, gas temperature 
300ºC, gas flow 8 L/min, and nebulizer pressure 15 psi. LC and source 
parameters are summarized in Table 6-1. 
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Table 6-1:  Summary of LC and Ion Source Parameters 
LC Parameters 
Column XDB-C8 RP column (150x4.6 mm,5 µm) with guard column of the same packing material 
Mobile phase ACN:IPA:H2O-40:40:20 (V:V:V) 
Flow rate 0.7 mL/min isocratic 
Injection volume 50 µL 
Column Temperature 30ºC 
Run Time 25 minutes 
Mass Spectrometry Parameters 
Operating mode ESI-positive mode 
Gas temperature 300ºC 
Gas flow 8 L/min 
Nebulizer Pressure 15 PSI 
Capillary Voltage 4500 V 
Scan mode MRM 
 
6.2.4 Meconium Samples 
Drug and alcohol free blank meconium samples used for development and 
validation of the method were obtained from a previous project from babies of 
drug and alcohol-free mothers and were stored at -20±2°C within FMS. Three 
pretested pooled meconium blank samples were prepared by pooling 6 to 10 
blank meconium specimens and mixing them thoroughly; the approximate total 
weight for each pooled blank sample was between 40–50 g. The pooled 
meconium blanks were stored at -20±2°C to be used for preparation of 
calibratior and quality control specimens. 
Eighty-four meconium case samples were collected from diapers of newborn 
infants delivered at the Royal Maternity Hospital in Glasgow. The meconium was 
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recovered using wooden spatulas and stored in plastic tubes at -4°C until 
transported to the laboratory. All samples were shipped in ice packs in closed 
containers, and they were stored immediately in the freezer at -20±2°C.  
The stability of FAEEs in meconium as previously reported by Moore et al. 
(2003)(153) and Pichini et al. (2008)(159) is summarised in Table 6-2. FAEEs 
degrade if not stored properly and therefore specimens should be immediately 
shipped packed in ice and stored in the freezer to eliminate the risk of 
degradation of FAEEs. The longer-chain FAEEs appear to be more susceptible to 
heat and light; this was hypothesised as no ethyl arachidonate was detected in a 
study of 436 specimens analysed. This loss could be from exposure to light and 
heat, because the specimens were not shipped in ice and stored at a proper 
temperature.(153)  
Table 6-2:  Summary of FAEEs Stability Study by Moore et al.(153) 
 
It has been reported that around 10% degradation of FAEEs from the initial 
concentration occurs after 3 freeze/thaw cycles.(159)  
6.2.5 Preparation of Stock Standard Solutions 
Individual stock standards were prepared at a concentration of 10 mg/mL for 
each analyte in cyclohexane. The intermediate standard was prepared from the 
individual stock standards at a concentration of 1 mg/mL. The working standard 
mixture solution was prepared at concentrations of 1, 10, and 100 mg/L from 
% loss of FAEEs Temperature/Conditions Hours/Days 
86% Room temperature in light 24 hours 
60% Room temperature in dark 24 hours 
40% Room temperature in dark under argon 24 hours 
10% Refrigerator 24 hours 
18% Refrigerator 24 hours 
11% Freezer 6 days 
≤ 50% Freezer 43 days 
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the intermediate standard solution to be used for spiking the calibrators. The 
working internal standard mixture (including ethyl-myristate-D5, ethyl palmitate-
D5, ethyl oleate– D5, ethyl stearate-D5, and ethyl heptadecanoate) was prepared 
at a concentration of 100 mg/L in cyclohexane from a stock standard of 10 
mg/mL. Internal standards used for the quantification of ethyl palmitate was 
ethyl palmitate-D5, for ethyl oleate was ethyl oleate–D5, for ethyl stearate was 
ethylstearate-D5. Deuterated ethyl oleate-D5 was used for the remaining 
analytes namely; ethyl arachidonate, ethyl palmitoleate, ethyl laurate, ethyl 
myristate, ethyl linolenate and ethyl linoleate as deuterated internal standards 
of these FAEEs were not commercially available for purchase.  
Tuning solutions were prepared at 10 mg/L in mobile phase from the mixed 
stock standard solution (1 mg/mL for all analytes). Cyclohexane was evaporated 
and the mobile phase solutions reconstituted with mobile phase. All standards 
and tuning solutions were stored at -20± 2ºC. 
The international unit used for the concentration of FAEEs in meconium is 
nmol/g which has been converted to ng/g for this project and the conversion is 
summarised in Table 6-3.    
6.2.6 Preparation of Quality Control (QC) Material 
Two QC's samples were prepared at two concentrations (400 and 8000 ng/g). An 
aliquot of 0.5 g from pooled meconium blank which was screened to be used for 
spiking QC were weighed into 15 mL screw cap round-bottom glass tubes and 
centrifuged at 2500rpm for 5 minutes. After centrifugation 250 µL of deionised 
water was added. QC samples were vortexed for 0.5–1 minute until a 
homogeneous suspension was formed after spiking with a specified amount of 
the FAEEs standard mixture QC samples were vortexed for 0.5–1 minute and then 
internal standard will be added and follow the same steps of sample extraction 
procedure. The QC's were prepared and extracted fresh with each batch and the 
mean and standard deviation calculated to evaluate the acceptability of each 
batch. 
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6.2.7 Sample Extraction Procedure 
Samples of 0.5 g of meconium were weighed into 15 mL screw cap round-bottom 
glass tubes, and centrifuged at 2500rpm for 5 minutes. After centrifugation 50 
µL of internal standards mixture (100 mg/L) was added to all tubes followed by 
250 µL of deionised water and 500µL acetone. Samples were vortexed for 0.5–1 
minute until a homogeneous suspension was formed, and then 5 mL of 
cyclohexane added before placing the tubes in a tube shaker for 10min and 
finally centrifuging at 2500 rpm. The organic layer was transferred to 5 mL screw 
cap disposable glass tubes, and the solvent was evaporated to dryness at 30ºC 
under a nitrogen stream. The samples were vortexed after being resuspended 
with 500µL of cyclohexane. The samples were then applied to preconditioned 
aminopropyl-silica solid-phase extraction (SPE) columns with 2 mL cyclohexane, 
and the sample extract was collected in round-bottom culture tubes. The 
analyte was eluted with 2 mL cyclohexane and collected in the same tube before 
evaporating to dryness at 30ºC under a nitrogen stream. The samples were then 
reconstituted with 120µL of mobile phase and 50µL injected onto the LC system.  
Table 6-3:  Conversion of FAEEs Concentrations from nmol/g to ng/g 
 
 
 
 
 
 
 
 
FAEES Formula weight ng/g nmol/g 
Ethyl Laurate  229 1 0.0044 
Ethyl Myristate  257 1 0.0039 
Ethyl Linolenate  307 1 0.0033 
Ethyl linoleate  309 1 0.0032 
Ethyl Palmitoleate  283 1 0.0035 
Ethyl Palmitate  285 1 0.0035 
Ethyl Palmitate-D5 290 1 0.0034 
Ethyl Oleate  311 1 0.0032 
Ethyl Oleate-D5 316 1 0.0032 
Ethyl Stearate  313 1 0.0032 
Ethyl Stearate-D5 318 1 0.0031 
Ethyl Arachidonate  333 1 0.0030 
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6.3 Instrument Method Optimisation  
6.3.1 Optimization of the Fragmentor Voltage and Collision 
Energy 
MS/MS characterization of the compounds of interest was achieved using the 
triple quadrupole and electrospray ionization in positive ionization mode. 
Compound specific optimization of MS/MS was performed using the automatic 
software optimizer (Mass Hunter) and product ion optimization. Analytes were 
dissolved in mobile phase at a concentration of 10 mg/L and fragmenter ion 
optimization was carried out to select the highest abundant precursor ions from 
the first quadrupole.  
Collision energy was optimized to get the most abundant product ions at a 
collision cell pressure of 10–50 psi using nitrogen gas for collision. Optimization 
results for the two most abundant ion transitions per analyte were selected in 
the multiple reaction monitoring scan mode (MRM). Similar product ions were 
generated when the same tuning solutions were injected in another LC/MS/MS 
using a Thermo Finnigan LCQ DECA XP Plus ion trap instrument.   
6.4 Method Validation  
6.4.1  Selectivity 
Selectivity is ‘the ability of an analytical method to differentiate and quantify 
the analyte in the presence of other potentially interfering substance in the 
samples’. There are two types of potential interferences: endogenous matrix 
interferences and exogenous interferences. Exogenous interferences might 
include structurally related analytes of interest, interferences or non-
structurally related interfering substances in biological samples such as 
endogenous matrix component, metabolites, impurities or matrix 
components.(169;215;216) 
Selectivity evaluation was carried out by checking any interference from 
endogenous compounds by the analysis of independent replicate blanks of 
meconium from different sources compared with an unextracted FAEEs standard 
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mixture of 1 mg/L prepared in mobile phase. There should be no signal or area 
response at the expected elution time of the analyte in the meconium blank.  
In many LC-MS/MS metods, both analytes of interest and isotope-deuterated 
internal standards are not chromatographically separated; this was in order to 
see if there is a contribution of the monitored product ions (from analyte to 
internal standard and vice versa) causing changes to the signal measured. This 
was assessed by duplicate analysis of blank meconium spiked with internal 
standard versus blank meconium spiked with FAEEs standard mixture at a 
concentration of 8000ng/g without adding internal standards. Exogenous 
interferences with compounds structurally related to FAEEs was investigated by 
spiking blank meconium with fatty acid methyl esters (FAMEs) in duplicate at a 
concentration of 8000ng/g with and without adding the analyte of interest 
(FAEEs) at the same concentration.  
6.4.2  Linearity 
Using the standard working solutions at concentrations of 1, 10, and 100 mg/L, 
calibration curves were prepared in meconium at concentrations ranging from 
20–16000ng/g. The concentrations of calibrator points were 20, 50, 100, 400, 
600, 1,000, 2,000, 4,000, 8,000, 12,000, and 16,000ng/g. The calibrators were 
prepared fresh before each batch. 
The calibration curve was generated by plotting the peak area ratio versus the 
spiked analyte concentrations, and the correlation of coefficient (R2) was 
calculated. The acceptable R2 should be greater than 0.99. 
6.4.3  Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The LOD and LOQ were determined by preparing meconium samples with 
decreasing concentrations of each analyte within the expected range of the LOD. 
LOD concentrations were 1, 2, 5,10, 20, 50, 100, and 400ng/g. Regression 
analysis was undertaken, and the LOD and LOQ were calculated in accordance 
with Miller and Miller.(217) The calculation for LOD and LOQ is described in 
chapter 2 section 2.2.9. 
Chapter 6  179 
6.4.4  Accuracy and Precision 
Accuracy is determined by replicate analysis of QC samples at 2 concentrations 
(400 and 8000ng/g). The accuracy was calculated as a percentage of the 
measured mean value against corresponding theoretical or nominal value (“true 
value”). The mean value should not deviate by more than 20% from the true 
value.  
Intra-day precision (within-day precision) was evaluated using five replicates of 
meconium control samples prepared at 2 concentrations (400 and 8000 ng/g) and 
extracted and injected on the same day. Inter-day precision (between-day 
precision) was evaluated using six meconium control samples prepared in 
duplicate at two concentrations (400 and 8000 ng/g) and then extracted and 
injected over a time period of 6 days. The percentage of the coefficient of 
variance (%CV) was calculated, with an acceptable %CV% of <20%. 
6.4.5 Recovery study 
Recovery was evaluated at two QC levels (400 and 8000ng/g). The mean peak 
area ratio of 3 meconium blank samples spiked with FAEEs and d5-FAEEs was 
compared with the mean peak area ratio obtained for 3 meconium blank samples 
where d5-FAEEs standard mixture was added before the evaporation step. (215)  
6.4.6 Assessment of Matrix Effects 
The matrix effect was assessed using the post-column infusion approach. Mobile 
phase and three pooled blank meconium (extract) were injected onto the 
column simultaneously with FAEEs internal standards at a concentration of 10 
mg/L, infused at constant rate into the eluate using a post column tee 
connection. The presence of a negative or positive peak or response would 
indicate ion suppression or ion enhancement, respectively. 
Matrix effects were also assessed by preparing 2 sets of spiked samples in 
triplicate at two concentrations (400 and 8000ng/g). The first set was prepared 
by spiking meconium blank samples, and the second set was prepared at the 
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same concentration without the matrix. The matrix effect was expressed as a 
percentage of the mean of the peak area ratio of the two sets. 
6.4.7  Carryover 
Carryove as assessed by injecting a mobile phase blank after the sample 
containing the calibration standard equivalent to the upper limit of quantitation 
(16,000ng/g).  
6.5 Results and Discussion 
6.5.1 Optimization of the Fragmentor Voltage and Collision 
Energy 
The fragmentor voltage was in the range of 100–140 for most of the FAEEs and 
 their deuterated analogues, for optimum abundance of the precursor ions as  
illustrated in Figures 6-1 and 6-2, respectively.  
 
 
Figure 6-1:  Fragmenter Ion Optimization of FAEEs 
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Figure 6-2:  Fragmenter Ion Optimization of D5-FAEEs and Ethyl Heptadecanoate 
 
Most analytes had an optimum collision energy of less than 10eV using LC-MS/MS 
as illustrated in Figure 6-3. However, using the same tuning solution with the ion 
trap LC/MS/MS, the collision energies were higher (27-42 eV for the same 
analytes). The collision energy and product ion optimization, using triple 
quadropole LC-MS/MS was not fully achieved as it was not reproducible. This is 
most likely due to the low collision energy required to fragment the ions (less 
than 5ev) which is much lower compared to the Thermo ion trap LC-MS/MS. A 
summary of the molecular and product ions and optimised collision energy is 
summarised in Table 6-4. 
 
Figure 6-3:  Collision Energy Optimization of FAEEs and D5-FAEEs 
 
Multiple Reaction monitoring (MRM) transitions of quantifiers and qualifiers in 
addition to the fragmenter voltage, collision energy, and retention time are 
listed in Table 6-5. The FAEEs retention times ranged from 7–21 minutes. 
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Table 6-4:  FAEES and FAEEs-d5 Optimization of Product Ion and Collision Energy (CE) 
FAEEs Molecular Ion 
Product  
Ions 
CE 
Ion Trap  Comment 
Ethyl Arachidonate 332.5 287 38 Commercial 
Ethyl Heptadecanoate 299 271 36 Commercial 
Ethyl Laurate 228.38 201 30 Prepared in house from its acid 
Ethyl Lenolenate 306.49 261/243 42 Commercial 
Ethyl Linoleate 308.51 263/245 32 Commercial 
Ethyl Miristate 256.43 229 32 Commercial 
Ethyl Oleate 310.53 265/247 30 Commercial 
Ethyl Palmitate 284.48 257 32 Commercial 
Ethyl Palmitoleate 283 237 30 Commercial 
Ethyl Stearate 312.53 285 34 Prepared in house from its acid 
Commercial Deuterated FAEEs-D5 
Ethyl Miristate-D5 262 230 30 Commercial 
Ethyl Oleate-D5 316 265 38 Commercial 
Ethyl Palmitate-D5 290 258 30 Commercial 
Ethyl Stearate-D5 318 286 32 Commercial 
 
 
 
Table 6-5:  MRM (m/z) Transitions for Quantification of FAEEs 
FAEEs 
MRM 
Transition 
(m/Z) 
Qualifier 
product 
ions 
Fragmentor 
voltage 
(V) 
CE 
(ev) 
Rt 
(min) 
Ethyl Laurate  229→201 - 84 2 7.06 
Ethyl Myristate  257→229 - 100 2 9.98 
Ethyl Linolenate  307→261 243 135 2 8.52 
Ethyl linoleate  309→263 245 120 2 11.16 
Ethyl Palmitoleate  283→237 - 108 2 10.44 
Ethyl Palmitate  285→257 - 136 6 14.24 
Ethyl Palmitate-D5 290→258 - 136 5 14.03 
Ethyl Oleate  311→265 247 135 2 15.23 
Ethyl Oleate-D5 316→265 247 140 2 14.94 
Ethyl Stearate  313→285 247 140 5 21.26 
Ethyl Stearate-D5 318→286 - 140 5 20.98 
Ethyl Arachidonate  333→287 - 128 5 9.98 
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6.5.2 Specificity 
No endogenous or exogenous interferences were identified at the FAEEs 
retention times (as summarised in Appendix 6-2) or from structurally-related 
analytes, as illustrated in Figures 6-4 and 6-5. No contribution from the internal 
standards to the analytes or vice versa was observed as illustrated in Figure 6-6. 
 
Figure 6-4:  Exogenous Specificity Study Spiked Meconium with FAME Mix Standard alone 
8000ng/g against Spiked FAEES 8000ng/g plus FAME 8000ng/g Compared with Unextracted 
FAEES and Unextracted FAME of 10 mg/L. [The arrow indicates no interference].  
 
 
Figure 6-5:  Total Ion Chromatogram (TIC) of Extracted FAEEs 8000 ng/g in Meconium 
Versus Extracted Blank and FAME standard of 8000 ng/g with Internal Standard. 
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Figure 6-6:  Extracted FAAEs With and Without Internal Standard. 
[The arrow indicated no contribution from analyte to internal standard] 
Ethyl Palmitoleate FAEEs Std No internal  Standard_1  
Ethyl Palmitoleate FAEEs Std No internal Standar_2  
Ethyl Palmitoleate FAEEs Std + internal Standar_1  
Ethyl Palmitoleate FAEEs Std + internal Standar_2  
Ethyl Palmitate Extracted Blank 
Ethyl Palmitate FAEEs Std No internal Standard_1  
Ethyl Palmitate FAEEs Std No internal Standar_2  
Ethyl Palmitate FAEEs Std + internal 
Ethyl Palmitate FAEEs Std + internal 
Ethyl Palmitoleate Extracted Blank 
D5-Ethyl Palmitate Extracted Blank 
Ethyl Palmitate FAEEs No internal 
Ethyl Palmitate FAEEs No internal 
Ethyl Palmitate FAEEs + internal 
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Ethyl Linolenate FAEEs No internal 
Ethyl Linolenate FAEEs No internal 
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6.5.3 Validation Results 
All regression lines had > 0.995 over the concentration range from LLOQ -
16,000ng/g for each analyte as summarised in Table 6-6. With the exception of 
ethyl laurate and ethyl arachidonate, the LOD and LOQ were acceptable and are 
listed in Table 6-6. 
Table 6-6:  Linearity, LOD, and LOQ of FAEEs in Meconium 
 
 
 
 
 
 
 
Intra-day and inter-day precision for all analytes met the criteria for 
acceptability of <20%. However, the precision for ethyl arachidonate was close 
to the acceptable limit. The accuracy of all analytes ranged from 75–110%, as 
detailed in Table 6-7. The mean and QC ranges are also listed in Table 6-7. Ethyl 
laurate was not reported for the 400ng/g QC as this was below the LOQ.  
FAEES Correlation Coefficient (R
2) and 
Regression Equations 
LOD 
(ng/g) 
LOQ 
(ng/g) 
Ethyl Laurate      0.998 (y = 0.00002x - 0.0002) 822 2740 
Ethyl Myristate 0.996 (y = 0.0001x + 0.02) 25 82 
Ethyl Linolenate 0.999 (y = 0.0007x + 0.173) 14 46 
Ethyl Linoleate  0.995 (y =0.0007x + 0.1984) 18 60 
Ethyl Palmitoleate  0.995 (y = 0.0002x + 0.0867) 14 46 
Ethyl Palmitate 0.992 (y = 0.0009x + 0.437) 11 37 
Ethyl Oleate  0.995 (y = 0.0007x + 0.2586) 11 38 
Ethyl Stearate 0.996 (y = 0.0011x + 0.2214) 11 37 
Ethyl Arachidonate   0.998 (y = 0.00002x + 0.0008) 102 339 
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Table 6-7:  Intra-day and Inter-day Precision and Accuracy 
 
6.5.4 Recovery and Matrix effect 
No ion suppression or enhancement was indicated for the mobile phase, or the 
three pooled blank meconium samples, as illustrated in Figure 6-7. The recovery 
for all analytes from meconium ranged from 56% to 138% as summarised in Table 
6-8. The percent matrix affect ranged from 54% to 118%. Most analytes (6 out of 
9) demonstrated ion suppression and enhancement (1–20%). Three of the 
analytes (ethyl Laurate, ethyl myristate, and ethyl arachidonate) showed ion 
suppression or enhancement of > 20%, although the post-column syringe infusion 
ion suppression study (see Figure 6-7) showed no negative or positive peak in the 
retention time of the FAEEs. No ion suppression or enhancement was observed.  
 
FAEES QC (ng/g) 
QC 
Mean ±2SD 
(ng/g) 
QC Mean 
(ng/g) 
n=13 
Intraday 
%CV 
n=5 
Interday 
%CV 
n=6 
Accuracy % 
Ethyl Laurate 400 8000 
- 
LOQ-5219 
- 
3641 
- 
11.3 
- 
12.1 
- 
76 
Ethyl Myristate 400 8000 
241-622 
3827-9622 
432 
6725 
18.3 
10.6 
19.3 
17.14 
81 
89 
Ethyl 
Linolenate 
400 
8000 
337-547 
5376-9821 
442 
7598 
12.1 
9.8 
17.1 
13.9 
80 
108 
Ethyl Linoleate 400 8000 
292-600 
5834-8679 
446 
7256 
11.2 
9.4 
11.2 
8.7 
90 
110 
Ethyl 
Palmitoleate 
400 
8000 
343-744 
6562-11880 5439221 
9.7 
9.5 
10.6 
15.7 
81 
88 
Ethyl Palmitate 400 8000 
219-509 
6404-10198 3648301 
8.3 
4.2 
8.2 
8.9 
110 
97 
Ethyl Oleate 400 8000 
258-598 
6884-10413 
428 
8648 
5.3 
3.7 
17.2 
7.3 
96 
93 
Ethyl Stearate 400 8000 
283-630 
6739-11272 
456 
9005 
9.2 
11.1 
14.3 
15.2 
83 
89 
Ethyl 
Arachidonate 
400 
8000 
LOQ-705 
4883-9817 4837350 
9.8 
15.5 
19.9 
18.7 
88 
85 
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Figure 6-7:  Ion Suppression Experiment. Figure (A) O
of Mobile Phase, three pooled meconium blanks show
enhancement. Figure (B) is same as (A) with separate
retention time of FAEEs ranged from 7–21minutes be
and (B) expected retention time. 
 
       Table 6-8:  Recovery and Matr
 
 
 
 
 
 
 
 
FAEES QC (ng.g) 
R
Ethyl Laurate 400 8000 
Ethyl Myristate 400 8000 
Ethyl Linolenate 400 8000 
Ethyl Linoleate 400 8000 
Ethyl Palmitoleate 400 8000 
Ethyl Palmitate 400 8000 
Ethyl Oleate 400 8000 
Ethyl Stearate 400 8000 
Ethyl Arachidonate 400 8000 
Overlaid Chromatogram mobile 
Phase and extracted pooled 
meconium extracted pooled blanks Extracted pooled blank 3    Extracted pooled blank 2 Extracted pooled blank 1 ver
ed 
d ch
twee
ix E
eco
(%
-
5
8
7
11
12
9
10
12
12
11
9
8
9
13
11
10
8Mobile phase  
laid Chromatograms  
no ions suppression or 
romatograms.  The expected 
n the black arrows indicated in (A) 
ffects for FAEEs 
very 
) 
Matrix Effect 
(%) 
 
6 
- 
54 
0 
1 
153 
134 
4 
2 
93 
79 
3 
7 
102 
87 
6 
3 
96 
118 
3 
7 
116 
118 
7 
9 
121 
108 
8 
1 
99 
109 
8 
1 
204 
157 
Chapter 6  188 
6.5.5 Carryover  
No carryover was observed after injecting mobile phase after the highest 
calibrator (16,000ng/g) as illustrated in Figures 6-8 and 6-9. 
 
 
 
 
 
 
 
Figure 6-8:  Carryover study – Total Ion Chromatogram of Highest Calibrator 
(16,000ng/g) Versus Blank Mobile Phase. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-9:  Carryover Study – (MRM) Chromatogram of Highest Calibrator  
(16,000ng/g) Versus Blank Mobile Phase. 
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6.5.6  FAEEs in Meconium 
A number of samples had concentrations of FAEEs exceeding the ULOQ and 
dilution was not always possible due to insufficient volume of sample remaining. 
Therefore, all results greater than the ULOQ were reported as >ULOQ, and all 
results that were less than lower limit of quantification (LLOQ) were reported as 
<LLOQ. A cut-off point of approximately 500ng/g (equivalent to 2nmol/g) was 
used to distinguish between positive and negative samples, although for most 
analytes the LLOQ is less than this value. 
A full list of the results for all FAEEs measured in the 84 meconium samples is 
listed in Appendix 6-3.  A total of 51 samples (61%) were positive for at least one 
FAEE and no FAEEs were detected in 33 samples (39%). Of the 51 positive 
samples, 49% of these were positive for only one FAEE. A comparison between 
the positive and negative results for each individual FAEE detected in meconium 
is illustrated in Figure 6-10.  
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Figure 6-10:  Comparison of Positive and Negative Findings for Individual FAEEs in 
Meconium 
 
Three case samples (case numbers 4, 62, and 101) had a number of the FAEEs 
concentrations exceeding the ULOQ and are summarised in Table 6-9. It was 
observed that the concentration of individual FAEEs varies from case to case, as 
can been seen in case number 4 where ethyl linoleate was >ULOQ while ethyl 
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palmitate is within the linearity range. However in case #62, ethyl palmitate was 
>ULOQ and ethyl linoleate was lower than that measured in case # 4.  
Table 6-9:  Case Samples With Results Exceeding ULOQ for most of FAEEs 
Case 
No. 
Ethyl  
Laurite 
(ng/g) 
Ethyl 
Myristate 
(ng/g) 
Ethyl 
Linolenate 
(ng/g) 
Ethyl 
Linoleate 
(ng/g) 
Ethyl 
Palmitoleate 
(ng/g) 
Ethyl 
Palmitate 
(ng/g) 
Ethyl 
Oleate 
(ng/g) 
Ethyl 
Stearate 
(ng/g) 
Ethyl 
Arachidonate 
(ng/g) 
4 >ULOQ (342611) 
>ULOQ 
(124527) 
>ULOQ 
(46627) 
>ULOQ 
(214140) 
>ULOQ 
(56089) 5931 
>ULOQ 
(56421) 906 
>ULOQ 
(4522790) 
62 >ULOQ (172912) 
>ULOQ 
(78746) 
>ULOQ 
(25803) 
>ULOQ 
(135051) 
>ULOQ 
(180002) 
>ULOQ 
(64782) 
>ULOQ 
(332134) 4976 
>ULOQ 
(4267963) 
101 >ULOQ (194179) 
>ULOQ 
(295840) 
>ULOQ 
(374173 
>ULOQ 
(532002) 
>ULOQ 
(462119) 
>ULOQ 
(23020) 
>ULOQ 
(283700) 4660 
>ULOQ 
(8354465) 
 
The positive 95% confidence interval limit (CI) of all FAEE ranged from 2935–
49032ng/g as summarised in Table 6-10. The negative 95% CI limit of all FAEE's 
ranged from 14–56ng/g. This is comparable to a study by Gareri(152), with the 
exception of ethyl arachidonate which was 10 times higher in this study. 
 
Table 6-10:  The Positive and Negative FAEEs Results and the 95% of Confidence Interval 
Level 
 
 
FAEEs 
Number of 
Positive 
Cases 
 
Positive Mean  
ng/g 
n=87 
95%(CI) 
ng/g 
 
Number of 
Negative 
Cases 
 
Negative 
Mean ng/g 
n=87 
 95%(CI) 
ng/g 
 
Ethyl Laurate 
10 
 
35154 
 
35153-35155 
 
79 
 
15 
 
14-15 
 
Ethyl Myristate 
38 
 
25884 
 
2588-25885 
 
51 
 
53 
 
52-53 
 
Ethyl Linolenate 
30 
 
30010 
 
30009-30010 
 
59 
 
50 
 
50-51 
 
Ethyl linoleate 
31 
 
49032 
 
49031-49032 
 
58 
 
42 
 
41-42 
 
Ethyl 
Palmitoleate 
26 
 
39255 
 
39254-39256 
 
53 
 
25 
 
24-25 
 
Ethyl Palmitate 
30 
 
7128 
 
7127-7129 
 
59 
 
35 
 
34-35 
 
Ethyl Oleate 
40 
 
31405 
 
31404-31405 
 
49 
 
32 
 
32-33 
 
Ethyl Stearate 
30 
 
2936 
 
2935-2938 
 
59 
 
56 
 
55-56 
 
Ethyl 
Arachidonate 
46 
 
514611 
 
514610-514611 
 
43 
 
26 
 
25-26 
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Cumulative results for all 9 FAEEs are shown in Figure 6-11. 37% of the samples 
were negative (< 500ng/g) for cumulative FAEEs and 63% were positive (26% 
ranged from 500–999.99ng/g and 37% were ≥ 10,000ng/g). By plotting the cases 
that were < 10,000ng/g versus the concentrations, 4 samples were ≥ 5000ng/g as 
illustrated in Figure 6-12.  In all positive samples, at least 3 analytes were 
positive.  
Cumulative Concentrations of All FAEE's 
ng/g
23, 26%
33, 37%
33, 37%
 
 
 
 
 
 
 
 
Figure 6-11:  Cumulative concentrations of the FAEES in meconium  
 
FAEEs quantified in case # 101 have been summarised in Figure 6-13 which 
contains an overlay of chromatograms for this case in comparison to the highest 
standard of the calibration curve (16000 ng/g) with only ethyl stearate being 
within the ULOQ. 
  ≥10,000 
  500- 999.99 
  0- 499.99 
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Figure 6-12:  Cumulative Concentration of all FAEE Results (500–10,000ng/g) 
 
 
 
 
 
 
 
 
 
  
 Figure 6-13:  Overlaid MRM chromatogram of High-Result FAEE Case samples  
 (101) against the Highest Point of Calibrator curve 
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Case # 62 (highly positive for most of FAEEs) has been integrated against a 
negative FAEEs results and illustrated in Figure 6-14. The black arrows highlight 
where the expected peak of FAEEs should be.   
 
 
 
 
  
Figure 6-14:  MRM Chromatogram of Negative FAEES Case Samples 
in Meconium versus Positive Samples.  
Ethyl Laurate - Negative  
Ethyl Myristate - Positive  
Ethyl Palmitoleate - Negative  
Ethyl Palmitoleate - Positive  
Ethyl Palmitate - Negative  
Ethyl Palmiate - Positive  
D5-Ethyl Palmitate - Negative  
D5-Ethyl Palmiate - Positive  
Ethyl Laurate - positive  
Ethyl Myristate - Negative  
D5 Ethyl Stearate - Negative  
D5 Ethyl Stearate - Positive  
Ethyl Arachidonate -Negative 
Ethyl Arachidonate - Positive  
Ethyl Linoleate - Negative  
Ethyl Linolenate - Negative  
Ethyl Linolenate - Positive  
Ethyl Insolate - Positive  
Ethyl Oleate - Negative  
Ethyl Oleate - Positive  
D5 Ethyl Oleate - Negative 
 
D5 Ethyl Oleate - Positive  
 
Ethyl Stearate - Negative  
Ethyl Stearate - Positive  
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In order to correlate the FAEEs concentrations in meconium to assess maternal 
gestational alcohol exposure, more information is required in relation to 
maternal drinking behaviours, history of drug and alcohol abuse, quantity of 
alcohol consumed, social status, time of drinking during gestation and stage of 
gestation, and age of the mother.  
No correlation between the concentrations of FAEEs in meconium and foetal 
alcohol exposure could be assessed in this study, as the samples were originally 
collected for the determination of the incidence of maternal drug use and the 
questionnaire completed by the mother did not ask specific questions about 
alcohol use. In any case, self-report is unreliable in these circumstances where 
the mother will not admit to drinking during her pregnancy for fear of punitive 
action. 
6.6 Conclusion 
An LC-MS/MS method has been developed and validated for the determination of 
FAEEs in meconium. This is the first LC-MS-MS method to use deuterated FAEEs 
as internal standards for the quantitation of FAEEs in meconium.  
The mean concentration in all positive cases was the highest for ethyl 
arachidonate followed by ethyl linoleate and correlated well with another study.  
(152;154;155;218)  It was not possible to correlate the FAEE concentrations 
found and gestational alcohol exposure or to indicate the specificity of individual 
FAEE with minimal or no maternal alcohol abuse history.  
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Chapter 7 - Conclusion and Future Work  
7.1 Conclusion 
This project initially involved the development and validation of quantitative 
methods for the analysis of common volatiles (methanol, ethanol, isopropanol, 
n-propanol and acetone) and alcohol biomarkers (beta-hydroxybutyrate, BHB and 
fatty acid ethyl esters, FAEEs) in biological matrices, utilising dual-column HS-
GC-FID, GC-MS and LC-MS/MS. This was achieved for each method in accordance 
with ISO/IEC 17025 and the methods were successfully applied to the analysis of 
real case samples. The stability of volatiles and BHB in blood was also 
investigated. 
The optimised HS-GC-FID method for volatiles was used to evaluate the use of 
two internal standards, namely n-propanol and t-butanol, for the quantitative 
analysis of volatiles in post-mortem samples. Both methods demonstrated 
excellent linearity, precision and accuracy. n-Ppropanol is an ideal internal 
standard for use with the dual-column system used in this study and when 
applied to the analysis of ethanol in blood from living subjects, e.g. road traffic 
arrests.  
Other studies have warned against using n-propanol as an internal standard in 
putrefied samples due to the production of this volatile post-mortem. A high 
concentration in the samples would result in an increased response for the 
internal standard and would correspond to an underestimate of the true 
concentration of volatiles in the sample. This is not supported with the findings 
in this study because the majority of samples, selected due to extensive 
putrefication, had n-propanol concentrations close to the LOQ and therefore had 
a negligible effect. 
The use of ethanol to n-propanol ratio to determine whether ethanol formation 
has occurred is unlikely to be an effective indicator and other criteria must be 
considered, including the case history, condition of the specimens, distribution 
of ethanol in different matrices, and the concentration of ethanol. The internal 
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standard t-butanol is an effective alternative internal standard for the 
quantification of volatiles in post-mortem blood, including the ability to measure 
n-propanol. However, t-butanol co-elutes with acetone using DB-ALC1 or RTX-
ALC1 GC capillary columns.  
The antioxidant (0.2% sodium metabisulphite) played a significant role in 
preventing oxidation between volatiles such as isopropanol to acetone, while the 
use of preservative alone such as (0.2 or 1% sodium fluoride) did not prevent 
oxidation completely. 1% sodium fluoride in addition to 0.2% (0.2% sodium 
metabisulphite) as an antioxidant improved the stability of the volatiles. These 
finding supports the findings of another study.(81) The stability of preserved 
blood samples, containing fluoride oxalate at 1-2%, was assessed after they were 
stored at room temperature for a period of between 1 to 5 years, following 
initial tests for ethanol. Ethanol concentrations measured when compared with 
the initial test demonstrated recoveries of 50% or more in 85% of the samples 
tested. 
 
A further study evaluated ethanol stability over a period of six months, with 
significant loss and formation of ethanol observed in both preserved and 
unpreserved paired post-mortem blood samples. These cases were submitted to 
the toxicology laboratories of Forensic Medicine and Science for routine testing 
and were refrigerated after initial tests. Further losses in ethanol concentration 
were not significant following an additional storage period of 10 months in the 
freezer at -22°C. 
The analysis of ethanol in bile or vitreous humour provides the forensic 
toxicologist with an alternative sample to blood in post-mortem cases where this 
is not available. In addition, lower ethanol concentrations in vitreous humour 
compared with blood may indicate post-mortem production of ethanol. Urine is 
not a suitable matrix to estimate ethanol or acetone concentrations in blood.  
A robust and sensitive method for the analysis of BHB in post-mortem blood and 
urine was validated. The analysis of different case samples in this study supports 
other studies that have suggested BHB is a suitable biomarker for Alcoholic 
Ketoacidosis (AKA) or Diabetic Ketoacidosis (DKA). This study has highlighted the 
potential underreporting of the role of AKA in deaths associated with chronic 
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alcohol abuse in the West of Scotland. Further, AKA does not always equate to 
low or negative ethanol levels. High levels of ethanol were reported in case 
samples with blood BHB levels >250 mg/L, which is in agreement to other 
studies. In all of the case samples with high blood BHB, the acetone 
concentration was high and as such, acetone can be used as an initial biomarker 
for AKA but the concentrations measured are not well correlated to BHB.  
Acetone is volatile and is unstable in blood, and the production of other volatiles 
may interfere with it due to putrefaction, therefore, its absence does not 
preclude pathologically significant ketoacidosis (BHB >250 mg/L). The 
recommendation following the findings in this study is that all cases associated 
with a history of chronic alcoholism, should be tested for BHB, even if acetone is 
low or absent. 
The method validation for BHB was successfully applied to post-mortem blood 
and urine, and plasma and urine from healthy subjects for the analysis of β-
hydroxy-β-methylbutyrate (HMB) and γ-hydroxybutyrate (GHB). 
The first LC-MS/MS method using commercially available deuterated 
FAEEs(158;159) as internal standards for the quantitation of FAEEs in meconium 
was also developed and validated. A third of the meconium samples tested had 
FAEEs totalling more than 10,000 ng/g which is indicative of foetal exposure to 
chronic maternal alcohol use. The mean concentration in all positive cases was 
the highest for ethyl arachidonate followed by ethyl linoleate and this correlates 
well. 
7.2 Future work  
A larger study would be required to investigate the prevalence of n-propanol 
concentrations in putrefied post-mortem blood samples from a range of case 
types to fully assess the risks associated with the use of this volatile as an 
internal standard for quantifying volatiles.   
The evaluation of different GC capillary columns for better resolution between 
t-butanol and acetone would be of value, and in addition, to investigate the use 
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of t-butanol as an internal standard with samples of high fat content as this has 
been highlighted in other studies as a potential interferent.   
Further stability investigations would be of interest to evaluate the effect of 
anti-coagulant in terms of antioxidation and to investigate the optimum 
antioxidant concentration required to prevent loss or formation of volatiles. 
Utilizing human whole blood would also help to evaluate the oxidative effect of 
enzymes, and extending the volatiles investigated to include, acetaldehyde, 
propionaldehyde (propanal). Investigation of the stability of volatiles using 
sodium metabisulfite without adding NaF to evaluate its role as a preservative 
should also be carried out. 
The study investigating the analysis of volatiles in vitreous humour and bile was 
limited due to the number of samples available for analysis and reanalysis. An 
extension of the study would provide greater insight into the relationship 
between femoral blood, vitreous humour and bile and the stability of acetone 
and ethanol in these alternative matrices.  
The evaluation of  the stability of BHB and GHB in blood in paired preserved and 
unpreserved sample when stored in different temperature and concentration of 
preservative would provide an insight into the presence of these substances at 
the time of death versus the time of collection. 
 A further investigation into the use of deuterated internal standards for each of 
the FAEEs tested would be of interest and then applying this method to 
investigate FAEE levels in maternal and newborn hair samples using HS-SPME-
GC/MS, as recommended by the Society of Hair Testing. A comparison could then 
be carried out between meconium and hair to identify which sample is better as 
an indicator of foetal alcohol exposure. The long-term stability of FAEEs in 
meconium or BHB in postmortem blood has as yet not been fully investigated.  
Lastly, the role of BHB as a biomarker should be extended to analyze a wide 
range of case types where individuals have a history of acute and chronic alcohol 
misuse. 
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Appendix 3-1 Stability Study of volatiles using t-butanol as an Internal Standard 
      Room Temperature RT 25°C±2 
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(I)                                                                                      (J) 
Stability graphs RT 25±2 °Cfor each analyte (20 and 80 mg/dL for all except acetone mg/L) (A) and (B) 
Ethanol, (C) AND (D) Acetone, (E) and (F) Isopropanol ,(G) and (H) Methanol and ,(I) and (J) n-propanol. 
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Appendix 3-1 continued 
Stability results at RT 25±2, °Cof spiked blood.  The bolded figures showed deviation from the acceptable range. 
 
RT 
25±2°C  DAY 20 80 
      ETHANOL ACETONE ISOPROPANOL METHANOL N_PROPANOL ETHANOL ACETONE ISOPROPANOL METHANOL N_PROPANOL 
No 
presertvative G1 1 21 32 20 20 20 80 91 79 77 78 
0.2% Naf G2 1 20 39 19 20 19 79 99 78 77 76 
0.2%Naf +0.2% 
antioxident G3 1 20 31 20 20 21 78 99 78 76 75 
1% Naf  G4 1 20 28 20 20 20 78 99 78 76 75 
1% Naf + 0.2% 
anti oxidant G5 1 19 31 19 19 20 76 89 77 76 78 
    MEAN 20 32 20 20 20 78 95 78 77 76 
    SD 0.75 4.10 0.43 0.46 0.41 1.50 4.74 0.86 0.66 1.47 
    2SD 1.50 8.21 0.86 0.91 1.23 2.99 9.47 1.73 1.32 2.94 
    u 0.6 1.0 0.4 0.8 0.6 2.3 2.9 1.6 3.1 2.3 
    Ue 1.2 1.9 0.8 1.6 1.2 4.7 5.7 3.1 6.1 4.6 
    Mean-Ue 19 30 19 18 19 74 89 75 70 72 
    Mean+Ue 21 34 20 21 21 83 101 81 83 81 
            
No 
presertvative G1 4 40 102 13 21 9 70 354 53 78 23 
0.2% Naf G2 4 18 63 16 19 16 76 107 77 76 78 
0.2%Naf +0.2% 
antioxident G3 4 20 49 18 19 21 77 87 80 77 75 
1% Naf  G4 4 18 78 14 19 16 74 141 72 75 68 
1% Naf + 0.2% 
anti oxidant G5 4 19 35 18 19 20 76 89 77 74 77 
No 
presertvative G1 7 50 94 13 20 15 104 190 66 75 64 
0.2% Naf G2 7 18 77 15 19 15 76 155 71 77 69 
0.2%Naf +0.2% 
antioxident G3 7 19 50 17 19 20 77 107 76 77 78 
1% Naf  G4 7 13 76 13 17 11 71 170 66 75 62 
1% Naf + 0.2% 
anti oxidant G5 7 20 35 19 20 20 75 89 76 73 76 
No 
presertvative G1 10 47 76 14 19 15 109 163 71 76 68 
0.2% Naf G2 10 17 45 18 19 15 74 118 75 74 69 
0.2%Naf +0.2% 
antioxident G3 10 19 53 17 19 20 75 105 58 73 77 
1% Naf  G4 10 11 109 12 20 9 74 134 74 75 72 
1% Naf + 0.2% 
anti oxidant G5 10 20 38 19 19 20 75 92 77 73 77 
No 
presertvative G1 15 43 70 14 19 13 2 93 70 70 2 
0.2% Naf G2 15 14 64 15 18 12 71 127 69 71 65 
0.2%Naf +0.2% 
antioxident G3 15 18 51 17 18 19 73 106 74 73 75 
1% Naf  G4 15 15 81 14 18 14 66 167 67 72 62 
1% Naf + 0.2% 
anti oxidant G5 15 18 36 18 18 19 72 93 74 72 73 
No 
presertvative G1 23 17 104 13 21 4 100 295 55 73 54 
0.2% Naf G2 23 12 107 11 19 3 76 247 59 72 61 
0.2%Naf +0.2% 
antioxident G3 23 16 56 15 17 15 74 108 74 74 76 
1% Naf  G4 23 16 96 12 19 14 71 202 63 72 66 
1% Naf + 0.2% 
anti oxidant G5 23 19 37 18 19 20 69 77 71 70 71 
No 
presertvative G1 30 29 103 11 18 6 95 281 57 75 47 
0.2% Naf G2 30 21 95 12 22 11 78 246 62 77 60 
0.2%Naf +0.2% 
antioxident G3 30 19 52 17 19 20 74 112 75 75 74 
1% Naf  G4 30 14 94 12 19 12 73 210 64 75 67 
1% Naf + 0.2% 
anti oxidant G5 30 19 36 18 19 20 76 92 79 76 79 
No 
presertvative G1 40 32 114 12 20 6 86 351 47 72 39 
0.2% Naf G2 40 23 122 10 19 9 84 336 54 77 57 
0.2%Naf +0.2% 
antioxident G3 40 18 52 17 19 19 73 105 74 74 75 
1% Naf  G4 40 14 114 11 19 11 69 274 57 74 62 
1% Naf + 0.2% 
anti oxidant G5 40 19 37 18 19 20 73 89 75 73 76 
No 
presertvative G1 50 28 185 5 20 5 87 305 51 71 41 
0.2% Naf G2 50 23 110 10 18 7 80 343 50 78 51 
0.2%Naf +0.2% 
antioxident G3 50 17 50 16 17 18 70 106 72 70 72 
1% Naf  G4 50 13 120 9 18 10 63 288 52 69 58 
1% Naf + 0.2% 
anti oxidant G5 50 18 36 18 18 19 70 86 72 70 73 
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         Appendix 3-1 continued - (4± 2°C) 
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  (I)                  (J) 
Stability graphs at 4±2°C for each analyte (20 and 80 mg/dL for all except acetone mg/L) (A) and (B) 
Ethanol, (C) AND (D) Acetone, (E) and (F) Isopropanol ,(G) and (H) Methanol and ,(I) and (J) n-propanol. 
228 
 
Appendix 3-1 continued 
Stability results at 4±2°C, of spiked blood.  The bolded figures showed deviation from the acceptable range. 
 
 
 
 
4± 2°C  DAY 20 80 
      ETHANOL ACETONE ISOPROPANOL METHANOL N_PROPANOL ETHANOL ACETONE ISOPROPANOL METHANOL N_PROPANOL 
No presertvative G1 1 21 32 20 20 20 80 91 79 77 78 
0.2% Naf G2 1 20 39 19 20 19 79 99 78 77 76 
0.2%Naf +0.2% 
antioxident G3 1 20 31 20 20 21 78 99 78 76 75 
1% Naf  G4 1 20 28 20 20 20 78 99 78 76 75 
1% Naf + 0.2% 
anti oxidant G5 1 19 31 19 19 20 76 89 77 76 78 
    MEAN 20 32 20 20 20 78 95 78 77 76 
    SD 0.75 4.10 0.43 0.46 0.41 1.50 4.74 0.86 0.66 1.47 
    2SD 1.50 8.21 0.86 0.91 1.23 2.99 9.47 1.73 1.32 2.94 
    u 0.6 1.0 0.4 0.8 0.6 2.3 2.9 1.6 3.1 2.3 
    Ue 1.2 1.9 0.8 1.6 1.2 4.7 5.7 3.1 6.1 4.6 
    Mean-Ue 19 30 19 18 19 74 89 75 70 72 
    Mean+Ue 21 34 20 21 21 83 101 81 83 81 
            
No presertvative G1 4 19 48 17 19 17 83 98 83 81 80 
0.2% Naf G2 4 19 63 16 19 17 78 93 78 76 76 
0.2%Naf +0.2% 
antioxident G3 4 20 37 19 19 21 73 88 73 71 74 
1% Naf  G4 4 18 67 16 19 18 73 89 74 71 73 
1% Naf + 0.2% 
anti oxidant G5 4 20 32 19 19 20 76 90 77 75 78 
No presertvative G1 7 18 77 15 20 15 69 182 68 75 61 
0.2% Naf G2 7 18 85 14 19 15 74 161 71 78 66 
0.2%Naf +0.2% 
antioxident G3 7 19 46 18 19 20 76 105 75 75 77 
1% Naf  G4 7 18 88 13 20 16 69 150 68 74 65 
1% Naf + 0.2% 
anti oxidant G5 7 19 38 18 19 20 77 92 77 76 78 
No presertvative G1 10 17 80 14 19 14 75 140 73 76 69 
0.2% Naf G2 10 17 104 13 19 13 70 180 70 76 63 
0.2%Naf +0.2% 
antioxident G3 10 20 51 17 19 20 77 109 75 75 77 
1% Naf  G4 10 18 126 10 19 15 74 200 67 74 69 
1% Naf + 0.2% 
anti oxidant G5 10 18 23 19 18 19 77 98 77 75 78 
No presertvative G1 15 17 65 15 18 15 68 155 67 73 59 
0.2% Naf G2 15 18 86 13 19 15 74 124 72 74 69 
0.2%Naf +0.2% 
antioxident G3 15 17 53 15 17 18 74 111 73 74 75 
1% Naf  G4 15 17 104 11 18 14 71 170 65 71 67 
1% Naf + 0.2% 
anti oxidant G5 15 18 42 17 18 19 72 96 72 72 74 
No presertvative G1 23 18 79 14 18 14 70 175 65 73 59 
0.2% Naf G2 23 17 140 8 19 13 72 196 65 74 64 
0.2%Naf +0.2% 
antioxident G3 23 19 60 16 18 20 75 120 73 74 76 
1% Naf  G4 23 18 75 14 19 16 73 171 66 72 69 
1% Naf + 0.2% 
anti oxidant G5 23 19 46 17 18 20 72 102 72 71 74 
No presertvative G1 30 27 76 14 19 14 89 193 65 76 61 
0.2% Naf G2 30 18 99 12 20 15 64 364 51 77 44 
0.2%Naf +0.2% 
antioxident G3 30 19 63 16 19 20 77 122 74 76 78 
1% Naf  G4 30 17 116 11 19 14 67 321 54 75 56 
1% Naf + 0.2% 
anti oxidant G5 30 19 44 17 19 20 74 102 73 73 75 
No presertvative G1 40 39 89 13 19 13 89 258 58 74 60 
0.2% Naf G2 40 18 121 10 19 14 75 244 62 76 67 
0.2%Naf +0.2% 
antioxident G3 40 19 63 15 18 19 74 123 72 73 76 
1% Naf  G4 40 17 75 13 18 15 72 192 64 72 67 
1% Naf + 0.2% 
anti oxidant G5 40 19 46 17 18 19 76 104 75 74 77 
No presertvative G1 50 40 92 13 18 12 89 253 57 71 59 
0.2% Naf G2 50 14 190 4 19 8 69 234 60 72 61 
0.2%Naf +0.2% 
antioxident G3 50 18 62 15 18 19 73 122 70 72 74 
1% Naf  G4 50 16 136 8 18 12 70 198 63 71 67 
1% Naf + 0.2% 
anti oxidant G5 50 18 46 17 18 19 72 102 71 70 74 
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Appendix 3-1 continued - (-20 ± 2°C)  
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(I)                     (J) 
Stability graphs at -22±2°C for each analyte (20 and 80 mg/dL for all except acetone mg/L) (A) and (B) Ethanol, (C) 
AND (D) Acetone, (E) and (F) Isopropanol ,(G) and (H) Methanol and ,(I) and (J) n-propanol. 
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Appendix 3-1 continued 
Study 2 stability results at -22±2°C, of spiked blood.  The bolded figures showed deviation from the 
acceptable range. 
-22±2°C   DAY 20 80 
      ETHANOL ACETONE ISOPROPANOL METHANOL N_PROPANOL ETHANOL ACETONE ISOPROPANOL METHANOL N_PROPANOL 
No presertvative G1 1 21 32 20 20 20 80 91 79 77 78 
0.2% Naf G2 1 20 39 19 20 19 79 99 78 77 76 
0.2%Naf +0.2% 
antioxident G3 1 20 31 20 20 21 78 99 78 76 75 
1% Naf  G4 1 20 28 20 20 20 78 99 78 76 75 
1% Naf + 0.2% 
anti oxidant G5 1 19 31 19 19 20 76 89 77 76 78 
    MEAN 20 32 20 20 20 78 95 78 77 76 
    SD 0.75 4.10 0.43 0.46 0.41 1.50 4.74 0.86 0.66 1.47 
    2SD 1.50 8.21 0.86 0.91 1.23 2.99 9.47 1.73 1.32 2.94 
    u 0.6 1.0 0.4 0.8 0.6 2.3 2.9 1.6 3.1 2.3 
    Ue 1.2 1.9 0.8 1.6 1.2 4.7 5.7 3.1 6.1 4.6 
    Mean-Ue 19 30 19 18 19 74 89 75 70 72 
    Mean+Ue 21 34 20 21 21 83 101 81 83 81 
            
No presertvative G1 4 21 32 19 20 20 80 85 79 78 78 
0.2% Naf G2 4 16 55 18 20 14 81 88 81 78 80 
0.2%Naf +0.2% 
antioxident G3 4 20 26 20 20 21 80 80 81 79 81 
1% Naf  G4 4 17 56 17 19 15 80 87 81 78 81 
1% Naf + 0.2% 
anti oxidant G5 4 20 24 20 19 21 76 80 78 75 77 
No presertvative G1 7 20 37 19 20 19 74 96 75 73 71 
0.2% Naf G2 7 21 32 20 20 21 77 89 78 75 77 
0.2%Naf +0.2% 
antioxident G3 7 21 25 21 20 21 77 79 78 76 78 
1% Naf  G4 7 20 28 20 19 21 77 82 79 76 78 
1% Naf + 0.2% 
anti oxidant G5 7 20 23 21 20 21 77 77 78 76 78 
No presertvative G1 10 20 51 18 20 18 72 100 73 72 69 
0.2% Naf G2 10 20 33 19 38 20 77 89 78 75 76 
0.2%Naf +0.2% 
antioxident G3 10 20 27 20 20 21 78 82 80 76 79 
1% Naf  G4 10 20 26 20 19 20 78 83 79 77 78 
1% Naf + 0.2% 
anti oxidant G5 10 19 24 20 19 20 74 78 77 73 76 
No presertvative G1 15 19 31 18 19 19 73 76 73 72 72 
0.2% Naf G2 15 19 27 19 19 19 74 80 74 73 73 
0.2%Naf +0.2% 
antioxident G3 15 19 24 19 19 19 74 75 75 73 74 
1% Naf  G4 15 19 24 19 18 19 72 78 74 71 73 
1% Naf + 0.2% 
anti oxidant G5 15 19 22 19 18 20 70 76 72 69 71 
No presertvative G1 23 19 31 19 18 19 74 82 75 74 73 
0.2% Naf G2 23 19 27 19 18 19 75 80 75 73 74 
0.2%Naf +0.2% 
antioxident G3 23 19 24 19 18 20 72 80 74 71 73 
1% Naf  G4 23 19 25 19 18 19 73 79 74 72 74 
1% Naf + 0.2% 
anti oxidant G5 23 19 23 19 18 20 70 78 72 69 72 
No presertvative G1 30 22 28 21 21 22 82 84 83 80 82 
0.2% Naf G2 30 20 25 20 19 20 79 84 80 77 79 
0.2%Naf +0.2% 
antioxident G3 30 19 23 20 19 20 74 81 76 72 75 
1% Naf  G4 30 20 24 20 19 20 79 83 80 76 80 
1% Naf + 0.2% 
anti oxidant G5 30 20 23 20 19 21 71 81 74 68 74 
No presertvative G1 40 20 24 20 19 20 72 71 72 70 72 
0.2% Naf G2 40 19 24 19 19 19 72 81 73 71 72 
0.2%Naf +0.2% 
antioxident G3 40 19 23 20 19 20 73 77 74 72 74 
1% Naf  G4 40 19 23 19 18 19 72 81 74 70 73 
1% Naf + 0.2% 
anti oxidant G5 40 19 22 19 19 20 72 75 73 71 73 
No presertvative G1 50 19 22 19 18 19 77 83 78 75 77 
0.2% Naf G2 50 19 24 19 18 20 72 82 73 71 73 
0.2%Naf +0.2% 
antioxident G3 50 19 22 20 19 20 74 79 75 72 75 
1% Naf  G4 50 18 23 19 18 19 73 81 75 71 74 
1% Naf + 0.2% 
anti oxidant G5 50 19 22 19 15 19 70 77 73 68 72 
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Appendix 3-2 Stability Study of volatile using n-propanol Internal standard – (4± 2°C) 
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Stability graphs at 4±2°C for each analyte (20 and 80 mg/dL for all except 
acetone mg/L) (A) and (B) Ethanol, (C) AND (D) Acetone, (E) and (F) Isopropanol 
and (G) and (H) Methanol. 
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Appendix 3-2 Stability results at 4±2 °Cof spiked blood.  The bolded figures showed deviation from 
the acceptable range.
4±2°C Group Day 20 
80 
   ETHANOL ACETONE ISOPROPANOL METHANOL ETHANOL ACETONE ISOPROPANOL METHANOL 
No presertvative G1 1 21 32 18 20 75 86 74 76 
1% Naf G2 1 21 25 18 19 75 84 75 75 
2%Naf G3 1 21 24 18 19 78 83 77 77 
1% Naf + 0.2% 
anti oxidant G4 1 21 22 18 19 77 78 76 76 
2% Naf + 0.2% 
anti oxidant G5 1 21 22 18 19 76 77 75 75 
  MEAN 21 25 18 19 76 82 75 76 
  SD 0.14 4.02 0.32 0.45 1.23 3.93 1.30 0.65 
  2SD 0.43 12.06 0.97 1.36 3.68 11.80 3.90 1.95 
  u 1 1 1 1 2 3 2 3 
  Ue 2 2 1 2 5 7 5 6 
  Mean-Ue 19 22 17 18 71 75 71 70 
  Mean+Ue 22 27 20 21 80 88 80 82 
 
No presertvative G1 4 24 48 16 20 78 117 76 79 
1% Naf G2 4 21 23 18 19 77 89 77 78 
2%Naf G3 4 21 30 18 19 78 88 78 77 
1% Naf + 0.2% 
anti oxidant G4 4 21 26 18 19 77 82 78 77 
2% Naf + 0.2% 
anti oxidant G5 4 21 26 18 19 78 83 78 77 
No presertvative G1 7 28 56 16 20 87 148 74 82 
1% Naf G2 7 20 38 17 19 76 95 77 76 
2%Naf G3 7 20 34 17 19 77 89 77 77 
1% Naf + 0.2% 
anti oxidant G4 7 21 29 18 20 79 85 77 79 
2% Naf + 0.2% 
anti oxidant G5 7 20 30 17 19 78 86 78 78 
No presertvative G1 10 35 102 12 20 87 196 65 76 
1% Naf G2 10 20 41 17 19 76 100 77 76 
2%Naf G3 10 20 37 17 19 76 93 77 75 
1% Naf + 0.2% 
anti oxidant G4 10 21 32 18 19 77 88 77 76 
2% Naf + 0.2% 
anti oxidant G5 10 20 32 17 18 77 87 77 75 
No presertvative G1 15 43 76 14 20 106 164 73 82 
1% Naf G2 15 20 47 16 20 79 111 77 82 
2%Naf G3 15 20 42 17 20 79 93 77 80 
1% Naf + 0.2% 
anti oxidant G4 15 21 35 17 20 80 91 77 81 
2% Naf + 0.2% 
anti oxidant G5 15 21 36 17 20 80 89 78 81 
No presertvative G1 23 59 95 12 21 116 268 63 83 
1% Naf G2 23 19 63 16 19 77 139 75 81 
2%Naf G3 23 20 45 17 19 79 97 79 81 
1% Naf + 0.2% 
anti oxidant G4 23 20 38 17 19 79 93 79 80 
2% Naf + 0.2% 
anti oxidant G5 23 20 40 17 19 78 91 77 78 
No presertvative G1 30 57 112 11 20 118 232 67 83 
1% Naf G2 30 20 70 15 20 77 132 76 81 
2%Naf G3 30 20 48 15 20 78 100 77 80 
1% Naf + 0.2% 
anti oxidant G4 30 21 38 17 20 80 92 77 81 
2% Naf + 0.2% 
anti oxidant G5 30 21 40 17 19 80 91 78 81 
No presertvative G1 40 58 148 7 21 103 299 55 75 
1% Naf G2 40 19 74 13 20 76 154 72 80 
2%Naf G3 40 18 55 14 20 77 109 75 80 
1% Naf + 0.2% 
anti oxidant G4 40 20 37 17 20 77 90 75 78 
2% Naf + 0.2% 
anti oxidant G5 40 20 40 17 19 78 93 78 77 
No presertvative G1 50 58 130 8 21 108 277 58 80 
1% Naf G2 50 19 78 13 19 73 153 71 77 
2%Naf G3 50 18 62 14 19 71 112 73 73 
1% Naf + 0.2% 
anti oxidant G4 50 20 36 16 19 75 93 73 74 
2% Naf + 0.2% 
anti oxidant G5 50 20 37 16 19 73 89 75 72 
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Appendix 4-1 BHB QC Charts 
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BHB Quality control charts at 50 mg/L (A and B), 300 mg/L (C and D) in blood and urine, respectively 
 
 
 
Quality Control ranges 
Blood Urine 
50 
mg/L 
300  
mg/L 
50 
mg/L 
300  
mg/L 
Average 49 301 48 294 
Standard 
Deviation (SD) 
2.72 17.95 6.40 20.34 
CV% 5.6 6.0 13.2 6.9 
 Mean ± 2SD  43-54 265-336 36-61 253-335 
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Appendix 4-2 BHB, Acetone and Ethanol Concentrations in Post-mortem                         
blood and urine 
(Shaded boxes information is not available) 
 
Case 
# 
 
Gender Age 
BHB          
mg//L 
Acetone    
mg//L Ethanol   mg/dL cause of death 
Blood Urine Blood Urine Blood Urine 
1 M 55 135  146  79  1a- unascertained 
2 F 67 14 NEG NEG NEG 330 440 
1a- head injury(haemorrhage from scalp 
laceration) presumed fall                 2a- 
Acute  alcohol intoxication pulmonary 
thromboembolism 
3 F 41 NEG  NEG  NEG  1a- Stab wound of heart 
4 M 66 NEG 27 NEG NEG NEG NEG 1a- Coronary artery atheroma; 1b- Ischaemic heart disease 
5 F 44 >500 >500 167 224 NEG 16 1a- Fatty degeneration of the liver                         1b- Chronic alcoholic 
6 F 78 142 <10 NEG NEG 232 225 
1a- Inhalation of smoke and fire gases in 
a house fire and hypertensive and 
valvular heart disease 
7 F 29 30  NEG  193  1a- Codeine and alcohol intoxication 
8 M 33 22 NEG NEG NEG NEG 98 1a- Heroin and ketamine intoxication 
9 F 58 89 86 NEG NEG NEG NEG 1a- Suspected alcohol related death 
10 M 54 13 NEG NEG NEG 325 393 1a- Chest injury; 1b Road traffic collision (driver) 
11 M 29 NEG NEG NEG NEG NEG NEG 1a- Hanging 
12 M 29 NEG NEG NEG NEG NEG NEG 1a- Heroin, methadone, diazepam intoxication 
13 M 39 23 NEG NEG NEG NEG NEG 1a- Bronchopneumonia and intoxication by heroin and methadone 
14 M 31 NEG  NEG  11  
1a- Hypoxia brain damage 
1b- Cardiac arrest; 1c- Cardiac 
enlargement 
15 F 33 19  NEG  60  
1a- Hypoxia -Ischaemic brain injury                                  
b- Cardiac arrest ; 1c- Heroin and alcohol 
intoxication- Cardiac enlargement 
16 M 73 195  50 56 NEG NEG 1a- Ischaemic heart disease 1b- Coronary artery atheroma 
17 F 18 >500 >500 >400 >400 NEG NEG 1a- Diabetic ketoacidosis; 1b. Insulin dependent diabetic mellitus 
18 M 33 86 79 NEG NEG 83 114 1a- Heroin intoxication 
19 M 19 10 NEG NEG NEG NEG NEG 1a- Head and chest injury                             1b- Road traffic collision (driver) 
20 F 28 10 NEG NEG NEG NEG 33 1a- Bronchopneumonia; 1b- Morphine intoxication 
21 M 44 NEG  NEG  NEG  1a- Cardiac enlargement 
22 F 30 21 97 NEG NEG 16 NEG 1a- Incised wound of arm 
23 F 36 85 >500 NEG 332 NEG NEG 1a- Viral pneumonia with secondary bacterial infection 
24 F 34 20 NEG NEG NEG 174 266 1a- Heroin and alcohol intoxication 
25 F 38 29 NEG NEG NEG NEG 13 1a- Head injury 
26 M 81 73 47 NEG NEG 15 18 1a- Acute pylonephritis; 2a- Coronary artery atheroma 
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Appendix  4-2  continued 
27 F 47 NEG NEG NEG NEG 19 NEG 1a-Ischaemic heart disease and bronchopneumonia 
28 F 38 57 NEG NEG NEG NEG NEG 1a- Acute exacerlation of chronic obstructive airways disease 
29 M 71 NEG NEG NEG NEG 205 164 1a- Multiple injuries; 1b- Road Traffic accident (pedestrian) 
30 F 66 237 452 15 26 NEG NEG 1a- Acute hepatic necrosis; 1b- paracetamol Toxicity 
31 M 62 19 NEG NEG NEG NEG NEG 1a- Hanging 
32 M 62 28  NEG NEG 14 NEG 1a- Probable sepsis, source uncertain 
33 F 44 15 NEG NEG NEG NEG NEG 1a- Ischaemic heart disease  1b- Coronary artery atheroma 
34 F 53 42 NEG NEG NEG NEG NEG 1a- Multiple injuries; 1b- Fall from height 
35 F 55 26  NEG  NEG  1a- Upper gastrointestinal haemorrhage; 1b- Duodenal ulcer 
36 M 34 16 NEG NEG NEG 21 31 1a- Gamma- hydroxybutyrate (GHB) intoxication 
37 F 43 22 NEG NEG NEG 140 208 1a- unascertained 
38 M 67 14  NEG NEG NEG NEG 1a- Ischaemic heart disease; 1b- Coronary artery atheroma 
39 F 48 69  NEG NEG NEG 10 1a- Head injury 
40 M 52 42 93 NEG NEG 227 373 1a- Bronchopneumonia; 1b- Chronic alcohol abuse 
41 M 40 99 NEG NEG NEG 329 442 1a- Acute alcohol intoxication 
42 M 57 10 NEG NEG NEG NEG NEG 1a- Hanging 
43 F 44 NEG  NEG  58  
1a- Hypoxic brain damage; 1b. 
Cardiorespiratory arrest; 1c. Acute 
severe asthma 
44 M 23 NEG NEG NEG NEG NEG NEG 1a- tramadol and methadone intoxication 
45 M 48 111  31 67 19 31 1a- Alcoholic ketoacidosis; 1b- Chronic alcohol abuse 
46 M 42 23 NEG NEG NEG 10 16 1a- Myocardial fibrosis  and ischaemia - cause unascertained 
47 F 37 NEG NEG NEG NEG NEG 15 1a- Heroin and methadone intoxication 
48 F 33 14 NEG NEG NEG NEG NEG 1a- Heroin intoxication 
49 M 59 18 NEG NEG NEG 56 79 1a- Hanging 
50 M 24 25 NEG NEG NEG 155 204 1a- Hanging 
51 M 40 NEG NEG NEG NEG NEG NEG 
1a-Bronchopneumonia; 1b- Chronic 
obstructive airways disease                    
2a- Methadone intoxication 
52 M 64 76  NEG  NEG  1a- Cardiac enlargement 
53 M 61 135 74 NEG NEG 15 12 1a-Bronchopneumonia; 1b- Chronic obstructive pulmonary disease 
54 M 63 38 NEG NEG NEG NEG NEG 1a- Head Injury; 1b. Presumed fall 
55 F 44 57 NEG NEG NEG 10 NEG 1a- Bronchopneumonia 
56 M 42 19 NEG NEG NEG 83 117 1a- Heroin intoxication 
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Appendix  4-2  continued 
57 F 34 NEG  NEG  NEG  1a- Multiorgan failure; 1b. Hypothermia and drug intoxication 
58 F 45 NEG NEG NEG NEG NEG NEG 1a- Clozapine intoxication 2a- Resolving Bronchopneumonia 
59 M 57 NEG NEG NEG NEG NEG NEG 1a- Ischaemic heart disease; 1b- Coronary artery atheroma 
60 M 41 54 NEG NEG NEG 59 103 1a- Drowning 
61 M 62 NEG  NEG  65  1a- Ischaemic heart disease and  Bronchopneumonia 
62 F 41 NEG NEG NEG NEG NEG 19 
1a- Methadone and dehydrocodone 
intoxication; 1b- Coronary artery 
atheroma 
63 M 63 17 NEG NEG NEG 235 260 1a- Hanging 
64 M 61 NEG NEG NEG NEG 73 10 1a- Hanging 
65 F 42 NEG NEG NEG NEG 34 NEG 1a- Multiple injuries; 1b- Fall from height 
66 F 26 NEG NEG NEG NEG 33 98 1a- Heroin intoxication 
67 M 25 25 NEG NEG NEG 146 272 1a- Heroin, methadone and alcohol intoxication 
68 M 49 NEG  NEG  NEG  1a. Hed and chest injuries; 1b. Road traffic accident 
69 M 44 NEG NEG NEG NEG NEG NEG 1a- Heroin intoxication 
70 M 33 NEG  NEG  NEG  1a- Hanging 
71 M 32 27 45 NEG NEG NEG NEG 1a- Fatty degeneration of the liver; 1b. Chronic alcohol abuse 
72 M 44 16 NEG NEG NEG 241 287 1a- Fatty degeneration of the liver                           1b- Chronic alcoholic abuse 
73 M 71 208 308 67 84 NEG NEG 1a- Acute puelonephritis; 1b- Possible hypothermia 
74 M 35 145 335 83 183 NEG NEG 
1a- Fatty degeneration and cirrhosis of 
the liver             1b- Chronic alcoholic 
abuse 
75    53 NEG NEG 59(liver blood) NEG External case 
76   18  NEG  NEG  External case 
77   19 NEG NEG NEG 204 266 External case 
78   32  NEG  NEG  External case 
79 M 33 NEG NEG NEG NEG NEG 27 1a- Cocaine Related Cardiac Arrythmia 
80 M 24 11 NEG NEG NEG 243 287 1a- head and chest injury 1b- Fall from height 
81 F 40 249 498 121 145 NEG 66 1a- Fatty degeneration of the liver                                    1b- Chronic alcoholic abuse 
82 M 51 NEG NEG NEG NEG NEG NEG 1a- Ischaemic heart disease; 1b- Coronary artery atheroma 
83 M 49 13 NEG NEG NEG NEG 25 
1a- Ischaemic heart disease; 1b- 
Coronary artery atheroma 2a- 
Hypoglycaemia due to insulin 
dependents diabetes mellitus 
84 M 36 13 NEG NEG NEG NEG NEG 1a- Coronary artery atheroma 
85 M 42 12 NEG NEG NEG 131 143 1a- Hanging 
86 F 35 33  NEG  NEG  1a- unascertained 
87 M 42 NEG NEG NEG NEG 11 NEG 1a- Heroin and Alcohol Intoxication 
88 M 48 29 NEG NEG NEG 190 267 1a- Heroin and alcohol intoxication 
89 M 34 >500 >500 297 >400 NEG NEG 1a- Drowning; 1b. Diabetic ketoacidosis; Insulin dependent diabetic mellitus 
90 M 45 16 NEG NEG NEG 124 169 1a- Sharp force injury of neck 
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Appendix  4-2  continued 
91 M 37 NEG NEG NEG NEG 196 198 1a- Stab wound of chest 
92 F 29 17  NEG  168  1a- Hanging 
93 F 24 46 348 NEG 226 NEG NEG 1a- Hanging 
94 M 41 16  NEG  NEG  1a- Hanging 
95 M 46 18 NEG NEG NEG 12 75 1a- Sudden unexpected death in epilepsy; 1b- Old head injury 
96 F 70 16  NEG  17  1a- Drowning 
97 M 65 16 NEG NEG NEG 247 315 1a- Chest injury; 1b- Road Traffic accident (driver) 
98 M 67 383 358 72 85 338 392 1a. Alcohol related death 
99 M 38  158 45 58 NEG 18 1a. Undetermined 
100 M 80 215 497 82 111 23 14 1a. Hypothermia 
101 M 25 24 NEG NEG NEG 38 84 1a. Unascertained 
102 M 36 11  NEG  NEG  1a. Unascertained 
103   10      External case 
104 M 61 263 >500 42 147 193 286 
1a. Ischaemic heart disease and gastro 
intestinal haemorrhage from erosive 
oesophagitis.  2a. Fatty degeneration of 
the liver 
105 F 56 396  177  34  1a. Fatty degeneration of the liver due to; 1b. chronic alcohol abuse. 
106   31      External case 
107 M 25 14 23 NEG  NEG  1a. Methadone, heroin and cocaine Toxicity. 
108   0      External case 
109 M 39 19  NEG NEG NEG NEG 1a. Methadone and alcohol Intoxication 
110 F 57 >500 >500 399 620 NEG NEG 
1a-Alcoholic Stetosis  and Ischaemic 
heart disease; 1a Fatty degeneration of 
the liver; 1b- Chronic Alcoholic 
111   >500 >500 419 448 85 NEG External case (Expected Ketoacidosis) 
112 M 42 >500  469  30 NEG 
1a-Ischaemic heart disease  1b- 
Coronary artery atheroma 2a- Insulin 
dependent diabetes mellitus 
113 F 36 165  40  NEG  Fatty  degeneration of the Liver Chronic Alcohol Abuse 
114   420      Suspected  Alcoholic ketoacidosis -BHB requested (External Case) 
115 M 36 24  14  314  1a. Fatty  degeneration of the Liver; 1b. Chronic Alcohol Abuse 
116 M 43 11 14 NEG NEG 376 476 
1a. Acute alcohol intoxication; 1b. Fatty 
degeneration of the liver due to chronic 
alcohol abuse 
117 F 60 44  NEG  55  
1a. Hepatic Failure,; 1b. Fatty  
degeneration of the Liver; 1c. Chronic 
Alcohol Abuse; 2a. Fracture of the 
humerus from fall 
118   44      Suspected GHB intoxication (External Case) 
119 M 64 51  NEG  112  1a- unascertained Chronic Alcohol Abuse 
120   372  57 71 257 305 
Fatty  degeneration of the Liver; Chronic 
Alcohol Abuse 
(External Case) 
121 M 76 48  NEG  NEG  1a. Perforation of oesophagus; 1b. Chronic stricture 
122 M 43 >500  169 247 NEG NEG 1a. Fatty  degeneration of the Liver Chronic Alcohol Abuse 
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Appendix 5-2 GHB concentrations in blood and urine postmortem case samples 
 (Shaded boxes information is not available) 
Case # 
 
Gender Age 
GHB mg/L 
Cause of Death             
Blood Urine  
1 M 55 NEG   
1a- unacertained 
2 F 67 20 NEG 
1a- head injury (haemorrhage from scalp laceration)                                 
1b- presumed fall                                 
 2a- Acute  alcohol intoxication pulmonary 
thromboembolism 
3 F 41 NEG   1a- Stab wound of heart 
4 M 66 11   
1a- Coronary artery atheroma   1b- Ischaemic heart 
disease 
5 F 44 22 * NEG 
1a- Fatty degeneration of the liver                                                                
1b- Chronic alcoholic 
6 F 78 13 * 14 
1a- Inhalation of smoke and fire gases in a house fire 
and hypertensive and valvular heart disease 
7 F 29 NEG   
1a- Codeine and alcohol intoxication 
8 M 33 13 NEG 
1a- Heroin and ketamine intoxication 
9 F 58 10 12 
1a- Suspected alcohol related death 
10 M 54 27 NEG 
1a- Chest injury   
1b Road traffic collision (driver) 
11 M 29 15 NEG 
1a- Hanging 
12 M 29 11 NEG 
1a- Heroin, methadone, diazepam intoxication 
13 M 39 NEG NEG 
1a- Bronchopneumonia and intoxication by heroin 
and methadone 
14 M 31 13   
1a- Hypoxia brain damage                  
1b- Cardiac arrest  
1c- Cardiac enlargement 
15 F 33 25   
1a- Hypoxia -Ischaemic brain injury                                                                   
1b- Cardiac arrest                            
 1c- Heroin and alcohol intoxication- Cardiac 
enlargement 
16 M 73 NEG NEG 
1a- Ischaemic heart disease               
1b- Coronary artery atheroma   
17 F 18  NEG   
1a- unacertained (Pending further investigation) 
18 M 33 NEG NEG 
1a- Heroin intoxication 
19 M 19 23 NEG 
1a- Head and chest injury                  
1b- Road traffic collision (driver) 
20 F 28 27 NEG 
1a- Bronchopneumonia                    
1b- Morphine intoxication  
21 M 44 16   
1a- Cardiac enlargement 
22 F 30 17 NEG 
1a- Incised wound of arm 
23 F 36 NEG NEG 
1a- Viral pneumonia with secondary bacterial 
infection 
24 F 34 21 NEG 
1a- Heroin and alcohol intoxication 
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Appendix 5-2 continued 
25 F 38 17 NEG 
1a- Head injury (Pending further investigation)  
26 M 81 28 23 
1a- Acute pylonephritis             
 2a- Coronary artery atheroma 
27 F 47 13 NEG 
1a-Ischaemic heart disease and 
bronchopneumonia 
28 F 38 17   
1a- Acute exucerlation of chronic obstructive 
airways disease 
29 M 71 13 NEG 
1a- Multiple injuries                            
 1b- Road Traffic accident (pedestrian) 
30 F 66 NEG NEG 
1a- Acute hepatic necrosis             
1b- paracetamol Toxicity 
31 M 62 14 NEG 
1a- Hanging 
32 M 62 NEG   
1a- Probable sepsis, source uncertain 
33 F 44 14   
1a- Ischaemic heart disease           
1b- Coronary artery atheroma   
34 F 53 16   
1a- Multiple injuries                             
1b- Fall from height 
35 F 55 14   
1a- Upper gastrointestinal haemorrhage                                       
1b- Duodenal ulcer 
36 M 34 >500 >500 
1a- Gamma- hydroxy butyrate (GHB) 
intoxication 
37 F 43 22 NEG 
1a- unacertained 
38 M 67 19   
1a- Ischaemic heart disease          
1b- Coronary artery atheroma  
39 F 48 NEG NEG 
1a- Head injury  
40 M 52 20   
1a- Bronchopneumonia                    
1b- Chronic alcohol abuse 
41 M 40 23   
1a- Acute alcohol intoxication 
42 M 57 17   
1a- Hanging 
43 F 44 18   
1a- unacertained (Pending further 
investigation) 
44 M 23 15   
1a- tramadol and methadone intoxication 
45 M 48 27   
1a- Alcoholic ketoacidosis                             
1b- Chronic alcohol abuse 
46 M 42 14   
1a- Myocardial fibrosis  and ischaemia - cause 
unacertained 
47 F 37 14   
1a- Heroin and methadone intoxication 
48 F 33 20   
1a- Heroin intoxication 
49 M 59 26   
1a- Hanging  
50 M 24 16   
1a- Hanging  
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Appendix 5-2 continued 
51 M 40 23   
1a- Bronchopneumonia                   
1b- Chronic obstructive airways disease                                               
2a- Methadone intoxication 
52 M 64 <10   1a- Cardiac enlargement 
53 M 61 25   
1a- Bronchopneumonia                
1b- Chronic obstructive pulmonary disease   
54 M 63 23 15 
1a- unacertained (Pending further investigation) 
55 F 44 22 NEG 
1a- Bronchopneumonia        
56 M 42 10 NEG 
1a- Heroin intoxication 
57 F 34 12   
1a- Multiorgan failure (Pending further investigation) 
58 F 45 19   
1a- Clozapine intoxication                                 
 2a- Resolving Bronchopneumonia   
59 M 57 17 NEG 
1a- Ischaemic heart disease          
1b- Coronary artery atheroma  
60 M 41 NEG   
1a- Drowning 
61 M 62 29   
1a- Ischaemic heart disease  and  Bronchopneumonia  
62 F 41 14 19 
1a- Methadone and dehydrocodone intoxication                                   
1b- Coronary artery atheroma  
63 M 63 30 NEG 
1a- Hanging 
64 M 61 22 18 
1a- Hanging 
65 F 42 19 NEG 
1a- Multiple injuries                            
1b- Fall from height 
66 F 26 22 NEG 
1a- Heroin intoxication 
67 M 25 26 NEG 
1a- Heroin, methadone and alcohol intoxication 
68 M 49 21   
  
69 M 44 27 NEG 
1a- unacertained (Pending further investigation) 
70 M 33 22   
1a- Hanging 
71 M 32 23 NEG 
1a- Suspected seizure-related death (Pending further 
investigation) 
72 M 44 NEG 21 
1a- Fatty degeneration of the liver                                                            
1b- Chronic alcoholic abuse 
73 M 71 18 NEG 
1a- Acute puelonephritis                   
1b- Possible hypothermia 
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Appendix 5-2 continued 
74 M 35 NEG NEG 
1a- Fatty degeneration and cirrhosis of the liver                             
1b- Chronic alcoholic abuse 
75       60 
External case 
76     23   
External case 
77     29 NEG 
External case 
78     50   
External case 
79 M 33 32 NEG 
1a- unacertained (Pending further investigation) 
80 M 24 19 NEG 
1a- head and chest injury                  
1b- Fall from height 
81 F 40 NEG NEG 
1a- Fatty degeneration of the liver                                                              
1b- Chronic alcoholic abuse 
82 M 51 NEG NEG 
1a- Ischaemic heart disease           
1b- Coronary artery atheroma  
83 M 49 18 NEG 
1a- Ischaemic heart disease           
1b- Coronary artery atheroma 2a- Hypoglycaemia 
due to insulin dependents diabetes mellitus  
84 M 36 17 NEG 
 1a- Coronary artery atheroma  
85 M 42 46 NEG 
1a- Hanging 
86 F 35 25   
1a- unacertained (Pending further investigation) 
87 M 42 NEG NEG 
1a- Cardiomegaly (Pending further investigation 
88 M 48 14 NEG 
1a- Heroin and alcohol intoxication 
89 M 34 NEG NEG 
1a- Drowning (Pending further investigation) 
90 M 45 14 NEG 
1a- Sharp force injury of neck 
91 M 37 12   
1a- Stab wound of chest 
92 F 29 20   
1a- Hanging 
93 F 24 29 NEG 
1a- Hanging 
94 M 41 15   
1a- Hanging 
95 M 46 27   
1a- Sudden unexpected death in epilepsy                                                 
1b- Old head injury 
96 F 70 21   
1a- Drowning 
97 M 65 22   
1a- Chest injury                                   
 1b- Road Traffic accident (driver) 
98 M 67 38 25 
Alcohol related death 
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Appendix 5-2 continued 
99 M 38   38 
Undetermined 
100 M 80 14 18 
Hypothermia 
101 M 25 54 NEG 
Unascertained 
102 M 36 65   
Unascertained 
103     369   
Suspected GHB/GBL Intoxication 
104 M 61 26 22 
Ischaemic heart disease and gastro 
intestinal haemorrhage from erosive 
oesophagitis.  Fatty degeneration of the 
liver due to chronic alcohol abuse 
105 F 56 25   
Fatty degeneration of the liver due to 
chronic alcohol abuse. 
106     300    Suspected GHB/GBL Intoxication 
107 M 25 30 2.00 
 Methadone, heroin and cocaine 
Toxicity. 
108     >500 >500 
Suspected GHB/GBL Intoxication 
109 M 39 
56 
  
Methadone and alcohol Intoxication 
110 F 57 12.00 8.00 
1a-Alcoholic Stetosis  and Ischaemic 
heart disease ,                       1a Fatty 
generation of the liver                                                                                     
1b- Chronic Alcoholic 
111     11 9 External case (Expected Ketoacidosis) 
112 M 42 82   
1a-Ischaemic heart disease  1b- 
Coronary artery atheroma                                                                
2a- Insulin dependent diabetes mellitus 
113 F 36 30   
Fatty  degeneration of the Liver Chronic 
Alcohol Abuse 
114 M   27   
Suspected  Alcoholic ketoacidosis -BHB 
requested 
115 M   45   
Fatty  degeneration of the Liver Chronic 
Alcohol Abuse 
116 M   32 17 
Very Fatty Liver , Cardiac enlargement 
117 M   17   
Hepatic Failure, Fatty  degeneration of 
the Liver Chronic Alcohol Abuse 
118 M   264   
Suspected GHB intoxication 
119 M   44   
1a- unacertained  Chronic Alcohol Abuse 
, Fatty Liver 
120 M   59   
Fatty  degeneration of the Liver Chronic 
Alcohol Abuse 
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Appendix 5-3 GHB QC Charts 
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(C)        (D) 
GHB quality control charts at 50 mg/L (A and B), 300 mg/L (C and D) in blood and urine, respectively.  
 
QC Ranges 
Blood Urine 
50 mg/L 300  mg/L 50 mg/L 300  mg/L 
Average 49 293 50 314 
Standard 
Deviation (SD) 
2.61 20.11 3.12 22.42 
CV% 5.4 6.7 6.3 7.1 
Mean ± 2SD  43-54 253-333 44-56 270-359 
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Appendix 5-4 HMB/BHB and GHB QC Charts 
HMB, BHB and GHB - Plasma_10 mg/L
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(C)                             (D) 
HMB, BHB and GHB-Plasma_300 mg/L
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(E)                             (F) 
Quality control charts for HMB, BHB and GHB in plasma and urine. at 10 mg/L (A and B), 50 mg/L (C 
and D) and 300 mg/L (E and F)  
 
10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L
AVERAVE 7.29 50 304 8.84 50 305 6.39 49 304 13 60 307 9.19 49 299 8.15 50 296
STDEV 2.14 4.26 26.96 0.97 1.78 13.71 1.62 2.54 14.26 3.95 8.14 44.53 1.61 2.96 10.34 5.16 5.03 10.97
2 SD 4.27 8.52 53.93 1.94 3.55 27.43 3.24 5.08 28.51 7.90 16.28 89.07 3.23 5.93 20.68 10.32 10.06 21.93
Mean + 2SD 12 59 358 11 54 333 10 54 333 21 76 396 12 55 319 18 60 318
Mean - 2SD 3 42 250 7 47 278 3 44 276 5 44 218 6 43 278 0 40 274
PLASMA URINE
HMB GHB BHBHMB GHB BHB
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Appendix 6-1 Preparation and optimization of in house deuterated internal standard  
 
Materials used for preparation in-house deuterated standards were ethanol 
Deuterated (D6) D, 99 % Anhydrous, from Cambridge Isotope Laboratories.Inc. 
(CIL) USA.  Ethanol 100 AR 99.9% Joseph Miller (Denaturants), Liverpool.  Thionyl 
Chloride from Sigma Aldrich Company Ltd.Dorset,UK 
Fatty acids standards (Arachidonic acid Approx. 99% GC grade, Heptadecanoic 
acid 98%, Linoleic Acid minimum ≥ 99%, Linolenic ≥ 99%. Lauric acid (Dodecanoic 
acid) 98%, Myristic acid 99-100%., Oleic Acid ≥ 99% GC grade, Palmitic acid 
minimum 99% GC grade, Palmitoleic Acid Approx. 99% GC grade, Stearic acid 
Grade I 99%  GC grade) were obtained from Sigma Aldrich Company 
Ltd.Dorset,UK 
FAEEs deuterated internal standard was prepared according to Pragst, et al. 
(220)10 mg of each FAEEs added with ethanol-D6 Place in dry ice at -78ºC add 
10uL thionyl chloride Heat at 40ºC for 2 hours. Cyclohexane was added after 
evaporation at 10 psi, then followed by vortex another evaporation steps.  This 
later step was repeated two times and then bring it up with cyclohexane to have 
2 mg/mL final concentrations and stored at-20ºC. 
 
 
 
 
 
 
Chemical reaction during preparation of deuterated FAEES  
 
R
O
OH
+ SOCl2 R
O
Cl
+ Hcl 
R
O
Cl
+
D
D
D
D
D
O D
D
D
D
D
D
O
R
O
Hcl +
Fatty Acid Thionyl Chloride Acyl Chloride
Ethanol-D6 Fatty Acid Ethyl Ester-D5Acyl Chloride
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Appendix 6-1 continued 
Purity of in house deuterated internal standard 
Deuterated in-house internal standards were prepared at concentration of 50 
mg/L to carry out the purity study. From stock solution (2 mg/ mL) a working  
standard of a concentrations of 50 mg/L was prepared. A 100 µl of 50 mg/L was 
added to a labelled vial. Cyclohexane was evaporated to dryness. 100 µL 
methanol was added to give final concentration was of 50 mg/L. All standards 
were stored at -20ºC 
Intrumentation and conditions  
Gas chromatography-mass spectrometry (GC-MS) was utilised using an Agilent 
GC-MS 7890A GC system, a 5975 mass spectrometry detector (MSD), and 
ChemStation software (Agilent, UK). A DB-5+ DG capillary column (30m x 0.25 
mm I.D., 0.25 µm film thickness), purchased from Agilent Technologies Ltd., UK, 
was used. Additional instruments included a nitrogen evaporator, micro-
centrifuge, heater block, and vortex.  
The  GC Program conditions of 50°C for 1 minutes then 10°C /min to 250°C  for 
60 minutes, total run time was 27 minutes using splitless mode. The ions for 
corresponding analytes were extracted includes(D5-ethyl arachidonate 338, D5- 
Ethyl Laurate 234, D5-ethyl myristate 262, D5-ethyl linolenate 312, D5 ethyl 
linoleate 314, D5-ethyl Palmitoleate 288, D5-ethyl palmitate, 290, D5-ethyl 
oleate 316 and D5-ethyl stearate 318, D5ethyl heptadecanoate 304). 
 Area percent report was generated and area peak percent of analyte in relation 
of the total peak areas present in the same chromatogram were for non 
derivatized ranging from 32-89%. Intensity report was also printed and the 
intensity for the area of (m/z+2), (m/z+3), (m/z+4), (m/z+5) were listed in the 
same excel sheet. purity was calculated as the percentage of the area intensity 
(m/z+5) for  all internal standards versus the sum intensities of m/z+2 plus 
m/z+3 plus m/z+4 plus m/z+5.  The purity ranged from 81- 98 % for as indicated 
in  
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Appendix 6-1 continued 
Purity of in-house deuterated standards 
Internal Standard 
Molecular 
ions from 
GC/MS  
RT (Area)  M/z+2   
(Area)  
M/z +3 
(Area)  
M/z+4 
(Area)  
M/z+5 
Total  
Intensities 
Purity 
% 
Ethyl arachidonate-D5 337.4 22.302 4790 4171 5200 59872 74033 81 
Ethyl heptadecanoate-
D5 
303.4 20.188 1280 4875 55632 3229696 
3291483 98 
Ethyl laurate-D5 233.3 14.997 225 676 3274 118720 122895 97 
Ethyl lenolenate-D5 311.4 20.799 3103 3023 6547 647616 660289 98 
Ethyl linoleate-D5 313.4 20.751 708 5633 14801 851072 872214 98 
Ethyl miristate-D5 261 17.212 917 3097 53936 1796608 1854558 97 
Ethyl oleate-D5 315.4 20.828 3091 5366 13177 389376 411010 95 
Ethyl palmitate-D5 289.4 19.234 606 4703 96920 3643392 3745621 97 
Ethyl palmitoleate-D5 287.4 19.013 453 4318 6252 552064 563087 98 
Ethyl stearate-D5 317.5 21.083 1016 4730 23400 1598464 1627610 98 
 
 
Fragmenter ion optimization of In house d5-FAEEs and ethyl heptadecanoate 
 
Most analytes have a collision energy of less than 10ev using LC/MS/MS triple 
quadrupole However, using the same tuning solution with the ion trap 
LC/MS/MS, the collision energies were higher (27-42 eV for the same analytes)  
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Appendix 6-1 continued  
Fragmentor ion optimization of in house internal standard was carried out and 
the range of optimum fragmentor voltage was between 100 and140  
FAEES and FAEEs-d5 Optimization of product ion and Collision Energy (CE) 
Name  Molecular 
Ion 
Product  
Ions  
Collision Energy  
By 
 Deca LC/MS/MS Comment  
FAEEs 
Ethyl Arachidonate 332.5 287 38 Commercial  
Ethyl heptadecanoate  299 271 36 Commercial  
Ethyl Laurate 228.38 201 30 Prepared in house from its acid  
Ethyl Lenolenate 306.49 261/243 42 Commercial  
Ethyl Linoleate 308.51 263/245 32 Commercial  
Ethyl Miristate 256.43 229 32 Commercial  
Ethyl Oleate 310.53 265/247 30 Commercial  
Ethyl plamitate  284.48 257 32 Commercial  
Ethyl Plamitoleate 283 237 30 Commercial  
Ethyl Stearate 312.53 285 34 Prepared in house from its acid  
Ethyl heptadecanoate  299 271 36 Commercial  
Ethyl Plamitoleate 283 237 30 Commercial  
Commercial Deuterated FAEEs- d5 
Ethyl Miristate_d5 262 230 30 Commercial   
Ethyl Oleate_d5 316 265 38 Commercial  
Ethyl plamitate_d5  290 258 30 Commercial  
Ethyl Stearate_d5 318 286 32 Commercial  
 In house Deuterated FAEEs- d5  
Ethyl Arachidonate_d5 338 287 30 Prepared in house from its acid  
Ethyl heptadecanoate_d5  304 272 40 Prepared in house from its acid  
Ethyl Laurate_d5 234 202 27 Prepared in house from its acid  
Ethyl Lenolenate_d5 312 261/243 30 Prepared in house from its acid  
Ethyl Linoleate_d5 314 263/245 32 Prepared in house from its acid  
Ethyl Miristate_d5 262 230 30 Prepared in house from its acid  
Ethyl Oleate_d5 316 265 38 Prepared in house from its acid  
Ethyl plamitate_d5  290 258 30 Prepared in house from its acid  
Ethyl Plamitoleate_d5 288 237 30 Prepared in house from its acid  
Ethyl Stearate_d5 318 286 32 Prepared in house from its acid  
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Appendix 6-1 continued 
Collision energy and product ions optimization using triple quadropole LC/MS/MS  
were not fully achieved  it was not reproducible ,this could be because very 
small CE was needed to fragment those ion (less than 5ev) which is too low 
compared to ion trap LC/MS/MS.   
Collision energy of  FAEEs analytes, including both commercial and In house  
internal standards, were lower than 10ev in a range of 2–6 (table 5-2); this made 
the optimization for some analytes more difficult, possibly due to the fragility of 
some compounds at this low collision energy. The optimum published collision 
energy of FAEEs ranged between 10 and 30 using triple quadrupole 
LC/MS/MS.(159) Collision energy was in a range of 27-42 ev when it was 
optimized by other ion trap LC/MS/MS in the same laboratory. This could be 
another reason not to have another ion transition for all analytes to be used as 
qualifiers  
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Appendix 6-2 Endogenous interference Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ethyl Laurate  
 
Extracted Blank 1  (A) Ethyl Palmitate  
 
D5-Ethyl Palmitate  
Extracted  Blank 3 
Extracted  Blank 1  
Extracted  Blank 2 
Extracted  Blank 3 
Extracted  Blank 2 
 
Ethyl Myristate  
Extracted  Blank 3 
 
Extracted Blank 1  
 
Extracted  Blank 2 
 
Ethyl Palmitoleate  
 
Extracted  Blank 1  
 
 
Extracted Blank 2 
 
Extracted  Blank 3 
  
Extracted  Blank 3  
Extracted  Blank 2 Extracted  Blank 1   
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Extracted  Blank 1  
Ethyl Linoleate  
Extracted  Blank 1  
Ethyl Arachidonate 
Extracted  Blank 2 
Extracted  Blank 3 
 
Extracted  Blank 1  
 
Extracted  Blank 2 
Extracted  Blank 3 
 
Extracted  Blank 1  
D5-Ethyl Stearate 
 
Extracted  Blank 2 
Extracted  Blank 3 
 
D5-Ethyl Oleate 
Extracted  Blank 1  
Ethyl Stearate  
 
Extracted  Blank 2 
 
Extracted  Blank 3 
 
Ethyl Heptadecanoate 
Extracted  Blank 1  
Extracted  Blank 1  
Ethyl Linolenate  
 
Extracted  Blank 2 
 
 
Extracted  Blank 2 
 
Extracted  Blank 3 
 
Extracted  Blank 3 
 
Extracted  Blank 1 
 Ethyl Palmitoleate  
Ethyl Oleate  
 
Extracted  Blank 2 
 
Extracted  Blank 3 
 
 
Extracted  Blank 3 
 
 
 
Extracted  Blank 2 
 
Arachidonate 
standard 
1mg/L  (B)  
ED pooled meconium blank samples with no internal standard versus unextracted 
centration of 1 mg/L. (B) magnified peak  of ethyl arachidonate  overlaid with extracted 
ank.  The arrow indicated no endogenous interference from analyte in extracted blanks. 
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v Huda M. Hassan and Gail A. A. Cooper. 2009. Determination of Beta-
hydroxybutyrate in Blood and Urine using Gas Chromatography-Mass Spectrometry. 
J. Anal. Toxicol. 33:502 - Abstract Only 
 The work presented  at the Society of Forensic Toxicology (SOFT) annual meeting, 
OKlahoma, USA, October 2009. 
 
 
v Maciegj J.Bogusz and Huda M. Hassan, Role of Accreditation Procedures in 
Maintaining Quality, In: "Quality Assurance in the Pathology Laboratory: 
Forensic, Technical and Ethical Aspects", (Chapter 7) J.B.Maciej, ed., CRC 
Press, (2011).139-204  
 
 
Publication Under Progress and Oral Presentation  
 
 
v Huda M. Hassan and Gail A. A. Cooper: Method for Quantification of Gamma-
Hydroxybutyrate (GHB) in Postmortem Blood by using Gas Chromatography Mass 
Spectrometry. Presented and in the proceeding of the Fourth Saudi International 
Conference 2010, SIC10 Held in University of Manchester, UK. July 2010 
  
v Huda M. Hassan and Gail A. A. Cooper:  The Effect of preservative and anti-oxidant 
on the volatiles in aged reconstituted Ante-mortem blood after short term storage. 
Abstract and manuscripts were submitted for JAT Special issues for year 2011. In 
progress  
 The work presented  at the Society of Forensic Toxicology (SOFT) annual meeting, 
Virginia, USA, October 2010. 
 
v Huda M. Hassan and Gail A. A. Cooper:  Simultaneous determination of of ß-
hydroxy-ß-methylbutyrate (HMB), beta-hydroxybutyrate (BHB) and gamma-
hydroxybutyrate (GHB) in urine and plasma using gas chromatography mass 
spectrometry (GC-MS).  Abstract and manuscripts were submitted for JAT Special 
issues for year 2011. In Progress 
 
 
v Huda M. Hassan and Gail A. A. Cooper: A Liquid Chromatography Tandem Mass 
Spectrometry Method for the quantification of FAEE’s in Meconium, Presented and in 
the proceeding of   UK & Ireland Association of Forensic Toxicologists (UKIAFT), 
Glasgow, UK.September  2010 
 
 
v Huda M. Hassan and Gail A. A. Cooper: Evaluation of Internal Standards for the 
Determination of Common Volatiles by Headspace Gas Chromatography Flame 
Ionisation Detection. In Progress for publication  
 
v Pamela Cabarcos Fernández, Pamela’s supervisor,Huda M. Hassan, Karen Scott: 
Determination of Ethyl Glucuronide in hair using LC/MS/MS. In Progress for 
publication  
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Posters 
 
v Huda M. Hassan and Gail A. A. Cooper: Determination of β-Hydroxybutyrate (BHB) 
in Blood and Urine using, Gas-Chromatography-Mass Spectrometry (GC-MS), IUPAC 
Glasgow UK, August 2009. 
 
v Huda M. Hassan and Gail A. A. Cooper: Evaluation of the Immunalysis Enzymatic 
Assay for the Quantitative Determination of Ethanol in Post-Mortem Blood, Saudi 
International Conference - University of Surry June 2009. 
 
v Huda M. Hassan and Gail A. A. Cooper: Comparison Study of Ethanol and Acetone 
Levels in Post-Mortem Blood, Vitreous Humour, Bile and Urine, Saudi 
International Conference (SIC) - University of Surry June 2009. 
 
v Huda M. Hassan and Gail A. A. Cooper: Stability of Ethanol, Acetone, Iso-propanol 
and Methanol in Human Blood, 50 the Years Anniversary of Forensic Toxicology 
department – University of Glasgow March 2009. 
 
 
Awards  
 
v Educational Research Award (ERA) - Society of Forensic Toxicology(SOFT) annual 
meeting, Oklahoma City, USA, October 2009.  
Huda M. Hassan and Gail A. A. Cooper (200)9. Determination of BHB in Blood and 
Urine using GC-MS 
 
v Silver Award (Best Research and Scientific paper) – 4th Saudi International 
Conference 2010. SIC2010 University of Manchester 30-31 July 2010. 
Huda M. Hassan and Gail A. A. Cooper:  Method for Quantification of GHB in 
Postmortem Blood using GC-MS. (2010) 
 
v Distinguished Researcher – 4th Saudi International Conference 2010 University of 
Manchester 30-31 July 2010 
 
v Best Poster (UKIAFT) – UKIAFT AGM, Aberdeen 27-28 July 2011 
Claire Parks, Huda M. A. Hassan and Gail A. A. Cooper (2011). Correlation of Volatile 
Concentrations in Biological Matrices.   
 
 
 
 
263 
 
 
 
 
 
264 
 
 
 
 
 
 
 
 
 
 
 
265 
 
 
 
 
 
 
 
 
 
266 
 
 
 
 
 
 
 
 
 
 
 
267 
 
 
 
 
 
 
 
 
 
268 
 
 
 
269 
 
 
 
 
 
 
270 
 
The Effect of Preservative and Anti-oxidant Reagents in Aged 
Reconstituted  Ante-mortem Blood after Short- Term Storage 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
Abstract 
The stability of common volatiles was investigated under controlled conditions over a period of 50 
days. Blood was spiked with ethanol, methanol, isopropanol and n-propanol at 20 and 80 mg/dL 
and acetone at 20 and 80 mg/L. Aliquots were stored at 25, 4, and -22 ºC with or without a 
preservative (sodium fluoride) or antioxidant (sodium metabisulphite). Samples were analysed 
using headspace gas chromatography with a flame ionisation detector (HS-GC-FID and utlising t-
butanol as internal standard. Acetone levels increased while isopropanol and n-propanol levels 
decreased in both preserved and unpreserved samples at room temperature and when refrigerated. 
Methanol remained stable in the presence of a preservative and antioxidant in all conditions. 
Formation of ethanol was observed in samples stored at room temperature or refrigerated without 
preservative. All volatiles were stable when stored in the freezer.  
An evaluation of the stability of ethanol in real case samples was also undertaken. Blood samples 
collected under Section 5 of the Road Traffic Act 1988 are stored in vials containing both 
preservative and anticoagulant. A total of 219 blood samples received within Forensic Medicine 
and Science at the University of Glasgow over a period of 5 years were initially analysed and 
refrigerated until the case was heard in court. Following completion the samples were removed 
from the refrigerator and stored at room temperature for varying periods of time spanning 5 years. 
A loss of on average 30% of the ethanol content was observed when the samples were re-analysed.  
Finally, seventy-one paired preserved and unpreserved post-mortem blood samples stored in the 
refrigerator for six months were re-analyzed. Loss of ethanol was observed in approximately 50% 
of the 71 preserved samples and 40% of unpreserved samples. An increase in ethanol concentration 
of between 34 to 55% was observed in approximately 7% of the preserved samples and 25% of 
unpreserved samples after 6 months of storage in a refrigerator.  
Key words: volatiles, stability, preservative 
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Simultaneous determination of of ß-hydroxy-ß-methylbutyrate (HMB), 
beta-hydroxybutyrate (BHB) and gamma-hydroxybutyrate (GHB) in 
urine and plasma using gas chromatography mass spectrometry (GC-
MS) 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
 
 
Abstract  
β-hydroxy-β-methylbutyrate (HMB) or  β-hydroxyisovaleric acid (β-HIV) is available as a nutritional 
supplement and is taken to increase strength and muscle mass in humans involved in resistance training 
programmes. Although in 1999 the International Olympic Committee’s medical advisory board categorized 
HMB as a legal substance the potential for misuse is considerable.  
The aims of this study were, to develop and validate a method for the determination of HMB in plasma and 
urine and to simultaneously determine other structurally related compounds, such as BHB and GHB and 
apply this method to analyse real case samples.  
A GC-MS method was developed for the simultaneous determination of HMB, BHB and GHB in plasma and 
urine using deuterated GHB-d6 as an internal standard. The method was linear over a range of 10-500 mg/L 
with a correlation coefficient (R2) greater than 0.99.  The inter-day and intra-day precision was measured in 
both matrices at less than 10%. The recovery and accuracy ranged between 42-77% and 98-102% 
respectively for all analytes in both plasma and urine. The limits of detection (LOD) for HMB, GHB and 
BHB were 2.3, 1.0 and 2.2 mg/L in urine respectively, and 2.3, 1.5 and 0.9 mg/L in plasma.  The lower limits 
of quantification (LLOQ) were 7.7, 3.3 and 7.3 mg/L and 7.8, 5.1 and 2.9 mg/L respectively, in urine in 
plasma.  
 
Keywords: β-hydroxy-β-methylbutyrate (HMB) or β-hydroxyisovaleric acid (β-HIV); β-hydroxybutyrate 
(BHB); gamma-hydroxybutyrate (GHB); Plasma; Urine 
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A Liquid Chromatography Tandem Mass Spectrometry Method for the 
Quantification of Fatty Acid Ethyl Esters in Meconium. 
 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
 
Abstract 
 
Babies born from mothers who consume alcohol during pregnancy are at elevated risk to have 
Neonatal alcohol related birth defects (ARBDs), Foetal Alcohol syndrome (FAS) and alcohol-
related neurodevelopment disorders (ARNDs). To facilitate earlier diagnosis and treatment and to 
prevent undesirable outcomes, screening for fatty acid ethyl esters as alcohol biomarkers could 
confirm maternal alcohol consumption. Foetal exposure of alcohol can cause central nervous 
system dysfunction, pre- and postnatal growth problems, cardiac defects in neonates and attention 
deficit disorders may leads to mental retardations.  
A Liquid Chromatography Mass spectrometry tandem MS (LC/MS/MS) method have been 
developed and validated for detection and quantification of fatty acids ethyl esters in meconium 
includes: ethyl lenolenate (E18:3), ethyl linoleate (E18:2), ethyl palmitoleate (E16:1), ethyl 
palmitate (E16:0), ethyl oleate (E18:1), ethyl stearate (E18:0) and ethyl arachidonoate (E20:4). The 
internal standards used were deuterated includes ethyl oleate-D5, ethyl steareate-D5 and ethyl 
palmitate-D5.  
The method have been applied to eighty four real neonatal meconium case samples  collected from 
Glasgow Royal Infirmary  in order to investigate the neonatal exposure to alcohol in the absence of 
maternal drinking history. Results have been compared with the published data to identify the most 
specific and sensitive fatty acid ethyl ester biomarker. The cut-off point to distinguish the positive 
from negative was also evaluated 
 
Key Words:  Meconium, Fatty acid ethyl esters, Alcohol, LC/MS/M 
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Internal Standards for the Determination of Common Volatiles by 
Headspace Gas Chromatography Flame Ionisation Detection. 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
 
Abstract 
The most common method for sensitive and precise analysis of ethanol and other volatile in 
biological fluids and tissues is Gas Chromatography.  This methods can also distinguish between 
ethanol and other volatiles and by using dual column system and it is fitted with dual column 
capability  and provides  two sets of data that can used in combination with increased confidence to 
identify analytes of interest, since it reduces the number of false positive results due to other post-
mortem volatiles that may be eluting in the same retention time.  . Head Space - Gas 
Chromatography copelled with Flame Ionization Detector (HS-GC-FID) technique is common in 
forensic and toxicology laboratories for medico-legal investigations and the interpretation of 
toxicology results.   
A wide range of volatile compounds may be produced in post-mortem specimens.  n-propanol is 
amongst these and is considered to be an indicator of putrefaction. Several studies have therefore 
recommend that n-propanol should not be used as an internal standard for quantification of alcohol 
by (HS-GC-FID).  A comparison between  two validated  procedures and evalauation of dual 
column system used  have been carried out  using  n-propanol and t- butanol as an internal 
standards.  The two validated methods used were robust, sensitive, and fully validated using GC-
FID-HS.  The correlation coefficients (R2) were >0.999 over the linear range of 10–500 mg/dL 
(and mg/L for acetone). The inter-day and intra-day precision was between 1-5% for all analytes in 
all methods used.  
One hundred and twenty one putrefied post-mortem blood samples received within laboratories of  
Forensic Medicine and Science  were analysed using both  methods.  Evaluation of other volatile 
levels mainly the amount of n-propanol and it is relation with ethanol level in post-mortem blood 
have been evaluated. The putrefied post-mortem blood samples produced several results in which 
n-propanol was present at a level that could be viewed as a result of putrefaction. It might tend to 
underestimate the concentration of other volatiles if n-propanol is used as an internal standard in 
post-mortem samples that are positive for n-propanol.  
Key words: volatiles, n-propanol, ethanol, putrefaction
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Quatification of Gamma-Hydroxybutyrate (GHB) in Postmortem Blood 
by using Gas Chromatography Mass Spectrometry. 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
 
  
 
Abstract  
 
Gamma–hydroxybutyric acid (GHB) and its precursors, gamma butyrolactone (GBL) and 1, 4 
butanediol (DB), are increasingly popular drugs of abuse. GHB misuse and accidental overdosing 
may lead to death and GHB has been detected in post-mortem blood in concentrations ranging  
from 3.2 – 168 mg/L in cases with no previous history of GHB use (Fieler, Coleman and Baselt, 
1998).  A sensitive and specific method for the determination of GHB in blood and urine was 
modified from a method previously validated and published (Hassan et al. 2009) using GC-MS.  
The method has been applied to identify GHB-related fatalities in postmortem cases and to evaluate 
the levels in postmortem cases with no known history of GHB intoxication.  
 
Keywords: GHB; GC-MS; Postmortem; Blood; Urine 
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